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Abstract  
Prion diseases are fatal neurodegenerative disorders associated with 
conformational conversion of normal cellular prion protein (PrPC) to an abnormal 
disease-associated conformer (PrPSc). The aim of this thesis was to investigate the 
earliest event in prion infection using a novel cell system. Specifically, it aimed to 
assess the timescale that PrPC is converted to PrPSc following exposure to RML prions 
and identify the initial cellular site of PrPSc formation and propagation. The cell 
biology of the initial events of cellular prion infection are poorly understood since 
newly formed cellular PrPSc is immunologically indistinguishable from infectious 
prions in the inocula. As a solution to this problem, an epitope-tag was inserted into 
the sequence of endogenous PrPC to delineate the formation of de novo PrPSc. A PrP-
knock down neuroblastoma cell line was reconstituted with mouse 3F4-, FLAG- and 
MYC-tagged PrPC. Following identification of cells expressing physiological levels of 
tagged PrPC, prion-susceptibility was determined by exposure to disease-associated 
prions. 
Cells expressing 3F4-tagged PrP, the MYC sequence at position 224 and the 
FLAG sequence at position 22 or 30 contained PrP resistant to formic acid and 
proteinase K digestion. A mouse bioassay demonstrated that the PrP-224AlaMYC cell 
line produce bona-fide infectious epitope-tagged PrPSc on exposure to RML prions. 
Investigation of de novo tagged PrPSc propagation in this novel cell system 
demonstrated that cellular prion infection is a dynamic process occurring within one 
minute of prion exposure and that the plasma membrane is the primary site of prion 
conversion. It was demonstrated that the late endosomes, lysosomes and endosomal 
recycling compartments do not appear to be key sites of PrP conversion and prion 
6  
 
propagation, whilst the plasma membrane and early endocytic compartments are 
involved in this key process.  
The work in this thesis provides new insights into the cell biology of the initial 
stages of prion conversion and propagation and has implications for neurodegenerative 
diseases where prion-like mechanisms have been proposed. 
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1 Introduction  
Prion diseases, or transmissible spongiform encephalopathies (TSE), are a 
family of fatal neurodegenerative disorders. These diseases affect both humans (e.g. 
Creutzfeldt-Jakob disease; CJD) and animals (e.g. bovine spongiform encephalopathy; 
BSE), and can be transmitted within or between animal species by inoculation or 
dietary exposure. They are associated with a conformational rearrangement of the 
normal cellular prion protein, PrPC (C for cellular) to abnormal conformers, PrPSc (Sc 
for scrapie). PrPC is soluble, monomeric and rich in α-helical structure, whereas 
disease-associated PrPSc is characterized by increased β-sheet structure, detergent 
insolubility and partial resistance to proteolysis. Neuro-pathologically, prion diseases 
produce a characteristic spongiform degeneration of the brain, with massive neuronal 
death, marked gliosis and the accumulation of amyloid plaques containing PrPSc. 
Currently, the cause of prion mediated neurodegeneration remains unknown and a 
major gap exists in understanding how the conversion of PrPC to PrPSc leads to 
neuronal dysfunction and ultimately cellular death.  
1.1 Animal prion diseases 
This section summarises animal prion diseases including scrapie in sheep and 
goats, BSE in cattle and chronic wasting disease (CWD) in deer and elk. 
1.1.1 Scrapie 
Scrapie is a naturally occurring disease of sheep and goats that was first 
described in the 18th century. Its name is derived from the predominant clinical 
symptom, whereby the animal has the tendency to rub against walls or fences to scrape 
off its wool. In 1936, scrapie was successfully transmitted to goats and two healthy 
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sheep by intraocular inoculation of brain or spinal cord tissue from an affected animal 
(Cuillé and Chelle, 1936). Thereby, the transmissible nature of the scrapie agent was 
firmly established. Further evidence came after scrapie was inadvertently transmitted 
to British sheep injected with a vaccine prepared from the brain, spinal cord, and 
spleen of affected sheep (Gordon, 1946). Since then, scrapie has been successfully 
transmitted between different species including laboratory mice (Chandler, 1961). To 
this date, the disease has never been shown to pose a threat to human health (Brown 
and Bradley, 1998). Despite all the studies into scrapie, remarkably little is known 
about its natural routes of transmission. Affected sheep and goats show the typical 
neuropathological symptoms for prion disease which are in general spongiosis, gliosis, 
and neural loss. Scrapie has been recognised in many countries, but its presence is 
imprecisely known in Europe, North America and Japan. 
1.1.2 Chronic wasting disease  
Chronic wasting disease (CWD) is a prion disease first recognised around 30 
years ago affecting mule deer, white-tailed deer, and Rocky Mountain elk in a limited 
area of North America (Williams and Young, 1980; Spraker et al., 1997). The natural 
history of CWD is incompletely understood, but differs from scrapie and BSE by 
virtue of its occurrence in non-domestic and free-ranging species. As yet, there is no 
evidence for CWD transmission to humans (Miller and Williams, 2003; Mathiason et 
al., 2006). In CWD, disease-associated prion protein has an early widespread 
distribution in lymphoid tissues, with later involvement of central nervous system 
(CNS) and peripheral tissues (Browning et al., 2004). Symptoms include weight loss, 
behavioural changes and hypotonic muscles, and typically lead to death after 7-8 
months (Williams and Young, 1980). 
Introduction 
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1.1.3 Transmissible mink encephalopathy  
Transmissible mink encephalopathy (TME) affects ranched mink and was first 
seen in Wisconsin and Minnesota in 1947. Sporadic outbreaks have since appeared in 
several countries including Canada, Finland, Russia and former East Germany (Marsh, 
1992). Mink appear to acquire TME through ingestion of scrapie and BSE 
contaminated meat (Marsh et al., 1991). Studies have shown that this disease can be 
experimentally transmitted to hamsters (Kimberlin and Marsh, 1975). A recent study 
in a transgenic mouse line suggests that the TME agent is not related to BSE agents, 
despite their apparent similarities (Baron et al., 2007). Initial symptoms include 
increased aggression and hyperaesthesia and usually progress to ataxia, tremors, and 
compulsive self-biting (Marsh et al., 1991). The time between initial symptoms and 
death vary from one week to several months (Marsh, 1992).   
1.1.4 Bovine spongiform encephalopathy  
BSE or ‘mad cow disease’ was recognised in Britain in 1986 by British 
veterinarians (Wells et al., 1987). In the UK, around 180,000 cattle have since 
developed clinical symptoms of the disease with the epidemic peak in 1992 (Beghi et 
al., 2004). Beside the UK, the disease has now been reported in most member states of 
the European Union, together with Switzerland, the United States, Canada and Japan 
(Ghani et al., 2002; Mallucci and Collinge, 2005). Affected cattle show typical prion 
disease neuropathology including diffuse cellular degeneration with spongiosis and 
astrocytic gliosis. The affected cattle die within six months of the initial signs of the 
disease. 
It has been suggested that the BSE epidemic was caused by the use of 
contaminated meat-and-bone-meal (MBM) as a high protein supplement feed for 
Introduction 
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cattle. MBM contains brain material from sheep, cattle and chicken. One possible 
origin of BSE was feeding cattle with scrapie-containing MBM (Prusiner et al., 1991; 
Wilesmith and Wells, 1991) as BSE is neuropathologically similar to scrapie 
(Wilesmith and Wells, 1991; Wilesmith et al., 1988; Smith and Bradley, 2003); It is, 
however, important to note that the BSE strain is molecularly and biologically 
different to the strain causing scrapie (Bruce et al., 1994). Another possibility is that 
BSE occurred sporadically in cattle and thus tissue from the affected animal was 
incorporated into MBM to seed the epidemic (Weissmann and Aguzzi, 1997). In 1988 
feeding of MBM to sheep and cattle was banned and following the emergence of 
variant CJD in 1996 the ban on feeding mammalian proteins to any farmed animals 
was re-enforced. The feed ban was extended to the EU in 2001. The route of BSE 
transmission is thought to be oral and since BSE has a long incubation time (~ four 
years), new epidemic peaks cannot be fully excluded in affected countries. 
1.1.5 Other animal prion diseases 
In addition to TSEs described above, Feline spongiform encephalopathy (FSE) 
and Exotic ungulate encephalopathy (EUE) are other animal prion diseases reported 
first in the UK and then in other European countries. Both of these diseases are 
considered to be related to BSE and thought to be caused by feeding animals with 
BSE-contaminated MBM. EUE has been recognised in exotic hoofed animals and FSE 
has been described in captive cheetahs, pumas, ocelots, and tigers (Kirkwood and 
Cunningham, 1994). Affected animals show spongiform degeneration in the neuropil 
of the brain and spinal cord with the most severe lesions localised to the medial 
geniculate nucleus of the thalamus and the basal nuclei (Ryder et al., 2001). 
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1.2 Human prion diseases 
Human prion diseases are rare and fatal disorders characterised by a wide range 
of clinical symptoms such as weight loss, insomnia, depression, memory problems, 
confusion, headache, and general pain sensation. Neurological features include cortical 
blindness, extrapyramidal signs, ataxia, and finally dementia. Human prion diseases 
have three distinct aetiologies (Prusiner, 1998a; Collinge, 2001): they might be 
acquired from exposure to prions; they may arise sporadically; or they can be inherited 
in an autosomal-dominant manner (Collinge, 2001; Kovacs et al., 2002b; Wadsworth 
et al., 2003; Mead, 2006b). 
1.2.1 Sporadic prion disease 
About 80 % of human prion disease cases occur sporadically as CJD (sporadic 
CJD). The disease occurs at a rate of 1-2 cases per million population per year across 
the world, with an equal incidence in men and women (Caramelli et al., 2006). The 
peak incidence is in the age group of 45-75 with median age at death of 68 years 
(Brown et al., 1987; Collins et al., 2006). Sporadic CJD progress rapidly and affected 
individuals show multifocal dementia, usually with myoclonus, leading to death within 
6-12 month of disease onset (Gambetti et al., 2003). Definitive diagnosis of sporadic 
CJD is by brain biopsy or neuropathological analysis at post-mortem, both of which 
must demonstrate spongiform change, neuronal loss and astrocytosis (Bell et al., 
1997). In sporadic CJD PrP amyloid plaques are not usually present, but PrP 
immunohistochemistry is nearly always positive (Budka et al., 1995). The cause of 
sporadic CJD is unknown, however, somatic mutation of the human PrP gene, PRNP, 
(Brown et al., 1987; Collinge, 1997; Wadsworth et al., 2006), or the spontaneous 
conversion of PrPC into PrPSc as a rare stochastic event (Collinge, 1997) are current 
Introduction 
25  
 
hypotheses. Susceptibility to human prion diseases is affected by polymorphism at 
residue 129 of human PrP encoding either methionine (M) or valine (V) (Mead, 
2006b). Approximately 38 % of Europeans are homozygous for the M allele, 51 % are 
heterozygous, and 11 % are homozygous for the V allele. Studies have suggested that 
homozygosity at PRNP codon 129 predisposes to the development of sporadic and 
acquired CJD (Collins et al., 2006; Collinge et al., 1991a; Palmer et al., 1991; Windl 
et al., 1996; Lee et al., 2001a; Mead et al., 2003). Further genetic studies have 
revealed that sporadic CJD is also associated with polymorphisms upstream of exon 1 
of PRNP (Mead et al., 2001) and a 129 MV independent polymorphism in the 5' un-
translated region (UTR) of PRNP locus (Vollmert et al., 2006). 
1.2.2 Inherited prion disease 
Around 15 % of human prion diseases are associated with automosal dominant 
pathogenic mutations in PRNP (Gambetti et al., 2003; Collinge, 1997; Collinge and 
Palmer, 1997; Kovacs et al., 2002a; Mead, 2006a). It is not known how pathogenic 
mutations in PRNP cause prion diseases. The mutations are thought to favour the 
spontaneous conversion of PrPC to the PrPSc state in the absence of an exogenous 
infectious agent (Cohen et al., 1994). It has also been shown that experimental 
mutation of the prion gene can lead to spontaneous neurodegeneration without the 
formation of detectable protease resistant PrP (Muramoto et al., 1997; Hegde et al., 
1998a). Traditionally, inherited prion diseases have been classified into three main 
sub-divisions of Gerstmann-Sträussler-Scheinker disease (GSS), familial CJD and fatal 
familial insomnia (FFI) according to their clinical symptoms. However, the existence 
of phenotypic overlap between individuals with different mutations and even in family 
members with the same PRNP mutation indicates that accurate classification of 
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inherited prion diseases should be based upon mutation alone (Collinge et al., 1992; 
Collinge and Prusiner, 1992). GSS presents the distinctive and defining 
neuropathological feature of widespread, multicentric amyloid plaques which are PrP 
positive. Mutation P102L of PRNP was the first to be reproducibly associated with 
GSS development (Hsiao et al., 1989); however, the disease is now linked to seven 
PRNP mutations. FFI is characterised by profound disruption of the normal sleep-wake 
cycle, prominent insomnia, sympathetic over-activity, diverse endocrine abnormalities 
and impaired attention. The disease is associated with a missense mutation at codon 
178 of PRNP, substitution of asparagine for aspartic acid (D178N), and coexisting 
methionine at the polymorphic codon 129 of PRNP (Medori et al., 1992). Sporadic FFI 
with no causative mutation in PRNP has been reported (Montagna et al., 2003). 
Familial CJD segregates with D178N mutation when combined with valine at codon 
129 (Zerr et al., 1998).  
1.2.3 Acquired prion disease 
Although human prion diseases are transmissible diseases, acquired forms are 
very rare and are associated with less than 5 % of human prion diseases.    
Iatrogenic CJD 
Iatrogenic CJD can arise after an individual is exposed to CJD-infected tissue, 
most commonly as a contaminant in medical procedures. For instances, cases of 
iatrogenic CJD, have been traced to corneal transplants, dura matter grafts, 
administration of growth hormone derived from cadaveric pituitary glands and the use 
of infected surgical instruments and electrocephalographic (EEG) electrodes (Brown et 
al., 1992; Brown et al., 2000). Patients with iatrogenic CJD display different 
symptoms on the route of exposure to human prions (Collinge and Palmer, 1997; 
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Brown et al., 2000; Belay, 1999). Where transmission is intracerebral, the symptoms 
are similar to sporadic CJD (Heath et al., 2006), whereas, peripherally acquired CJD 
resembles kuru due to the prominent early ataxia.   
Variant CJD 
Variant CJD was first reported in the United Kingdom in 1996 (Will et al., 
1996) and has affected around 173 individuals in the UK to date 
(www.cjd.ed.ac.uk/figures.htm). Clinical, neuropathological, molecular and 
transmission characteristics of variant CJD all indicate that it is acquired by the 
consumption of beef from BSE-affected cattle (Bruce et al., 1997; Collinge, 1996; 
Will et al., 1996). Experimental evidence that variant CJD is caused by the same BSE 
prion strain detected in cattle has raised the possibility that a major epidemic of variant 
CJD will occur in the UK and other countries in which livestock were exposed to BSE 
prions (Cousens et al., 1997; Ghani et al., 1999; Collinge, 1999). Variant CJD affects 
primarily young adults and it is clinically characterised by a progressive 
neuropsychiatric disorder with ataxia, dementia, and involuntary movements. In 
contrast with sporadic CJD, patients with variant CJD are much younger (19-39 years 
old), have a longer duration of illness (7.5-22 months) and beyond the CNS, PrPSc can 
also be found in the spinal cord and immune cells in the periphery (Spencer et al., 
2002). 
To date, all definite variant CJD cases are homozygous for methionine at PRNP 
codon 129 (Hill et al., 1997; Hill et al., 1999). However, an unusual case published by 
Kaski et al. in 2009 reported a 30-year old man who was heterozygous at PRNP codon 
129 (MV) and died of variant CJD (Kaski et al., 2009). Recent quantitative trait locus 
studies in mouse have shown that regions unrelated to PRNP play a role in the variable 
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incubation times in prion disease, including BSE (Stephenson et al., 2000; Lloyd et al., 
2001; Lloyd et al., 2002). Further investigations have also identified two novel 
candidate loci, RARB and STMN2, as potential variant CJD risk factors (Mead et al., 
2009). At present, there is concern that some individuals are carriers of the infection 
and thus pose a risk of horizontal spread. Variant CJD transmission by blood 
transfusion had already been documented (Llewelyn et al., 2004; Peden et al., 2004; 
Hewitt et al., 2006; Wroe et al., 2006). As a result, many countries have passed laws to 
diminish the use of blood from donors at risk of exposure to BSE or variant CJD. In 
February 2009, the ‘’Health Protection Agency’’ (HPA, London, UK) confirmed the 
first case of variant CJD transmission via blood in a patient with haemophilia.    
Kuru 
A well-known example of acquired human prion disease is kuru which was 
recognised as a major epidemic in the 1950s. The disease was transmitted by 
cannibalism among the Fore linguistic group of the Eastern Highlands of Papua New 
Guinea (Gajdusek, 1977; Mead et al., 2003). The epidemic of kuru is thought to have 
originated when brain tissue from an individual with sporadic CJD was consumed in a 
ritualistic mortuary feast. Besides dietary exposure as route of transmission, 
inoculation with brain or other tissue via cuts or sores could also have occurred 
(Prusiner et al., 1982). The central clinical feature of kuru is progressive cerebellar 
ataxia but, in contrast to CJD, dementia is often absent (Alpers, 1987). The incubation 
period for kuru can exceed 50 years (Collinge et al., 2006) and it has been shown that 
PRNP codon 129 genotype has a prominent effect on both incubation periods and 
susceptibility. Individuals with MM genotype have the shortest incubation period (Lee 
et al., 2001a), followed by VV homozygotes. Most elderly survivors of the kuru 
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epidemic, who were exposed to mortuary feasts, are MV heterozygotes (Collinge et al., 
2006). The introduction of Christianity and subsequent prohibition of cannibalism 
resulted in virtual elimination of kuru, however some cases are still reported (Collinge, 
2001).  
1.3 Neuropathology and diagnosis of human prion 
diseases 
Neuropathology in prion diseases has remained the most important tool in 
obtaining a definitive diagnosis, and neuropathological research has contributed 
considerably to our current pathogenetic understanding of prion diseases. 
Gross inspection of prion infected brains does not reveal obvious 
abnormalities. However, some degree of brain atrophy is seen in occipital lobe, 
striatum, thalamus, and cerebellum based on preferential involvement of specific 
regions (Heidenhain et al., 1929; Brownell et al., 1965; Richardson and Masters, 
1995). In contrast to other degenerative diseases, the hippocampus is usually well 
preserved in prion diseases even in cases of severe brain atrophy (Budka, 2003). 
Furthermore, prominent cerebellar atrophy and degeneration of spinal tracks is seen in 
individuals with GSS disease (Hainfellner et al., 1995). 
Histopathological examination of brain tissue at post-mortem remains the best 
method of confirming prion disease diagnosis. Human prion diseases are characterised 
by a classical triad of spongiform change, neuronal loss, astro- and microglia-gliosis 
(Kubler et al., 2003). The spongiform change is the most specific feature of prion 
diseases and may be mild, moderate, or severe (Almer et al., 1999). Spongiosis is 
mostly seen in grey matter but cases involving white matter have also been described 
(Park et al., 1980). Spongiform change is observed as diffuse or focally clustered, 
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small, round vacuoles in the neurophil of the deep cortical layers, cerebella cortex or 
subcortical grey matter (Budka et al., 1997). Presence and distribution of spongiform 
change varies significantly between cases and disease subtypes. Spongiosis rarely 
presents in the brain stem and spinal cord, despite PrPSc accumulation at these sites 
(Almer et al., 1999). In sporadic CJD, the regional distribution of spongiform change 
was shown to depend upon codon 129 PRNP genotype PrPSc fragment sizes and 
glycotypes (Parchi et al., 1999; Hill et al., 2003). However, some prion diseases such 
as FFI, have equivocal, little, or no spongiform changes (Almer et al., 1999). In these 
cases, immunohistochemistry for PrP and PRNP genotyping have a decisive diagnostic 
role (Hainfellner et al., 1996). In prion diseases as a whole, PrPSc accumulates in the 
CNS and has become an important diagnostic marker (Almer et al., 1999). 
Immunohistochemistry for PrPSc has emerged as an indispensable adjunct to the 
neuropathological confirmation of prion diseases, especially in cases with equivocal 
histopathological changes (Budka, 2003). Current neuropathological criteria for 
diagnosis of human prion diseases are listed in Table 1-1.  
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Table 1-1 Neuropathological criteria for diagnosis of human prion diseases1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1From the World Health Organisation, http://www.WHO.int 
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1.4 Protein-only hypothesis of prion transmission 
The transmissible nature of prion diseases was first demonstrated in 1937, 
when a population of Scottish sheep developed scrapie after inoculation against a 
common virus with a formalin extract of brain tissues unknowingly derived from an 
animal with scrapie. As aforementioned, scrapie was subsequently transmitted 
experimentally to sheep, goats and mice (Cuillé and Chelle, 1936; Cuillé and Chelle, 
1939; Chandler, 1961). This was followed by the demonstration of transmission of 
human prion diseases such as kuru, CJD and GSS to monkeys (Gajdusek et al., 1966; 
Gibbs et al., 1968; Masters et al., 1981). The nature of the causative agent in prion 
diseases is the focus of much attention. Because of the unusually long incubation time 
of prion diseases, the agent was initially thought to be a slow virus (Cho, 1976). 
Further research, however, indicated that the agent differed substantially from viruses 
and other conventional agents. In 1967, Alper and colleagues reported that the disease 
agents were extremely resistant to treatments known to destroy nucleic acids, such as 
UV and ionising radiation (Alper et al., 1967). In addition, the minimum molecular 
weight necessary for infectivity (~ 2 x 105 Da) was sufficiently small as to exclude 
viruses and any other known types of infectious agents (Alper et al., 1966). In 1967, 
Griffith introduced, for the first time, the possibility that the material responsible for 
disease transmission might be a protein that had the surprising ability to replicate in the 
body (Griffith, 1967). This ‘protein-only’ hypothesis of transmissible spongiform 
propagation was subsequently extended by Stanley Prusiner and colleagues, who chose 
the name ‘prion’ for this new proteinaceous infectious particle (Prusiner, 1982). 
According to the protein-only hypothesis the infectious agent in human and animal 
spongiform encephalopathies is composed exclusively of a single kind of protein 
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molecule, designated PrPSc, without any encoding nucleic acid (Cohen et al., 1994; 
Prusiner, 1998b; Collinge, 2001). PrPSc is, in fact, a conformationally altered form of 
normal host encoded membrane glycoprotein called PrPC (Prusiner et al., 1991). These 
conformational changes are followed by alterations in other biochemical properties, 
such as protease resistance, solubility and ability to form large-order aggregates. PrPSc 
impresses its abnormal conformation on PrPC, thereby generating additional molecules 
of PrPSc in an autocatalytic reaction. This self-propagating change in protein 
conformation therefore outlined a novel pathogenic mechanism specific for prion 
diseases. 
A wealth of evidence has accumulated over the past decade supporting the 
protein-only hypothesis. As mentioned previousely, most familial cases of prion 
diseases are linked to mutation(s) in PRNP (Collinge, 2001; Prusiner, 1998b). These 
findings support the central role of PrP in disease pathogenesis; they also provide 
strong evidence in favour of the protein-only hypothesis by describing how a genetic 
disease could be propagated in an infectious way. Weissmann and colleagues showed 
that mice lacking the PrP gene were resistant to scrapie infection, neither developing 
clinical symptoms of scrapie nor allowing propagation of the disease (Bueler et al., 
1993). They also demonstrated successful stable propagation of infectivity in 
neuroblastoma cells infected with brain homogenate containing PrPSc (Rubenstein et 
al., 1984; Race et al., 1987). A further milestone in the prion protein-only hypothesis 
was the discovery that pure PrPC, and even recombinant PrP produced in E. coli can be 
converted into an abnormal conformer associated with disease. In their original system, 
Caughey and co-workers incubated radioactive PrPC with unlabelled PrPSc in a cell-
free system to show generation of radioactive PrPSc, as defined by its physical 
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properties (Kocisko et al., 1994). Interestingly, an increase in infectivity was not 
demonstrated in these experiments. A new in vitro conversion system called PMCA 
(protein misfolding cyclic amplification) has been shown to transform large quantities 
of PrPC using a very low amount of PrPSc (Saborio et al., 2001). This system confirms 
the crucial feature of the protein-only hypothesis: prion replication is a cyclical process 
and prion propagation is maintained with newly produced PrPSc triggering further 
misfolding.       
1.5 Prion gene structure 
The PrP gene (PRNP in human, Prnp in mouse and PrP gene in other species) 
appears to be a single gene in the genomes of rodents, human and ruminants (Oesch et 
al., 1985; Westaway and Prusiner, 1986; Liao et al., 1986; Goldmann et al., 1990). It 
is located on the short arm of chromosome 20 in human and in the same region on the 
mouse chromosome two (Robakis et al., 1986; Sparkes et al., 1986). The PrP gene is 
highly conserved and so far it has been analysed in more than 70 species (Schätzl et 
al., 1995; Wopfner et al., 1999; Strumbo et al., 2001; Suzuki et al., 2002; Rivera-Milla 
et al., 2003). Beside mammals, the PrP gene is also found in birds (Harris et al., 
1993b), marsupials (Windl et al., 1995), amphibians (Strumbo et al., 2001) and prion-
related proteins have been identified in organisms such as Drosophila, the nematode 
Caenorhabditis elegans and even yeast (Westaway and Prusiner, 1986; Rivera-Milla et 
al., 2003; Premzl et al., 2003). The first description of an almost full-length PrP 
complimentary DNA (cDNA) in hamster (Oesch et al., 1985) was followed by 
descriptions of partial PrP gene sequences of other rodents, human, ruminants and a 
carnivore (Basler et al., 1986; Locht et al., 1986; Kretzschmar et al., 1986b; Liao et 
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al., 1986; Liao et al., 1987; Goldmann et al., 1990; Puckett et al., 1991; Goldmann et 
al., 1991; Kretzschmar et al., 1992).  
The promoter region of the PrP gene has no TATA-Box but contains multiple 
copies of GC-rich repeats- a typical feature of house-keeping genes. These may acts as 
a binding for transcription factors SP-1 and AP-1 (McKnight and Tjian, 1986). All 
known PrP genes consist of one (e.g. in hamster, humans, wallaby) or two (e.g. in rat, 
mouse, bovine, sheep) short exons at the 5’- end and one bigger exon at 3’- end, the 
latter coding for the entire open reading frame (ORF) of the prion protein (Hsiao et al., 
1989; Gabriel et al., 1992; Schätzl et al., 1995). The ORF exon of the PrP gene is 
about 85 % of the total messenger RNA (mRNA) length and since the entire protein-
coding region is contained within one exon, the possibility of generating different 
proteins by alternative splicing of the mRNA is excluded (Basler et al., 1986; 
Westaway et al., 1994). PrP-mRNA is between 2.1 and 4 kb in length and codes for a 
protein of approximately 250 amino acids (aa) depending on species. In summary the 
PrP gene has a) a single exon for the entire PrP ORF and the entire 3’ untranslated 
mRNA region b) one or two small exons coding for 5’ leader sequence of PrP mRNA 
c) a promoter with regulatory elements and d) 1 or 2 introns separating the 5’ exon(s) 
and promoter from the OFR exon.  
1.6 Cell biology and life cycle of prion protein 
1.6.1 PrPC 
Structure and biosynthesis   
PrPC is a normal cell surface glycosyl phosphatidylinosiol GPI-anchored 
protein which has a broad, diverse and developmentally regulated expression pattern. 
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This 30-35 kDa protein is expressed in skeletal muscle, kidney, heart, secondary 
lymphoid organs, and the CNS (Kretzschmar et al., 1986a; Moser et al., 1995). Within 
CNS, high PrPC expression levels can be detected in synaptic membranes of neurons as 
well as astrocytes (Borchelt et al., 1994; Billette de Villemeur et al., 1995; Herms et 
al., 1999). In the periphery, PrPC expression is detected on lymphocytes and at high 
levels on follicular dendritic cells (FDC) (Aguzzi and Polymenidou, 2004). PrPC is 
encoded by the PrP gene (Section 1.5) and it consists of approximately 250 amino 
acids (Caughey et al., 1988; Diedrich et al., 1991). 
This protein has an N-terminal signal peptide, a series of five proline and 
glycine-rich octapeptide repeats, a highly conserved hydrophobic domain (HD) in the 
centre, and a C-terminal hydrophobic region with a signal for addition of a GPI anchor 
(Figure  1-1) (Harris, 1999). Mutations in the N-terminal segment of PrP have been 
identified as the cause of some human prion diseases, raising the possibility that it may 
be an important factor in some PrPSc conformations and/or disease manifestation 
(Mead, 2006b; Mead et al., 2006; Hill et al., 2006). The octapeptide repeat region has 
been suggested to be important in association of PrPC with copper and might be 
important in prion disease pathogenesis (Riek et al., 1998; Hosszu et al., 1999; 
Jackson et al., 2001). The internal HD (aa 112-135) of PrP was first described as a 
putative transmembrane domain (Lopez et al., 1990). Short peptides compromising 
amino acid residues 106-126 form fibrils in vitro (Tagliavini et al., 1993) and induce 
cell death in cultured cells (Brown et al., 1996; Forloni et al., 1993; Deli et al., 2000). 
Transgenic mice expressing PrP mutants lacking the HD (PrPΔHD) spontaneously 
develop a non-transmissible neurodegenerative disease (Baumann et al., 2007; Li et 
al., 2007b; Shmerling et al., 1998). Recently, it has been shown that the HD promotes 
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dimer formation of PrP, which is linked to a stress-protective activity (Rambold et al., 
2008).  
Structural studies of mature PrPC have demonstrated that mouse, human, cattle 
and Syrian hamster share common PrPC features including a long, flexible N-terminal 
tail (residues 23-128), three α-helices (residues 144-154, 175-193 and 200-219) and a 
two-stranded anti-parallel β-sheet (residues 128-131 and 161-164) that flanks the first 
α-helix. The carboxyl terminus of PrPC is stabilised by a disulfide bond linking helices 
two and three (Riek et al., 1997) (Figure  1-1). Nuclear magnetic resonance (NMR) 
spectroscopy of mouse PrP has shown that the second β-sheet is connected to the third 
α-helix by a large loop which is very flexible in most species, with the exception of elk 
and deer (Gossert et al., 2005). This structural peculiarity might be related to 
susceptibility of elk and deer to develop CWD. 
Like other membrane proteins, PrPC is synthesised in the rough endoplasmic 
reticulum (ER) and travels to the membrane through the Golgi apparatus. During its 
biosynthesis, PrPC undergoes several post-translational modifications, including 
cleavage of the amino (N)-terminal signal peptide, addition of N-linked 
oligosaccharide chains at two sites (asparagine residues 181 and 197), formation of a 
disulfide bond and attachment of a GPI anchor following cleavage of the C-terminal 
hydrophobic peptide, which facilitates its association with specific lipid membrane 
domains called ‘’rafts’’ (Harris, 2003; Campana et al., 2005). Studies on purified 
hamster PrPC and PrPSc have demonstrated that there are at least fifty different sugar 
chains capable of attaching to the glycosylation sites, with differences between the two 
isoforms (Endo et al., 1989; Somerville and Ritchie, 1990; Rudd et al., 1999; Rudd et 
al., 2001). Prion protein is always isolated as a mixture of three forms; non-, mono-, or 
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di-glycosylated (Haraguchi et al., 1989) and its final, processed form contain amino 
acids 23–231 from the original translation product of 254 amino acids.  
 
 
 
 
 
Figure 1-1 Schematic representation of the domain structure of murine PrP 
The N- and C-terminal signal peptides are cleaved from the translation product and a GPI 
anchor is attached to the C-terminal end of the protein. The molecule can be N-glycosylated 
twice, and a disulphide bond is built. The final product consists of 209 aa.  
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Localisation and trafficking  
To date, the precise cellular localisation of PrPC in neurons remains elusive. 
Most studies have shown that PrPC is predominantly present in detergent-resistant 
microdomains (DRM or lipid rafts) on the plasma membrane, in particular in the axon 
or synaptic membrane (Mironov et al., 2003). Other putative sites of PrPC localisation 
are: the ER (Sarnataro et al., 2004), the Golgi (Magalhaes et al., 2002), endolysosomes 
(Magalhaes et al., 2002), exsosomes (Fevrier et al., 2004), the plasma membrane 
(Sarnataro et al., 2002), clathrin coated pits (Sunyach et al., 2003), caveolae (Peters et 
al., 2003), lipid rafts (Vey et al., 1996; Kaneko et al., 1997a), and the cytosol 
(Mironov et al., 2003). Although PrPC is known as a cell-surface GPI-anchored 
protein, it does not remain on the cell surface; it constitutively cycles between the 
plasma membrane and an endocytic compartment from which most of the PrPC is 
recycled back to the cell surface (Shyng et al., 1993). More than 90 % of surface PrPC 
is internalised within two minutes and returned to the cell surface within six minutes 
(Sunyach et al., 2003). During this process, PrPC is cleaved near residue 110, probably 
in an acidic cellular compartment (Harris et al., 1993a). The biological role of PrPC 
internalisation is unknown, but studies have demonstrated that internalisation is 
induced by copper and zinc ions and thus could have a physiological function in 
chelating extracellular copper ions or in modulating the signal activity of the protein 
(Pauly and Harris, 1998; Lee et al., 2001b; Watt and Hooper, 2003). Understanding the 
endocytic itinerary of PrPC is fundamental, since data in the literature indicate that both 
general inhibition of endocytosis (Grigoriev et al., 1999; Godsave et al., 2008) and/or 
a direct modification of the internalization route of PrPC, by replacing the GPI anchor 
with a transmembrane sequence containing a coated pits localization motif (Fournier et 
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al., 2000) affect both the infection and the conversion processes (Caughey et al., 1991; 
Borchelt et al., 1992; Beranger et al., 2002; Veith et al., 2008). 
The mechanism of PrPC uptake is currently debated and dynamin, clathrin-
coated pits, rafts and caveolae appear to be involved (Figure  1-2). Immunogold 
localisation of PrPC in clathrin coated pits and vesicles suggest that PrPC internalises 
via clatrin-mediated endocytosis (Sunyach et al., 2003; Sarnataro et al., 2009). 
Magalhaes and co-workers also demonstrated that cells transfected with a dominant 
negative mutant of dynamin I (K44A), which blocks fission of invaginated coated pits 
from the plasma membrane, inhibited PrPC endocytosis suggesting that PrPC is 
internalised via a dynamin dependent pathway (Magalhaes et al., 2002). A basic amino 
acid motif in the N-terminal half of PrPC polypeptide chain was shown to be essential 
for efficient clathrin-mediated endocytosis as deletion within this region diminishes 
internalisation of PrPC (Sunyach et al., 2003). This finding led to the proposal that 
PrPC binds through this N-terminal region to a ‘PrPC receptor’, a transmembrane 
protein, that has a coated-pit localisation signal causing it to enter the clathrin-
dependent internalisation pathway. Several candidate proteins have been proposed as 
PrP-interacting partners including 37-kDa laminin receptor precursor (Lee et al., 
2003). It is believed that this receptor can only account for 25-50 % of all protein 
internalisation (Section 1.6.1, ‘PrPC partners in endocytosis’) (Lee et al., 2003). Parkyn 
and colleagues also showed that low-density lipoprotein receptor-related protein 1 
(LRP1), which binds to multiple ligands through basic motifs, associates with PrPC 
during its endocytosis and is functionally required for this process (Parkyn et al., 
2008).  
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In Chinese hamster ovary cells, which express caveolin-1, PrPC is absent in 
clathrin-coated pits and vesicles, instead being localised in caveolae at the trans-Golgi 
network, the plasma membrane and in interconnecting chains of endocytic caveolae 
(Peters et al., 2003). To date, however, no caveolae have been identified in adult 
mammalian neuronal cells, suggesting this pathway is unlikely to be relevant to prion 
trafficking in neurons (Morris et al., 2006). 
An alternative hypothesis regarding PrPC internalisation involves lipid rafts, 
also called caveolae-like domains (CLDs) (Figure  1-2), which have similar lipid 
composition to caveolae but lack cavealin-1 (Orlandi et al., 1998; Sabharanjak et al., 
2002; Deinhardt et al., 2006). Studies have suggested that PrPC internalisation can be 
raft-dependent and/or raft-mediated depending on the cell type. Sarnataro and 
colleagues demonstrated that PrPC is internalised in Fischer rat thyroid (FRT) cells via 
raft-mediated endocytosis. Cholesterol depletion and inactivation of cell division cycle 
42 (Cdc-42) in FRT cells impaired uptake of PrPC, suggesting a role for lipid rafts in 
PrPC endocytosis. In the same cells, Inhibition of clathrin-dependent endocytosis by 
knock down of clathrin and by the expression of dominant negative epidermal growth 
factor receptor substrate 15 (Eps15) and Dynamin 2 mutants impaired PrPC 
internalisation suggesting that a clathrin-dependent pathway was also participating in 
PrPC endocytosis as well as lipid rafts (Sarnataro et al., 2009). Co-
immunoprecipitation of PrPC with clathrin and detergent-insoluble microdomains 
during internalization indicates that rafts and clathrin cooperate in the internalization of 
PrPC (Sarnataro et al., 2009). Moreover, a raft-mediated mechanism for PrPC 
internalization has been described in primary neurons and GT-1 cells (Schatzl et al., 
1997; Galvan et al., 2005; Sarnataro et al., 2009). In contrast, Sunyach et al. and other 
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researchers have reported that PrPC in N2a cells leaves lipid rafts to enter non-raft 
membrane from where it is internalized by the classical clathrin-mediated pathway 
(Sunyach et al., 2003; Morris et al., 2006). Recent work by Wadia and colleagues 
reported that recombinant PrP internalisation in N2a neuroblastoma cells is sensitive to 
cholesterol depleting agents and macropinocytosis inhibitors. This suggests that raft-
dependent macropincytosis may also play a role in PrP uptake (Wadia et al., 2008). 
In summary, the above studies support the hypothesis that PrPC can be 
internalized by different mechanisms in different cell types, presumably reflecting 
differences in the expression of partner proteins that determine the trafficking of PrPC 
that lacks a cytoplasmic domain into which endocytic trafficking motifs could be 
embedded. On N2a cells, PrPC is endocytosed constitutively by means of coated pits 
(Shyng et al., 1994; sunyach et al., 2003); whereas cells that do not endogenously 
express PrPC but transfected with a vector encoding PrPC can require Cu2+ to initiate 
coated pit endocytosis (Taylor and Hooper, 2007) or else slowly internalise PrPC by 
non-coated pit mechanisms (Peter et al., 2003). The discovery of multiple endocytic 
pathways of PrPC could be crucial in determining the ability of different strains to 
infect, replicate and induce cell death. Moreover, entry through distinct endocytic 
pathways in response to different stimuli could allow PrPC to exert both the 
neuroprotective and neurodegenerative functions with which it has previously been 
associated. 
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Figure 1-2 Pathways of PrPC internalisation2 
Internalization of PrPC molecules can occur throughout many different pathways: the classical, 
clathrin-mediated pathway (1); the clathrin-independent raft-dependent pathway (2); the raft-
mediated clathrin-dependent route (3) and caveolae (4). At the cell surface, PrPC is localized in 
DRM. As PrPC remains in these domains during its internalization a classical clathrin-
dependent pathway (1) seems to be excluded. Conversely, PrPC can undertake a rafts 
dependent pathway (2) and/or rafts might promote its recruitment to clathrin domains inducing 
its internalization (3). PrPC resides in caveolae at the plasma membrane but is not internalized 
via the caveolae pathway (4). 
 
 
2Reprinted from PLoS one, Vol 4, Sarnataro et al., Lipid Rafts and Clathrin Cooperate in the 
Internalization of PrPC in Epithelial FRT Cells, 2009, pp 5829-5844. 
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PrPC partners in endocytosis 
Different proteins have been proposed to bind to and act as endocytic partners 
of PrPC. The basic residues (NH2KKRPKP-) of the PrPC N-terminal domain of PrPC, 
which is necessary for coated pit endocytosis, have been identified as a major heparin 
sulphate/glycosoaminoglycan binding site (Sunyach et al., 2003; Pan et al., 2002; 
Warner et al., 2002). These residues also serve as binding motifs for extracellular 
cargos by binding to low density lipoprotein (LDL) receptor-related protein (LRP1). 
Recently, Parkyn et al. showed that LRP1 associates with endogenous PrPC on the 
neuronal cell surface leading to PrPC internalisation (Parkyn et al., 2008). In addition, 
LRP1 binds to PrPC to facilitate its trafficking to the neuronal surface. Taylor and 
colleagues demonstrated that LRP1 is required for Cu2+-dependent endocytosis of 
exogenous PrPC in SH-SY5Y cells (Taylor et al., 2005). Cu2+ draws PrPC from lipid 
rafts prior to its endocytosis (Taylor and Hooper, 2007). Non-integrin laminin receptor 
precursor (LRP; 37 kDa) and the mature laminin receptor (LR; 67 kDa) have also been 
reported to bind to recombinant PrP, suggesting a role as cell-surface receptors for 
PrPC (Rieger et al., 1997; Gauczynski et al., 2001; Hundt et al., 2001), further research 
is required to assess whether these findings are also applicable to endogenously 
expressed PrPC.   
PrPC function 
The amino acid sequence of mammalian PrPC is highly conserved between 
different species and suggests an important physiological role. Studies have 
demonstrated that both embryonic PrPC-null and adult-onset PrPC knock-out mice 
show no clear phenotypes (Bueler et al., 1992; Mallucci et al., 2002). Importantly, 
PrPC knock-out mice are completely resistant to prion disease following inoculation 
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and do not replicate prions (Bueler et al., 1993). However, embryonic PrPC-null mice 
have been shown to develop abnormalities in synaptic physiology, circadian rhythm 
and sleep patterns (Collinge et al., 1994; Tobler et al., 1996). Furthermore, PrPC 
knock-out mice display a reduction in the slow after-hyperpolarisations evoked by 
trains of action potentials (Tobler et al., 1996). 
PrPC has been implicated in a wide range of cellular functions: transport and 
metabolism of copper and/or zinc ions (Watt and Hooper, 2003; Brown, 2001), 
protection from oxidative stress (Brown, 2001), cellular signalling (Chiarini et al., 
2002), membrane excitability (Mallucci et al., 2002), synaptic transmission (Collinge 
et al., 1994), neuritogenesis (Graner et al., 2000), self-renewal of hematopoietic stem 
cells (Zhang et al., 2006), differentiation of neuronal stem cells (Steele et al., 2006)  
and apoptosis (Solforosi et al., 2004). PrPC can achieve these functions through its 
interaction with different partners, ligands and/or effectors, such as laminin, the 
chaperone BiP, glial fibrillary acidic protein (GFAP) and Bcl-2, at different locations 
in the cell (Lee et al., 2003; Campana et al., 2005). Recently, links between Alzeimer’s 
disease (AD) and prion diseases have been proposed as PrPC was shown to inhibit β-
secretase cleavage of amyloid precursor protein (APP) and reduce Aβ formation 
(Parkin et al., 2007). As above mentioned, endogenous PrPC is reported to associate 
with LRP1 on the cell surface and facilitate its internalisation (Parkyn et al., 2008). 
Furthermore, the same study showed that PrPC binds to LRP1 in biosynthetic 
compartments to enable its trafficking to the neuronal surface. It remains unclear 
whether prion disease pathology arises from a loss of normal PrPC function or a toxic 
gain of function by PrPSc (Campana et al., 2005), or more likely, a combination of 
both. 
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1.6.2 PrPSc  
Structural and biochemical properties 
It has been indicated that PrPC and PrPSc are chemically identical; however, the 
biophysical features of PrPSc are significantly different from PrPC in respect to 
solubility, structure and stability (Riesner, 2003). PrPC has a high α-helix content 
(about 42 %) and relatively little β-sheet (about 3 %), whereas PrPSc is composed of 
around 30 % α-helices and 45 % β-sheet (Gasset et al., 1993; Pan et al., 1993; Pergami 
et al., 1996). Unlike PrPC, PrPSc is detergent insoluble (Riesner, 2003) preventing 
detailed structural analysis by NMR or X-ray analysis. Electron microscopy and 
spectroscopic analysis of 2D crystalline-like arrays of PrPSc led to the development of 
an in vitro PrPSc model (Pan et al., 1993; Wille et al., 2002). In this model, the α-
helical N-terminus of PrPSc is located on the inner part of the hexagonal unit, helices 
two and three face outwards and glycosyl-groups point towards the inter-hexagonal 
space. This structure does not offer a definitive description of PrPSc, but remains the 
best model described to date. 
 PrPC is almost completely degraded with proteinase K (PK). In contrast, only 
the N-terminal domain of PrPSc (up to aa 23-90) is digested with PK (Prusiner et al., 
1984; Oesch et al., 1985) leaving a well defined resistant core of apparent mass 27-30 
kDa. This structure is termed PrP27-30 and is known to be fully infectious (Turk et al., 
1988) (Figure  1-3 A). Therefore, there is a clear biochemical distinction between the 
two isoforms of the prion protein (PrPC and PrPSc). Western blot analysis of PrP 
following SDS-PAGE shows a characteristic three band pattern (i.e. without, with one 
and with two glycosyl groups). On PK digestion of uninfected samples, the triplet 
pattern disappears completely. In samples containing PrPSc bands remain at a similar 
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intensity but shift to lower molecular weights (Riesner, 2003) (Figure  1-3 B). The 
protease-resistant core of PrPSc re-arranges into amyloid rods, which stain with Congo 
red and show green-gold birefringence, typical of amyloids (Prusiner et al., 1983). As 
well as PK, PrPSc is also resistant to the protease thermolysin used for diagnosis of 
animal prion diseases (Owen et al., 2007). This thermostable protease cleaves at the 
hydrophobic residues Leu, Ile, Phe, Val, Ala and Met. These residues are absent in the 
protease accessible N-terminal region of PrPSc (Owen et al., 2007). Thus, PrPc is fully 
digested with thermolysin, whilst full-length PrPSc remains resistant. This contrasts 
with PK digestion where an N-terminally truncated PrPSc species is produced, PrP27–30. 
In general, routine tests presently available for BSE and scrapie are based on the PK 
resistance of PrP27–30. Recently, however, thermolysin has been used in the diagnosis 
of prion diseases such as ovine scrapie, BSE and variant CJD and produced 
comparable sensitivity to assays using proteinase K digestion (Owen et al., 2007). 
In addition to PK and thermolysin, cathepsin D is also reported to digest 
sequences in PrP. The protease targets the C-terminal end of PrPSc, liberating the GPI 
anchor, with no effect on amplification of PrPSc or prion infectivity (Lewis et al., 
2006). Chesebro et al., generated a transgenic mouse line that expresses GPI-
anchorless secreted PrP. When infected with the Rocky Mountain laboratory (RML) 
strain of mouse prions, the mice produce widespread deposits of PrPSc without 
evidence of a clinical syndrome (Chesebro et al., 2005), thereby suggesting that the 
GPI anchor is not a prerequisite for prion propagation. Unlike PrPC, which can be 
readily cleaved from membranes by treatment with phosphatidylinositol-specific 
phospholipase C (PIPLC) (Stahl et al., 1987), PrPSc is resistant to such treatment 
(Caughey et al., 1990; Borchelt et al., 1993). This suggests that the conversion of PrPC 
Introduction 
48  
 
to PrPSc involves a conformational change (Pan et al., 1993; Cohen et al., 1994) rather 
than a covalent modification (Stahl et al., 1993). 
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Figure 1-3 Proteinase K resistance of PrP3 
(A) ‘Full-length’ and N-terminal truncated PrP are presented in this panel. Only the N-terminal 
domain of PrPSc is digested with proteinase K (PK), leaving resistant core of apparent mass 27-
30 kDa. PrP27-30 is known to be fully infectious. (B) A denaturing polyacrylamide gel 
electrophoresis with antibody staining shows characteristic three band pattern of prion protein 
(di-glycosylated, mono-glycosylated and un-glycosylated). Note the triplet pattern disappears 
completely in non-infected sample (PrPC) after PK digestion. However, in PK-digested 
samples containing PrPSc the triplet bands remain similar but shifts to lower molecular weights.  
 
 
 
 
3Rienser D, Biochemistry and structure of PrPC and PrPSc, Br Med Bull, 2003, 66: 21-33, by 
permission of Oxford University Press. 
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Cellular localisation of PrPSc 
Investigation of the sub-cellular distribution of PrPSc remains challenging due 
to the lack of antibodies specific to PrPSc. Early studies reported that the majority of 
PrPSc is intracellular, mostly co-localised with Golgi markers and sequestered within 
lysosomes of scrapie-infected N2a (ScN2a) cells (Caughey et al., 1991; McKinley et 
al., 1991b; Borchelt et al., 1992). Vey et al., demonstrated accumulation of PrPSc in 
CLDs derived from the plasma membrane in ScN2a cells (Vey et al., 1996). In prion-
infected brains, PrPSc accumulates at the plasma membrane (Caughey and Raymond, 
1991) and occasionally in structures which contain the cation-independent mannose 6-
phosphate receptor, ubiquitin-protein conjugates, β-glucuronidase, and cathepsin B, 
termed late endosomal/lysosomal compartments (Arnold et al., 1995; Veith et al., 
2008). More recent reports have described the accumulation of PrPSc in various cellular 
compartments: the perinuclear Golgi region of neurons in scrapie-infected transgenic 
mice (Barmada and Harris, 2005); the late endosomal compartments in infected GT1-7 
and N2a cells (Pimpinelli et al., 2005) and the cell surface and early endocytic/ 
recycling vesicles in hippocampal neurons (Godsave et al., 2008). In SN56 cells and 
hamster cortical neurons, exogenous Alexa-labelled PrPSc internalised into vesicles 
which stain positive for late endosomal/lysosomal markers (Magalhaes et al., 2002). 
Mange et al. showed accumulation of PrPSc in the nuclei of prion-infected N2a cells 
(Mange et al., 2004) by demonstrating that nuclear PrP interacts with chromatin in 
vivo. Several in vitro studies have shown accumulation of PrPSc-like conformers (prion 
protein conformers that are not necessarily infective) in the ER (Lehmann and Harris, 
1997; Ivanova et al., 2001), Golgi (Ivanova et al., 2001) and plasma membrane of 
infected cells (Ivanova et al., 2001). Under certain conditions, PrPSc-like conformers 
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have been reported to accumulate in the cytosol (Ma and Lindquist, 2002) and there is 
also evidence for cytosolic PrPSc-containing aggresomes in prion-infected cells 
following proteasome inhibition (Kristiansen et al., 2005). The tentative conclusion 
from these studies is that PrPSc is widely distributed within infected cells, although 
improved methods for in-situ detection of PrPSc are clearly needed to establish the 
relative proportion of the protein in these cellular sites. 
PrPSc trafficking 
In contrast to PrPC, the trafficking of PrPSc is less well described. This is due to 
the fact that the site of conformational conversion of PrPC to PrPSc has not been 
identified. Several studies have suggested that the PrP conversion could take place at 
the plasma membrane, where the first contact between endogenous PrPC and 
exogenous PrPSc is likely to occur (Prado et al., 2004). Alternatively, the conversion 
may take place immediately after internalisation into the endolysosomal compartment 
(Borchelt et al., 1992). 
Several studies indicate that PrPSc production is a post-translational event that 
occurs after PrPC reaches the plasma membrane (Caughey and Raymond, 1991; 
Borchelt et al., 1992; Taraboulos et al., 1992). PrPSc formation can be prevented by 
exposure to monoclonal anti-PrP antibodies and PIPLC digestion which removes PrPC 
from the cell surface (Enari et al., 2001). Taraboulos et al. found that treatment of 
ScN2a and scrapie-infected hamster brain (ScHaB) cells with brefeldin A (BFA) 
inhibits PrPSc synthesis by preventing PrPC exit from the ER-Golgi (Taraboulos et al., 
1992). Thus, transport of PrPC to the plasma membrane is important in production of 
PrPSc.  
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In addition to the plasma membrane, the endocytic pathway has been 
implicated in the conversion of PrPC to PrPSc (Borchelt et al., 1992; Taraboulos et al., 
1992). In fact, blocking the endocytosis and internalisation of PrPC by lowering the 
temperature is known to inhibit PrPSc formation (Borchelt et al., 1992). Biochemical 
analysis of PrPSc has revealed N-terminal truncation by endogenous proteases in 
lysosomes (Caughey et al., 1991; Borchelt et al., 1992). These results imply that the 
conversion of PrPC to the protease-resistant state occurs in the plasma membrane or 
along an endocytic pathway, before PrPSc is exposed to proteases within endo-
lysosomal compartments. Impairment of plasma membrane recycling through 
expression of dominant-negative mutant Rab4 (GDP-bound Rab4S22N mutant) in 
ScN2a cells results in an accumulation of PrPSc, suggesting that PrPSc formation occurs 
within an intracellular compartment (Beranger et al., 2002). A recent study by 
Marijanovic and colleagues suggested that prion conversion occurs in the endosomal 
recycling compartments (ERC), rather than early or late endosomes (Marijanovic et 
al., 2009). Another recent study by Wadia et al. showed that inhibition of 
macropinocytosis in N2a cells was sufficient to prevent conversion of PrPC to PrPSc 
indicating that pathogenic amplification of PrPSc may occur in macropinosomes 
(Wadia et al., 2008).  
Several lines of evidence suggest a role for rafts in the formation of PrPSc in 
scrapie infected cultured cells: a) both PrPC and PrPSc are found in rafts (Taraboulos et 
al., 1995; Vey et al., 1996; Naslavsky et al., 1997; Baron et al., 2002; Botto et al., 
2004); b) cholesterol depletion diminishes PrPC degradation and PrPSc formation in 
ScN2a cells (Taraboulos et al., 1995); c) recombinant transmembrane forms of PrPC 
which are not directed to rafts do not seed PrPSc formation in ScN2a cells (Taraboulos 
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et al., 1995; Kaneko et al., 1997b) and (d) treatment with pharmacological compounds 
disrupting rafts inhibits PrPSc synthesis (Taraboulos et al., 1990a; Marella et al., 2002). 
Thus, membrane lipid rafts are a clear candidate site for PrPSc conversion in cells.  
Once PrPSc forms, it appears to accumulate on the cell surface, in intracellular 
vesicles such as lysosomes or autophagosomes, or in extracellular deposits (Jeffrey and 
Gonzalez, 2004). Internalised PrPSc can undergo retrograde transport to the Golgi 
apparatus and/or the ER, thereby disrupting the biogenesis of newly formed PrPC and 
triggering the production of PrPSc from PrPC precursor (Campana et al., 2005). 
Stimulating retrograde transport of PrPc in the ER through over-expression of the 
constitutively active, small GTPase Rab6a leads to increased production of PrPSc in 
infected cells (Beranger et al., 2002). This suggests that the ER might have a 
significant role in the formation and production of PrPSc. Several studies have 
suggested that the presence of a mutation in the PrP gene favours spontaneous 
conversion of PrPC to PrPSc in the ER, without contact with exogenous prions (Harris, 
2003). Thus, it appears that the ER has two possible roles in the conversion of PrPC to 
PrPSc. Firstly, in inherited prion diseases, the ER could be directly involved in mutant 
PrPC conversion to PrPSc (Harris, 2003). Secondly, in infectious prion diseases, the ER 
could act as a site of amplification for PrPSc produced elsewhere in the cell (Campana 
et al., 2005). 
Various mechanisms have been proposed to account for the spread of PrPSc 
infectivity between cells. PrPSc may transfer from one cell to another in exosomes 
secreted upon fusion of multivesicular endosomes with the plasma membrane. Studies 
have shown that exosomes bearing PrPSc are infectious (Fevrier et al., 2004). 
Alternatively, the spread of prions may be mediated by direct cell-surface contact 
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between PrPC on uninfected neurons and PrPSc on infected neurons (Kanu et al., 2002). 
This hypothesis is supported by reports of infection by contact with contaminated 
stainless steel wires (Flechsig et al., 2001). Uninfected neurons can also incorporate 
PrPSc from the extracellular milieu using heparin sulphate proteoglycan (HSPG) and 
LRP/LR, distributing it along neural pathways and initiating propagation of new PrPSc 
(Morris et al., 2006). Recent evidence suggests that prions can be transferred from 
immune cells to neurons and between neurons via tunnelling nanotubes (TNTs) 
(Gousset et al., 2009). TNTs connect dendritic cells (DC) to primary hippocampal 
neurons and cells of CNS. These conduits permit the intracellular transfer of 
endogenous and exogenous PrPSc within neurons in the CNS and from the peripheral 
site of entry to the peripheral nervous system (Gousset et al., 2009). 
1.7 Mechanisms of prion conversion 
PrPC is known to be essential for production and propagation of PrPSc since PrP 
knock-out mice can neither be infected nor transmit the disease (Bueler et al., 1993). 
Prion conversion from PrPC to PrPSc is characterised by the formation of a large β-
sheet structure from two shorter β-sheets and the first α-helix. The precise mechanisms 
underlying structural conversion remain unclear; however both the α-helices and 
intramolecular disulfide bond must be preserved for PrPSc infectivity (Hornemann et 
al., 1997; Prusiner, 1998b; Wille et al., 2002). 
The current model of prion propagation proposes that PrP fluctuates between a 
native state, PrPC, and a series of minor conformations, a subset of which can self-
associate to form a stable supra-molecular structure, PrPSc, composed of misfolded PrP 
monomers. Studies using a recombinant protein mimetic of PrPSc, β-PrP, have shown 
that β-PrP aggregation occurs until it reaches a critical size at which a stable ‘seed’ 
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structure is formed. Following this, the recruitment of unfolded PrP and/or β-PrP 
monomers can lead to an explosive, auto-catalytic formation of PrPSc (Brown et al., 
1990; Jarrett and Lansbury, 1993; Caughey et al., 1995). Such a mechanism could 
explain all three aetiologies (sporadic, inherited and acquired) of human prion disease. 
Initiation of this pathogenic self-propagating conversion reaction, with accumulation 
of aggregated β-PrP, may be induced following exposure to a ‘seed’ of aggregated β-
PrP following prion inoculation, as a rare stochastic conformational change, or as an 
inevitable result of expression of a pathogenic mutant PrPC form, which is prone to 
form β-PrP (Collinge, 2005). Currently, it is unacquainted whether certain cofactors 
are needed for each or some steps in the PrPSc or amyloid formation, respectively. 
1.8 Prion strains and species barriers  
The protein-only hypothesis postulates that both pathogenic and infectious 
PrPSc consists only of protein and is derived from the normal prion protein isoform, 
PrPC (Prusiner, 1982). There are several lines of evidence that support the protein-only 
hypothesis (Section  1.4). The existence of distinct strains or isolates in the absence of 
informational nucleic acid has proved challenging to accommodate within this model. 
Mammalian prion strains are classically defined by their different incubation times and 
neuropathological profiles in the CNS. Differences in glycosylation pattern and 
degrees of PK-resistant resolved by SDS-PAGE (Collinge et al., 1996; Safar et al., 
1998) support the notion of different PrPSc strains (Telling et al., 1996b; Scott et al., 
1997).  
Prion strains can be serially propagated in inbred mice of the same genotype; 
therefore, they cannot be encoded by differences in PrP primary structure. Moreover, 
strains can be re-isolated in mice after passage in intermediate species with different 
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PrP primary structures (Bruce et al., 1994). Serial propagation of two distinct strains of 
TME prions (hyper (HY) and drowsy (DY)) in hamsters provided support for the idea 
that strain specificity is encoded by PrP structure alone. These strains showed different 
physicochemical properties of PrPSc (Bessen and Marsh, 1992; Bessen and Marsh, 
1994). For example, HY and DY showed strain-specific migration patterns of PrPSc on 
polyacrylamide gels following limited proteolysis. Several human PrPSc types have 
also been identified and are associated with different CJD phenotypes (Collinge et al., 
1996; Parchi et al., 1996). These types are distinguished diagnostically by the different 
fragment sizes of PK-treated samples on western blot. In summary, different prion 
strains seem to originate from different three-dimensional conformations of PrPSc, and 
different properties of the prion strains are likely to be encoded in different folds of 
PrPSc. 
 Infectious PrPSc has the capacity to infect across a range of species. This 
infectivity is restricted by a ‘species barrier’ (Pattison, 1965). When passaging prions 
from species A to species B, those that develop the disease have longer and more 
variable incubation periods than affected animals of the same species. Additionally, 
species B show an altered neuropathological distribution (Schatzl, 2003). During serial 
passages, the incubation period shortens in the foreign host and stable pathological 
properties are acquired (Kimberlin and Walker, 1979; Laurent, 1998). It has been 
hypothesised that the species barrier, and thereby transmission of prion diseases, is 
encoded by the PrP primary sequence (Scott et al., 1989; Scott et al., 1992; Scott et al., 
1993; Telling et al., 1994; Priola et al., 2001). This hypothesis is supported by studies 
showing that transgenic mice expressing hamster PrP were, unlike wild type mice, 
highly susceptible to infection with Sc237 hamster prions (Prusiner et al., 1990). 
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Another line of evidence supporting the above hypothesis is that acquired or sporadic 
CJD mostly occurs in individuals homozygous at polymorphic residue 129 of PrP 
(Collinge et al., 1991b; Palmer et al., 1991; Collinge, 2001). Furthermore, in 
heterologous systems in which two different strains of prion protein are co-expressed, 
only the prion protein homologous to the pathogenic isoform is converted into the PK-
resistant, pathogenic form. Studies with chimeric prion protein revealed that a defined 
sequence region (aa 112-187) is responsible for sequence specificity (Scott et al., 
1992; Priola et al., 1995; Priola and Chesebro, 1995). 
Human prion disease transmission studies have revealed an interesting 
connection between species barrier and prion strains. Sporadic CJD prions can be 
transmitted efficiently to transgenic mice expressing human PrPC, but encounter a 
significant barrier on transmission to wild type mice (Collinge et al., 1995; Hill et al., 
1997). Conversely, variant CJD prions transmit readily to wild type mice, whereas 
transmission to transgenic mice expressing human PrPC is relatively inefficient (Hill et 
al., 1997). Therefore, since PrP molecules with identical amino acid sequences, but 
different strains have distinct patterns of transmissibility, the term ‘transmission 
barrier’ might be more appropriate than ‘species barrier’ (Collinge, 1999). 
1.9 Prion mediated neurotoxicity 
Despite extensive knowledge regarding the nature of the prion disease 
infectious agent, mechanisms of replication and associated neuropathology, the 
molecular pathways of neurotoxicity remains unclear. The ultimate cause of cell death 
mediated by prions appears to be caused via apoptosis; however the underlying 
mechanisms are still poorly understood. This section summarises current knowledge of 
prion mediated neurotoxicity. 
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1.9.1 PrPSc as the neurotoxic species  
It has been proposed that prion mediated neurotoxicity may result from a toxic 
gain of function of PrPSc. Both full length PrPSc (Hetz et al., 2003) and shorter PrP 
peptides are toxic to primary neuronal cultures in vitro (Forloni et al., 1993), however 
their relevance to in vivo pathogenesis is under debate. For example, primary neuronal 
cultures underwent cell death when exposed to a low concentration of PrP106-126 
(Forloni et al., 1993). Importantly, the PrP106-126 peptide has never been detected in 
vivo. Full length PrPSc has been shown to induce apoptosis in vitro in neuroblastoma 
cells with the induction of ER-stress and activation of caspase-12 (Hetz et al., 2003). 
In addition, there is evidence that exogenous PrPSc can induce the release of 
chemokines such as RANTES (regulated upon activation, normal T cell expressed, and 
secreted) that recruit microglia, which in turn could secrete neurotoxic factors (Marella 
et al., 2004). Kristiansen et al., demonstrated that PrPSc directly inhibits proteasome 
activity in vitro (Kristiansen et al., 2007). Furthermore, reduced proteasome activity 
was detected in prion infected cells and mice. These results suggest that PrPSc may 
access the cytosol of infected cells and inhibit the proteasome to cause neuronal death 
during disease pathogenesis through many different mechanisms, as the proteasome is 
involved in transcriptional regulation, cell cycle control, and control of apoptosis 
(Goldberg, 2003). 
Whilst purified PrPSc is known to be neurotoxic at very low concentrations, several 
observations suggest this model is likely to be an oversimplification. For example, 
Prnp knockout mice do not show characteristic neurodegeneration, despite PrPSc 
deposition (Mallucci et al., 2003). Selective postnatal knockout of Prnp in neurons can 
stop or even reverse damage caused by pre-existing PrPSc and newly generated PrPSc 
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from adjacent non-neuronal cells (Mallucci et al., 2003). Another line of evidence 
against direct PrPSc toxicity comes from cases of CJD, where no direct correlation 
between PrPSc plaques and neuronal loss has been demonstrated (Parchi et al., 1996) 
Indeed, PrPSc is not detectable in some cases of fatal familial insomnia (Gambetti et 
al., 1995), in lethal scrapie-like diseases in mice over-expressing mutant PrP 
transgenes (Telling et al., 1996a) and wild type mice inoculated with BSE (Lasmézas 
et al., 1997; Manuelidis et al., 1997). Furthermore, prion-infected transgenic mice 
expressing PrPC without a GPI anchor produce infectious prions, accumulate 
extracellular PrP amyloid plaques, but do not succumb to disease (Chesebro et al., 
2005). 
These observations have led to two theories of PrPSc toxicity, which are not 
mutually exclusive. Neurotoxicity of PrPSc may be linked to its propagation in 
neuronal cells and is therefore dependent on the expression of PrPC. Alternatively; 
PrPSc may trigger a deadly signal through a PrPC dependent signalling pathway 
(Section 1.9.2). 
1.9.2 Gain and loss of PrPC function 
Although the physiological activity of PrPC remains unknown (Section 1.6.1, 
‘PrPC function’), it is possible that the corruption or subversion of the normal functions 
of PrPC lead to the characteristic pathology seen in prion disease. Several experimental 
results support the idea that PrPC functions as a cytoprotective molecule (Roucou and 
LeBlanc, 2005). For example, PrPC over-expression has been shown to rescues 
cultured neurons, some mammalian cell lines, and yeast (Li and Harris, 2005) from 
several kinds of death-inducing stimuli. Endogenous PrP is known to protect cultured 
neurons against oxidative stress and brain tissue against ischemia or trauma in vivo 
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(Harris and True, 2006). In a recently published study, PrP was also found to be 
important for self-renewal of hematopoietic stem cells during serial transplantation, a 
phenomenon that may depend on an antiapoptotic activity of the protein (Zhang et al., 
2006). Finally, co-expression of wild type PrP in Tg (PrPΔ32-134) mice, which 
express an N-terminally truncated form of PrP, completely abrogates their 
neurodegenerative phenotype (Behrens and Aguzzi, 2002). Moreover, N-terminally 
truncated PrPC mutants have been shown to activate both Bax-dependent and 
independent neurotoxic pathways, suggesting that this region could be crucial for the 
putative neuroprotective function of PrPC (Li et al., 2007a). Therefore, if the normal 
function of PrPC is neuroprotection, then loss of this function by conversion to PrPSc 
might contribute to prion-induced neurodegeneration. The loss of function of PrPC is 
unlikely to be the sole cause of pathology because neither embryonic nor adult knock-
out of PrPC results in neurodegeneration (Bueler et al., 1992; Manson et al., 1994; 
Mallucci et al., 2002). 
Another possibility is that PrPC may gain a toxic function due to either the 
presence of PrPSc or its interaction with it (Caughey and Baron, 2006). Several lines of 
evidence have shown that PrPC acts as a signal transducer or mediator of neurotoxicity 
(Soto, 2008) (Figure  1-4 A). This concept has been supported by several experimental 
situations in which expression of membrane anchored PrPC is essential for the 
development of neurodegeneration or toxicity in prion diseases (Solforosi et al., 2004). 
First, Prnp0/0 neurons are resistant to the pathological effects of PrPSc supplied from 
grafted brain tissue (Brandner et al., 1996) or from nearby astrocytes (Mallucci et al., 
2003). Second, scrapie-inoculated mice expressing a GPI anchor-negative version of 
PrP develop PrP develop minimal brain pathology and neurological dysfunction 
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despite the accumulation of substantial amounts of PrPSc amyloid (Chesebro et al., 
2005). Third, PrP-null primary neurons in culture have been found to be resistant to 
apoptosis induced by exposure to the synthetic peptide PrP106-126, which has been 
used as a model for PrPSc (Brown et al., 1994). Finally, a recent study has shown that 
PrPC exerts a protective activity against cellular stress, and that PrPSc abrogates this 
activity by activating stress-related signalling cascades (Rambold et al., 2008). 
Taken together, the above evidence suggests a ‘subversion-of-function’ 
hypothesis to explain prion-induced pathology whereby interaction with PrPSc (or other 
pathogenic intermediates) alters normal, physiological activity of PrPC leading to 
neurotoxicity (Figure  1-4 A). 
1.9.3 Aberrant PrPC trafficking  
Several studies have shown that PrP can be neurotoxic when its import into the 
ER is partially or completely compromised (Hegde et al., 1998b; Hegde et al., 1999; 
Yedidia et al., 2001; Ma et al., 2002). Studies in cell-free translation/translocation 
systems have shown that PrP can be found in several topological forms (Hay et al., 
1987). CtmPrP is one minor isoform of PrP, which spans the membrane once (at a 
hydrophobic domain from residues 112-135) with the N-terminal domain exposed to 
the cytosol (Hegde et al., 1998b). Increased synthesis of CtmPrP has shown to coincide 
with progressive neurodegeneration both in GSS patients with an A117V mutation and 
in transgenic mice carrying a triple mutation within the hydrophobic domain (Hsiao et 
al., 1991; Hegde et al., 1998b; Stewart et al., 2005). Indirect evidence in transgenic 
mice suggests that CtmPrP levels might also be increased upon PrPSc accumulation 
(Hegde et al., 1999). Thus, CtmPrP may be a critical intermediate in the pathway of 
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prion-mediated neurodegeneration, by means of escaping the ER quality control 
mechanisms (Hegde et al., 1998b; Hegde et al., 1999). 
In separate studies, a transgenic mouse model revealed that preventing the 
import of PrP into the ER leads to the formation of a neurotoxic PrP species in the 
cytosol. Mice expressing a PrP mutant lacking the N-terminal ER targeting signal 
(cytoPrP) acquired severe ataxia due to rapid cerebellar granule neuron degeneration 
(Ma et al., 2002). A recent study supported the toxicity of cytoPrP and demonstrated 
that this activity is seen in different neuronal populations (Wang et al., 2009) and 
mammalian cell culture models (Ma et al., 2002; Rambold et al., 2008; Rane et al., 
2004). The relevance of this observation to either familial or transmissible prion 
diseases remains unclear. 
Several recent studies have linked cytoPrP production to prion disease 
pathogenesis. First, prion infection and PrPSc accumulation indirectly cause ER stress 
(Hetz and Soto, 2006; Rane et al., 2008). Second, during ER stress, translocation of 
PrP into the ER is reduced, leading to increased cytoPrP production (Kang et al., 2006; 
Coimbra et al., 2006). Third, reduced PrP translocation at levels comparable to that 
seen during ER stress was sufficient to cause mild age-dependent neurological 
dysfunction in transgenic mice despite essentially quantitative degradation of cytoPrP 
(Rane et al., 2008). Finally, proteasome activity may decline with age (Dahlmann, 
2007) and upon PrPSc accumulation (Kristiansen et al., 2007). Thus, it is possible that 
through the combined effects of a weak PrP signal sequence, reduced PrP translocation 
during ER stress, and reduced proteasome activity due to PrPSc accumulation, 
sufficient amount of cytoPrP is generated during prion diseases to cause neurotoxicity 
(Rane et al., 2008; Chakrabarti and Hegde, 2009) (Figure  1-4 B). 
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1.9.4 Intermediate PrP species 
Several lines of evidence have suggested that both PrPC and PrPSc are required 
for toxicity. In addition to the models of neurotoxicity described above (Section  1.9.1, 
Section 1.9.2 and Section  1.9.3) an alternative explanation is that an undetectable, cell-
associated and transient oligomeric intermediate, which requires PrPC expression for 
its continuous formation, might be responsible for neurotoxicity (Soto, 2008) (Figure 
 1-4 C). For example, Hill et al., proposed the presence of a transient neurotoxic 
intermediate, PrPL (L for lethal), which forms during the conversion of PrPC to PrPSc 
(Hill et al., 2000; Hill and Collinge, 2003). It is important to note that the precise 
nature, or even existence, of such a species remains unclear.   
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Figure 1-4 Role of PrPSc and mechanism of neurodegeneration3 
Although PrPSc is certainly associated with the pathogenesis of TSEs, its role in 
neurodegeneration is controversial. Several observations suggest that PrPSc levels do not 
correlate with the extent of brain damage and that the natively folded PrPC is required for 
neurodegeneration. Three non-mutually exclusive models can be proposed to explain the 
discrepancies and the implication of PrPC. (A) PrPC located in the cell surface may act as a 
receptor for PrPSc, triggering a signal transduction pathway leading to neurodegeneration. (B) 
As proposed by Rane and colleagues (Rane et al., 2008), induction of ER stress by PrPSc may 
lead to translocation of nascent PrPC molecules to the cytosol for proteasomal degradation as a 
way to alleviate the damaged ER (‘pre-emptive’ quality control system (pQC) pathway). 
However, this mechanism of defence turns negative under chronic ER stress conditions, 
overwhelming the proteasome and leading to the cytosolic accumulation of potentially toxic 
PrP molecules. (C) The infectious and neurotoxic PrP species might not be the same. Indeed, it 
is possible that an undetectable misfolded intermediate might be responsible for neurotoxicity 
in a way similar to that proposed for other neurodegenerative diseases. The transient nature of 
these intermediates determines that its presence depends on the permanent synthesis of new 
PrPC.   
 
3Reprinted from Developmental Cell., Vol 15, Soto, C., Endoplasmic reticulum stress, PrP 
trafficking and Neurodegeneration, pp 339-341, ©2008, with permission from Elsevier. 
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1.10 Therapeutic approaches in prion diseases    
Attempts to find a therapeutic for the treatment of prion disease patients has 
proved difficult due to long disease incubation times, a short symptomatic phase and 
the lack of a preclinical diagnostic. 
In various model systems, thousands of compounds and substances with anti-
prion activity have been identified (Gilch et al., 2008). For instance, sulphated glycans 
like pentosan polysulfate or dextrane sulphate 500 are known to interfere with binding 
of PrP to glycosaminoglycans (GAG) (Farquhar and Dickinson, 1986; Ladogana et al., 
1992). Similarly, Congo Red (Caughey and Race, 1992; Ingrosso et al., 1995) induces 
reduction of cell surface PrPC (Caspi et al., 1998), and suramin aggregates PrPC and re-
direct it to lysosomes (Gilch et al., 2001). Polyene antibiotics like amphotericin B 
which bind to cholesterol (Mangé et al., 2000) and tetracyclic compounds which may 
induce structural changes in proteins by direct interaction are other potent anti-prion 
compounds (Caughey et al., 1998). In addition, phosphorous containing dendrimers, 
known to induce proteolytic digestion of PrPSc by causing disaggregation at acidic pH 
(Solassol et al., 2004) and lysosomotropic agents like quinacrine  (Doh-ura et al., 
2000; Korth et al., 2001) have been identified as anti-prion compounds.  
Small interfering RNAs (siRNA) targeting PrP mRNA abrogate PrPSc 
accumulation in cell culture (Daude et al., 2003) and successful knock down of PrPC 
expression in livestock has been demonstrated (Golding et al., 2006).  Expressing short 
hairpin RNA (shRNA) directed against PrPC mRNA in neuronal cells prolongs 
incubation time in prion-infected chimeric mice (Pfeifer et al., 2006). Another 
approach to reduce levels of the infectious agent is to target the tertiary structure of 
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PrPSc. Structural transitions occurring in misfolded PrPSc have been reversed by beta-
sheet breaker peptides (Soto et al., 2000). In addition, direct binding of RNA or 
peptide aptamers to PrPC interferes with PrPSc biogenesis (Gilch et al., 2007).  
In prion diseases, no obvious humoral immune response is stimulated due to 
autotolerance (Porter et al., 1973), however, various elements of the immune system 
can be manipulated. Efforts have focused on the therapeutic application of antibodies 
or of stimulation of antibody responses. Initial attempts to produce anti-prion 
antibodies included immunisation with purified proteins (Bendheim et al., 1984) or 
scrapie-associated fibrils (SAF) (Kascsak et al., 1987), with a greater response 
observed in prion knockout mice compared to wild type mice (Prusiner et al., 1993). 
These in vivo immunisation experiments suggest a possible use of anti-PrP antibodies 
as a therapy for prion diseases (Heppner et al., 2001; Sigurdsson et al., 2002; Gilch et 
al., 2003; Gilch and Schatzl, 2003). An alternative approach could be to target 
antibodies against the putative cellular prion receptor LRP since this has been shown 
to inhibit prion conversion in cell culture models (Zuber et al., 2008).  
In summary, since prion diseases are fatal neurodegenerative disorders with no 
effective treatment, the search for efficient therapy and/or prophylaxis in prion disease 
will be critical. As TSE are diseases of the CNS, compounds selected for therapy must 
efficiently cross the blood-brain-barrier (BBB). Due to the short symptomatic phase of 
prion diseases, efforts have to be made to facilitate earlier diagnosis to allow 
therapeutic intervention before disease manifests. 
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1.11 Aims of the thesis 
• To generate a unique cell system that can produce epitope-tagged PrPSc 
molecules in a neuroblastoma cell line where the endogenous PrPC has been 
silenced 
• To study the earliest events in prion infection of cells and subsequent PrP 
misfolding 
• To assess the timescale that PrPC is converted to PrPSc following exposure to 
mouse-adapted RML prions 
• To identify the initial cellular site of PrPSc formation and propagation. 
• To examine how trafficking impairment of PrPSc affects the PrP conversion and 
prion propagation.  
• To map the intracellular trafficking pathways of PrPSc 
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2 Materials and Methods  
All chemicals were purchased from Sigma-Aldrich Ltd and were used as 
received unless otherwise stated. 
2.1 Cell culture 
Work with mouse cell lines was carried out in a designated tissue culture 
facility using strict aseptic technique. All media and solutions were bought pre-
sterilised and sterile plastic-ware was used. All procedures, including preparation of 
media, were performed in a tissue culture hood with a laminar flow unit. All solutions 
and media were pre-warmed to 37°C prior to use.  
2.1.1 Cell lines 
N2aPK-1 cell lines 
N2aPK-1 cell line (PK1 cells) was a kind gift from Dr Peter Kloehn (MRC 
Prion Unit, UCL Institute of Neurology). This cell line was driven from the mouse 
neuroblastoma cell line N2a (Klohn et al., 2003) purchased from the American Type 
Culture Collection (ATCC-CCL131). N2a cells were challenged with a 10-6 dilution of 
Mouse-adapted Rocky Mountain laboratory (RML) prions, to yield clone N2aPD88. 
Further sub-cloning of N2aPD8 yielded the more sensitive N2aPK-1 cell line (PK1 
cells). 
N2aPK-1 knock down cell lines 
PrP-knock down cell lines (P8(11)4.5 and PK1-10Si8) were generated by Dr 
Liza Sutton and Professor Parmjit Jat in the MRC Prion Unit, UCL Institute of 
Neurology, using RNA interference (RNAi) technology (Section 2.2.1).  
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PhiNX-ecotropic packaging cell lines 
PhiNX-eco cells were a kind gift from Professor Parmjit Jat (MRC Prion Unit, 
UCL Institute of Neurology). The cell line is a second generation retroviral producer 
line (MuLV-based) for the generation of helper-free ecotropic retroviruses. The line is 
based on the 293T cell line; a human embryonic kidney line transformed with 
adenovirus E1a, carrying a temperature sensitive T antigen co-selected with neomycin 
(Lamb et al., 1993). These were used for gene transfer into cells. PhiNX-eco cells 
produce virus particles that are able to infect mouse cells. 
2.1.2 Cell culture methods 
Cell growth condition 
All chemicals were from Sigma unless otherwise stated. N2aPK-1 cells were 
grown in standard growth medium which consisted of Opti-MEM containing penicillin 
50 U/ml (Invitrogen), streptomycin 50 µg/ml (Invitrogen), and 10 % v/v foetal calf 
serum (FCS, Invitrogen). For PK1-10Si8 cells 4 µg/ml puromycin (Invitrogen) and for 
P8(11)4.5 cells 4 µg/ml puromycin as well as 50 µg/ml hygromycin (Invitrogen) were 
also added to the standard growth medium. 400 µg/ml Geneticin (G418, Invitrogen) 
was also added to the growth medium of cells reconstituted with tagged-PrP 
constructs. 
Cell culture maintenance and harvesting 
All cells were grown in 10 cm plastic culture dishes. Their medium was 
changed two to three times weekly. To subculture the cells, the existing medium were 
exchanged with pre-warmed medium and cells were suspended by trituration with a 
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Gilson pipette. Cells were seeded 1:3 to 1:8 in new culture plates and incubated at 
37°C to grow in a humidified 5 % CO2 incubator.   
Cell freezing and defrosting 
A confluent plate of cells were suspended in the existing media by trituration 
with a Gilson pipette and centrifuged at 200 x g for 5 minutes. The pellet was re-
suspended in an appropriate volume of freezing media containing 30 % FCS and 8 % 
dimethyl sulfoxide (DMSO). 1 ml of cells were dispensed into sterile cryovials and put 
in isopropanol-regulated cryopreservation box at – 80°C overnight before transfer to 
vapour liquid nitrogen for long term storage. 
Frozen cells were removed from liquid nitrogen and were thawed rapidly in a 
37°C water bath. Cell suspension was transferred to 10 ml of appropriate pre-warmed 
media and was centrifuged at 200 x g for 5 minutes. Then, the supernatant was 
decanted and the cells re-suspended in 10 ml fresh standard growth medium overnight 
at 37°C. The day after, the media on the cells was replaced with fresh growth medium. 
Nuclear fragmentation using DAPI for the detection of apoptosis   
From time to time cells were checked for nuclear fragmentation to ensure cells 
were not infected with Mycoplasma; nuclear fragmentation is an early indicator of 
apoptosis (Simbulan-Rosenthal et al., 1999). This was done using 4’, 6-diamidino-2-
phenylindole (DAPI), a UV-excited, blue-emitting fluorochrome, (excitation 358 nm, 
emission 461 nm) which stains the nuclei of cells. Cells were plated on poly-L-lysine 
coated glass 13 mm coverslips. Coverslips were washed three times in PBS and fixed 
in fresh pre-warmed 4 % w/v paraformaldehyde (PFA), pH 7.4, for 20 minutes at room 
temperature (RT). After washing the coverslips three times in PBS, cells were 
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permeabilised with pre-cooled 100 % methanol for 15 minutes at - 20°C and then 
washed again three times in PBS. 1 µg/ml DAPI was added to each coverslip; 
coverslips were mounted on glass slides in 10 µl anti-fade (DAKO). Slides were left to 
dry and then placed at 4°C until analysis.  
Prion infection of cell lines 
Cells were infected with mouse adapted RML prions. Brains of scrapie-sick 
mice infected with RML prions was homogenized by passing eight times each through 
21 and 25 gauge needles and adjusted to 10 % (w/v) with PBS. Brain homogenate was 
centrifuged for 5 minutes at 1,000 rpm at RT; supernatants were recovered and stored 
at – 80oC. Cells were seeded into 6-well plates to yield 50 % confluence for 24 hours 
before exposure to 0.1 % RML-infected mouse brain homogenate. The homogenate 
was diluted in pre-warmed culture medium, mixed thoroughly by vortexing and added 
to cells for 72 hours unless otherwise stated. The inocula were then removed and the 
cells were either seeded on coverslips if it was necessary or were split 1:8 every 3 
days. After three 1:8 splits, the infectivity of the cells (production of PrPSc) was 
screened by the scrapie cell assay (SCA) (Klohn et al., 2003) (Section 2.5). Cells were 
cultured in standard growth medium and maintained at 37oC in 5 % CO2.  
2.2 Molecular biology 
2.2.1 Knock down of Prnp using RNA interference 
As mentioned in section  2.1.1, PrP-knock down PK1 cells were used for our 
experiments. The cells were produced by Professor Parmjit Jat and Dr Liza Sutton, at 
the MRC Prion Unit, UCL Institute of Neurology, using RNAi technology 
(unpublished data). Three 19-mer small interfering RNA (siRNA) duplexes were 
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designed to exactly target mouse Prnp mRNA and contained a 3´UU overhanging (to 
prevent nuclease digestion; Table 2-1). Sequence number 2 and 4 were designed by 
Professor Parmjit Jat using a set of empirical design rules. It includes targeting 
sequences 50-100 base pairs upstream of Prnp, starting with an AA dimer and using 
the next 19 nucleotides, avoiding stretches of more than four A and T (a termination 
signal for polymerase III) and ensuring the GC content was between 30 % and 50 %. 
Sequence number 8 was designed by Dharmacon Inc. (USA) using SMART 
SelectionTM technology, which employs an algorithm to select functional siRNAs 
(Reynolds et al., 2004). All three siRNAs targeted the 3´UTR of mouse Prnp.  
SiRNA oligonucleotides were cloned into the pSUPER.retro.puro expression 
vector (OligoEngine Inc., USA). To allow for co-expression of two siRNA sequences 
in the same cell, siRNA 2 and 8 expression cassettes were cleaved from 
pSUPER.retro.puro vector and cloned into another retroviral vector: pMSCV, with a 
hygromycin B selectable marker (Clontech, USA). siRNA expression vectors were 
packaged in PhiNX-eco cells before transducing PK1 cells (unpublished data). 
Combination of construct 8 and 2 was used to generate P8(11)4.5 cell line and 
construct 8 alone was used to generate PK1-10Si8 cell line.   
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Table 2-1 Location of siRNA target sequences in mouse Prnp mRNA 
 
2.2.2 Construction of mouse PrP-3F4, FLAG and MYC insertion 
mutants in pLNCX2 
Mouse PrP expressing vectors  
Mouse 3F4-tagged Prnp was generated by Dr Mark Kristiansen, MRC Prion 
Unit, UCL Institute of Neurology (unpublished data). Mouse FLAG- and MYC-tagged 
Prnp were generated by Dr Dave Emery, Henry Welcome Laboratories for Integrated 
Neuroscience (Appendix I and Appendix II). Mouse Prnp open reading frame was 
cloned as a EcoR I- Xho I restriction fragment into pBluescript SK(-) (Stratagene) to 
generate mouse FLAG- and MYC-tagged Prnp. They were then excised as a BamH I-
Sa1 I fragment and transfected into Bg1 II-Sa1 I-digested retroviral vectors, pLNCX2 
(Clontech, USA, Appendix III). To protect 3F4-, FLAG- and MYC-tagged PrP 
mRNAs from siRNAs directed at the 3´ untranslated region (3′ -UTR) of PrPC mRNA 
in PrP-KD cells (Section 2.2.1), only the mouse PrPC open reading frame lacking 3′ -
UTR was inserted in pLNCX2 vectors.   
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Polymerase chain reaction (PCR) 
Primary and secondary PCRs were carried out to generate mouse FLAG- and 
MYC- tagged PrP constructs, using the reactions showed in Table 2-2. For primary 
PCR, cycling conditions on the tetrad thermal cycler were polymerase activation step 
of 94°C for 5 minutes and then 30 cycles of DNA template denaturation at 94°C for 30 
seconds, primer annealing at 57°C for 40 seconds, 72°C extension step for 1 minute, 
and a final extension step of 72°C for 7 minutes. For secondary PCR, cycling 
conditions on the tetrad thermal cycler were polymerase activation step of 94°C for 5 
minutes, DNA template denaturation at 80°C for 10 minutes. After that, 1 µl (5 U) 
Herculase (stratagene) was added to the reaction prior and the extension step was 
carried out at 72°C for 10 minutes. Then, 2.5 µl of each flanking primer (Appendix IV) 
was added to the tube and then 30 cycles of DNA template denaturation at 94°C for 30 
seconds, primer annealing at 57°C for 30 seconds, 72°C extension step for 1 minute, 
and a final extension step of 72°C for 7 minutes was carried out. PCR products were 
run on a 1.3 % agarose gel and were purified with a standard spin column purification 
kit following manufacturer’s kit (Qiagen). 
Table 2-2 Primary and secondary PCR reactions 
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Cloning of mouse FLAG- and MYC- tagged Prnp into pBluescript SK(-)  
Full length mouse FLAG- and MYC- tagged Prnp was digested with EcoR I 
and Xho I (10 U each) using Roche buffer H in a volume of 50 µl for 2 hours at 37°C. 
The digested products were gel purified as above and approximately 20 ng of 
pBluescript digested in a similar way was incorporated into ligation reactions with a 
molar (3 times) excess of fragment overnight at 17°C. Electrocompetent XL1-B E.coli 
was transformed and recombinant colonies were selected by Blue/White selection.  
Sub-cloning of mouse FLAG- and MYC- tagged Prnp into pLNCX2 
20 µl of pBluescript miniprep DNA for each FLAG and MYC clone was first digested 
with BamH I (10 U) with REACT 3 buffer (invitrogen, UK) in a final volume of 1 ml 
at 37°C for 2 hours. The DNA was ethanol precipitated; the pellet was washed with 70 
% and 100 % ethanol and air-dried. It was then dissolved and digested with Sal I (10 
U) in REACT 10 buffer (Invitrogen, UK) ) in a final volume of 40 µl at 37°C for 2 
hours and was run on a 1.3 % agarose gel and purified with a standard spin column 
purification kit following manufacturer’s kit (Qiagen). Approximately 200 ng of each 
insert was ligated with approximately 10 ng of pLNCX2 vector prepared in the same 
way (replacing BamH I with Bgl II) in a total volume of 20 µl with 1 U ligase at 17°C 
overnight.  These were then transformed into Electromax Stbl 4 E.coli (Invitrogen, 
UK). 
Midipreps 
100 ml cultures were grown overnight and DNA extracted using an Invitrogen 
kit.  DNA was finally ethanol precipitated, air-dried and dissolved under tissue culture 
conditions. 
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2.2.3 Tagged PrP expression 
Packaging of mouse 3F4-, FLAG-, and MYC-tagged PrP into retroviral 
producer cell line  
Mouse 3F4-, FLAG-, and MYC-tagged PrP expression vectors, pLNCX2, was 
transiently transfected into the PhiNX-eco cell line to produce retroviral particles 
containing tagged mouse Prnp open reading frame (ORF). PhiNX-eco cells were used 
to produce supernatant to infect mouse lines. PhiNX cells were seeded at 1 x 106 cells 
per 10 cm dish 24 hours prior to transfection to achieve exponential growth phase. 
Transfection was performed with FuGene 6 (Roche) according to manufacturer’s 
instructions; 10 µg plasmid DNA and 12 µl FuGene were used per transfection 
reaction. 10 ml retroviral tagged mouse PrP supernatant was harvested from each 
culture dish 48 hours and 72 hours after transfection and passed through a 0.45 µm 
filter to remove cells. Supernatant was used fresh or 5-10 ml aliquots made for storage 
at - 80°C.  
Retroviral transduction of PK1 cell lines 
Cells for retroviral transduction (P8(11)4.5 and PK1-10Si8) were seeded in 10 
cm dishes to achieve exponential growth phase 24 hours later. 2 ml of viral supernatant 
were added dropwise to each dish supplemented with 8 ml of culture medium and 10 
µl polybrene (Sigma, 8 µl/ml). Polybrene is a cationic polymer, which improved viral 
infection efficiency by facilitating membrane fusion. Cells were incubated overnight at 
37oC and the following morning, the existing media was replaced with fresh selection 
medium for RNAi knock down constructs ( Section 2.2.1). In addition to tagged PrP 
construct vectors, cells were also transduced using pLNCX2 vector-only control 
supernatants. 72 hours after infection, transduced cells were split at a low density 
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(25,000 cells per 10 cm dish in quintuplicate). Cells successfully transduced with the 
PrP-tagged expression vector were selected with 400 µg/ml of G418. After the 
selection was completed, cells reconstituted with FLAG- and MYC-tagged PrP 
constructs were bulked up as mixed clones, however, single cell clones were isolated 
from the cells reconstituted with the 3F4-tagged PrP construct as described in section 
 2.2.4. PrPC expression levels were assessed in the reconstituted cells by 
immunoblotting and immunofluorescence staining.  
2.2.4 Isolation of mouse 3F4-tagged PrP expressing single cell 
clones  
To produce single cell clones from the 3F4-tagged PrP transduced cells, the 
medium on top of the reconstituted cells was replaced with fresh medium in 10 cm 
dishes and single discrete colonies expressing sequence of interest were picked with a 
sterile 200 µl Gilson tip. Each clone was transferred to one well of a 96-well plate 
containing culture medium (50 µl per well). Clones were grown to confluence and 
passaged 1:8 to two replica 96-well plates. One plate of the pair was infected with 
mouse-adapted RML prions (Section 2.1.2, ‘prion infection of cell lines’). The other 
plate was grown to confluence and frozen in 100 µl freezing medium (Section  2.1.2), 
wrapped in tissue and aluminium foil and stored at - 80oC. If the infected plate 
revealed any RML prion-infected clones, its replica plate would be thawed and the 
RML prion-susceptible clones expanded and re-infected (Figure 2-1). Two hundred 
single cell clones were isolated from each 3F4-reconstituted cell line (P8(11)4.5 and 
PK1-10Si8) and their susceptibility to RML prion-infection was analysed by scapie 
cell assay (Section  2.6.1). Susceptible clones were expanded from the master plate for 
further analysis. 
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Figure 2-1 Isolation of RML prion susceptible single cell clones expressing 3F4-tagged 
PrP 
Two hundred single cell clones were isolated from each 3F4-reconstituted cell line (P8(11)4.5 
and PK1-10Si8) to assess their susceptibility to mouse-adapted RML prions following the 
method demonstrated in this figure.  
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2.3 Protein chemistry and immunoblotting 
2.3.1 Cell lysate preparation for inoculation of Tg20 mice 
Cell lysates were prepared from PK1, PrP-KD PK1 and PrP-224AlaMYC cell 
cultures exposed to RML prions for 72 hours then sub-passaged five times 1:8 as 
described in section 2.1.2 (‘prion infection of cell lines’). Cells were harvested in 
sterile PBS, washed twice then re-suspended to 30 million cells/ml.  Control PrP-
224AlaMYC cells not exposed to RML prions were harvested the same way. Cell 
lysates were stored in sterile vessels at - 80°C until use.  Animals were cared for per 
institutional and Home Office regulations. For each of the test conditions, groups of 
five Tg20 mice were inoculated intracerebrally with 30 μl of cell suspension. Animals 
were observed daily for clinical signs and culled on diagnosis of prion disease. Two 
animals not diagnosed with prion disease (control group) were culled in parallel with 
diseased animals, and the remaining animals were culled four to five weeks after the 
last diseased animal was diagnosed. Brains were excised and examined by 
immunoblotting (Section  2.3.3 and Section  2.3.6) and histopathology. 
Histopathological experiments were performed by Miss Caroline Powell, MRC Prion 
Unit, UCL Institute of Neurology and Miss Julie Moonga, Department of 
Neurodegenerative Disease, UCL Institute of Neurology. 
2.3.2 Protein assay 
The Pierce BCATM protein assay reagent was used to assess the protein 
concentration in cell lysates. This system combines the reduction of Cu2+ to Cu1+ by 
protein in an alkaline medium with the highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu1+) by bicinchoninic acid (BCA). The purple 
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reaction product of BCA and Cu1+ is water soluble and exhibits a strong absorbance at 
562 nm. To conserve lysates, the microplate procedure was used. For each assay a 
fresh set of protein standards was prepared using dilutions of bovine serum albumin 
(BSA) in the same diluents as the unknown samples.  The BSA standards were made 
to cover the range of protein concentrations expected for each type of sample, in the 
range 0, 25, 125, 250, 500, 750, 1000, 1500 and 2000 µg/ml. The assays were 
performed according to manufacturer’s instructions. Each sample was pipette into a 
96-well plate to which 200 µl working reagent (50 parts of BCA reagent A and 1 part 
of BCA reagent B) was added. This was done in duplicate for standards and triplicate 
for unknown samples. The plate was covered and incubated at 37oC for 30 minutes. 
The plate was cooled to RT before reading at 562 nm on a Tecan plate reader 
(Sunrise). A standard curve was prepared and unknown protein concentrations 
calculated using a statistical analysis program (GraphPad Instant Version 3.02, 
GraphPad Software). 
2.3.3 Extraction of protein from brain homogenates 
100 µl of 10 % w/v mouse brain homogenate was treated with benzonase for 20 
minutes on ice (50 U/ml; Merck) to hydrolyse the nucleotides in the solution. After 
that an aliquot was taken off for protein assay to ensure equal loading. According to 
the protein assay results, brain homogenate samples were diluted to 1 mg/ml in PBS 
and 0.01 % v/v Tween-20 on ice. The samples were digested with proteinase K (PK; 
Roche; 5 µg/ml) if it was necessary for 45 minutes at 37°C. The PK digestion was 
ended by adding 1 mM PMSF to each sample and then 900 µl of pre-cold 100 % 
methanol was added to both PK and non-PK treated samples and they were stored in - 
20°C for at least 15 minutes. Samples were then centrifuged at 16,000 x g for 15 
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minute to pellet the debris. The supernatant was discarded and the pellet was air-dried. 
100 µl of 2 X reducing sample buffer (125 mM Tris, pH 6.8, 20 % glycerol, 0.05 % 
bromophenol blue, 4 % SDS) was added to each sample and then they were stored at - 
80°C. 
2.3.4 Extraction of protein from cultured cells 
Cells were harvested on ice and spun twice at 4°C (1000 x g, 5 minutes) in ice-
cold PBS to eliminate any media. The resulting pellet was then re-suspended in 
minimal volume of ice-cold PBS on ice. Cells were lysed 3 times by freeze-thawing in 
liquid nitrogen. Lysates were benzonase-treated for 15 minutes on ice (50 U/ml; 
Merck). Ice-cold PBS was added to acceptable viscosity and an aliquot was taken off 
for protein assay to ensure equal loading. The remaining supernatant was frozen at – 
80°C.  
2.3.5 Proteinase K digestion of cells for detection of PK resistant 
PrPSc  
To digest the cells with proteinase K, upon thawing cells were treated by 
adding PK (Roche) to a final concentration of 50 µg/ml for 30 minutes at 37°C. 
Samples were then centrifuged at 16,000 x g for 1 minute to pellet cellular debris; 
digestion was ended in samples by adding 8 mM AEBSF (Merck) in an equal volume 
of 2 X reducing sample buffer. 
2.3.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein 
Reducing sample buffer was added to 1 X concentration and samples were 
boiled at 100°C for 10 minutes. Samples were then spun at 16,000 x g for 1 minute, 
Materials and Methods 
82  
 
briefly vortexed and finally spun at 16,000 x g for 1 minute before loading onto 16 % 
Tris-Glycine mini gels (Novex, Invitrogen). Gels were electrophoresed vertically in 
Tris/Glycine SDS running buffer (National Diagnostics) in a X-Cell SureLock™ Mini-
Cell system (Invitrogen) for 80 minutes at 200 V (or until the dye front run off at the 
end of the gel). Pre-stained Seeblue® Protein Standard (Novex, Invitrogen) was used 
as a molecular weight marker.  
2.3.7 Electroblotting of gels 
Protein was transferred onto PVDF membranes (Millipore). PVDF membrane 
was pre-cut at the same size as the gels and pre-soaked in 100 % methanol for 2 
minutes to ensure even hydration prior to transfer into blotting buffer (National 
Diagnostics). Protein was transferred from the gel to the membrane in Novex X-Cell 
II™ Blot modules (Invitrogen) at either 35 V for 90 minutes or 14 V overnight.  
2.3.8 Immunoblotting of gels 
After electroblotting, membranes were transferred to square tissue culture petri 
dishes and washed in PBS containing 0.05 % v/v Tween-20 (1 X PBST). Blots were 
then blocked for 1 hour at RT with gentle agitation using either 5 % w/v BSA or 5 % 
w/v non-fat milk powder. Blocking solution was made in 1 X PBST.  Membranes were 
washed briefly with 1 X PBST before overnight incubation with the appropriate 
primary antibody at RT with gentle agitation. To detect prion protein, mouse 
monoclonal ICSM35 anti-PrP antibody (D-GEN; 0.25 µg/ml) was used. After 
incubation with the primary antibody, the membranes were then washed in 1 X PBST 
for a minimum of 45 minutes changing buffer 5 times. Secondary detection was 
performed by incubating with the appropriate secondary antibody (diluted in 1 X 
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PBST) for 45 minutes at RT. Alkaline phosphatase goat anti-mouse IgG (fab-specific) 
was diluted 1:10,000 and used as a secondary antibody to detect prion protein. 
Detection of bound antibody was performed with SuperSignal West Pico 
Chemiluminescent substrate (Pierce) or by CDPStar (Tropix) according to 
manufacturer’s instructions. Excess reagents were poured off and the membranes were 
placed between acetate films and transferred to a photographic cassette. Biomax MR 
Films (Kodak from Anachem) were developed using Kodak developer and fixer by 
hand or by using a Xograph imaging machine (Xograph Imaging Systems). Developed 
films were scanned using an Epson scanner for electronic format and densitometry of 
digital images was achieved by using a Kodak Image Station 440 CF.  
2.3.9 Determination of equal protein loading 
The Re-Blot Plus Western Blot Strong Antibody Stripping Solution 
(Chemicon) consists of specially formulated solutions that quickly and effectively 
remove antibodies from Western blots without significantly having an effect on the 
immobilized proteins. Blots were washed in 1 X PBST buffer for 10 minutes before 
being incubated for 15 minutes with 1 X Re-Blot Plus (in water) Strong Antibody 
Stripping solution. Following this, blots were briefly washed with 1 X PBST and 
subsequently blocked with 5 % milk powder in 1 X PBST for 1 hour. Mouse 
monoclonal anti-β-actin antibody (1:10,000) was added for an overnight incubation to 
probe for the control loading protein. 
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2.3.10 Densitometry  
Densitometry on immunoblots was performed using the Kodak™ Digital 
Science Image station 440CF (IS440CF) system and analysed using the Kodak™ ID 
Image Analysis Software (PerkinElmer Life Sciences).  
2.4 Cell Biology 
2.4.1 PrPSc trafficking impairment using pharmacological agents  
Cells were grown on poly-L-lysine coated coverslips to about 70 % confluence. 
The medium was aspirated from cells and was replaced with different pharmacological 
agents (Table 2-3) diluted in pre-warmed media. The plate was rocked gently and 
incubated at 37°C for 4 hours unless otherwise stated (see Section 5.3 for details of 
each treatment). 5 µg/ml Texas-red labelled transferrin (Invitrogen) was added to cells 
for the last 10 minutes of the incubation period to assess the efficacy of manipulations 
on the cellular endocytosis unless otherwise specified. After that, the cells were 
washed with PBS three times and were fixed to be observed. Control experiments 
replicating the conditions for each treatment but lacking the active reagents were 
carried out to check that conditions outside of our treatments did not affect RML prion 
infection. No significant differences were observed. All the inhibitors were obtained 
from Sigma-Aldrich Ltd, except U18666A that was purchased from Merck-Chemicals 
Ltd.    
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Table 2-3 Pharmacological agents used to manipulate intracellular trafficking of PrPSc  
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2.4.2 Immunofluorescence methods  
Preparation of coverslips 
For immunofluorescence experiments, autoclaved 22 or 13 mm glass coverslips 
(VWR) were coated with 1 mg/ml poly-L-lysine for 10 minutes at RT. Coverslips were 
subsequently washed three times with sterile double-distilled water and air dried. Poly-
L-lysine enhances electrostatic interaction between negatively-charged ions of the cell 
membrane and positively-charged surface ions of attachment factors on the culture 
surface. When adsorbed to the culture surface it enhances the number of positively-
charged sites available for cell binding. 
Immunofluorescence analysis protocol 
Cells were grown on poly-L-lysine coated coverslips until to 70 % confluence. 
They were washed three times with PBS and were fixed with 4 % w/v pre-warmed 
PFA, pH 7.4, for 20 minutes at RT. 4 % pre-warmed PFA, pH 7.4, was used to fix the 
coverslips unless otherwise specified. After fixation, coverslips were washed three 
times with PBS, and then were permeablised in 100 % methanol at - 20°C for 15 
minutes. After washing cells 3 times with PBS, cells were then incubated with 10 % 
normal goat diluted in PBS for 30 minutes at 37°C in a humid chamber. Primary 
antibodies (Table 2-4) were diluted to appropriate concentrations in 1 % normal goat 
serum in PBS and applied to coverslips at 37°C for 1 hour. After washing, suitable 
AlexaFluor488 and 543 labelled secondary antibodies diluted in 1 % normal goat 
serum was applied to cells at 37°C for 45 minutes. Coverslips were then washed 
several times in PBS and mounted in anti-fade medium (DAKO) containing 1 ug/ml 
DAPI. 
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Table 2-4 Antibody concentrations used for immunofluorescence analysis 
 
Removal of PrPc immunoreactivity using formic acid  
98 % formic acid was used to remove PrPC and reveal PrPSc (Kristiansen et al., 
2005). Coverslips seeded with cells were incubated for 20 minutes in 4 % pre-warmed 
PFA, pH 7.4, at RT and then transferred to 98 % formic acid at RT for 5 minutes. Cells 
were washed 3 times in PBS, and then were permeablised with methanol at - 20°C for 
15 minutes. Complete removal of PrPC was checked by incubating non-infected cells 
alongside RML prion-infected cells. It was seen that 5 minutes formic acid is efficient 
enough to denature most of PrPC.  
Removal of PrPc immunoreactivity using Guanidine hydrochloride 
Guanidine hydrochloride (GdnHCl) is a chaotropic agent used as a denaturant 
to disrupt the structure of proteins, unfold them and turn them into their original 
polypeptide chains. GdnHCl is widely used in prion field to denature PrPC and expose 
PrPSc. 4 % pre-warmed PFA, pH 7.4, was added to the cells for 20 minutes at RT. 
Coverslips were washed three times with PBS, and then were permeablised in 100 % 
methanol at - 20°C for 15 minutes. After washing cells 3 times with PBS, cells were 
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then treated with 6 M GdnHCl for 10 minutes at room temperature and washed 3 times 
with PBS and were stained as explained above. Complete removal of PrPC was 
checked by incubating non-infected cells alongside RML prion-infected cells. 
Removal of PrPc immunoreactivity using PK 
Cells were grown on poly-L-lysine coated coverslips to about 70 % confluence. 
Cells were washed three times with PBS and were fixed and permeablised with 8 % 
formaldehyde/ 0.1 % glutaraldehyde and 0.1 % digitonin for 1 hour at RT. Coverslips 
were washed three times with PBS, and then were treated with PK (20 µg/ml, Roche) 
for 15 minutes at 37°C and washed once with PBS. Digestion was stopped with 2 mM 
phenylmethylsulphonyl fluorride (PMSF) for 15 minutes at RT. The coverslips were 
washed with PBS three times and then were stained as explained above. Complete 
removal of PrPC was checked by incubating non-infected cells alongside RML prion-
infected cells. 
Dual-labelling immunofluorescence 
For dual labelling experiments, the two sets of antibodies were added 
sequentially, i.e. primary antibody was applied followed by the appropriate 
fluorochrome-conjugated secondary antibody. After washing, the second primary 
antibody was added followed by the appropriate flurochrome-conjugated secondary 
antibody. Then the protocol was followed as explained above (Section 2.4.2, 
‘immunofluorescence analysis protocol’). All the necessary controls, including 
secondary antibodies only, were performed to examine for any potential cross-
reactivity.  
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Image acquisition 
Confocal microscope (Zeiss microscope LSM510 META) was used to take 
fluorescence images equipped with ‘plan-Apochromat’ 63 x/1.40 Oil DIC objectives at 
RT and is controlled by Zeiss LSM software. Fluorescence was recorded at 488 nm 
using 30 mW Ar-laser for excitation or at 543 nm using 1 Mw HeNE-laser for 
excitation. Zeiss ImmersolTM 518 F was used as imaging medium. Images taken for 
countings were obtained using an Axioplan 2 MOT microscope (Zeiss) with filters for 
FITC, Rhodamine and DAPI and Plan Neofluar 10x/0.30 Ph1 objective at RT. An 
AxioCam MRm (Zeiss) camera was used and was controlled using the Axiovision 
Control software (Zeiss). Orthogonal projections were generated from z-stacks using 
Zeiss LSM software. 
Quantification of RML prion infected cells 
 Control non-infected cells were processed for each experiment and LSM 
settings were chosen to give minimal background staining. The same settings were 
used to examine all RML prion-infected cells in that experiment. To determine RML 
prion infection, at least 300 cells from eight randomly chosen fields (unless otherwise 
specified) were counted for each condition, and the proportion of cells showing PrPSc 
immunostaining after PrPC removal was calculated. 
2.5 Assaying for PrPSc in cells (Scrapie Cell Assay) 
The scrapie cell assay (SCA) is an ELISA-based assay that was developed in 
the MRC Prion Unit as a quantitative, highly sensitive in vitro assay for mouse-
adapted RML prions (Klohn et al., 2003) that can detect single PrPSc positive cells. 
The assay was used to detect infectivity in cells following infection with mouse-
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adapted RML prions. All steps were carried out at RT unless otherwise stated and the 
assay was undertaken in class I microbiological safety cabinet in containment level III 
laboratory. Solutions were aspirated by a vacuum pump into a trap containing sodium 
hypochlorite (20 % final concentration) for decontamination. Guanidinium thiocynate 
(GCSN)-containing solutions were decontaminated with 2 M sodium hydroxide 
because GCSN-containing solutions react with sodium hypochlorite to produce 
chlorine gas. 
Elispot plates (Enzyme-Linked Immunospot Multiscreen Immobilon-P 96-well 
Filtration Plates, Millipore) were activated by wetting the 0.45 µl PVDF membrane of 
each well with 70 % ethanol, aspirating and washing once with PBS. 25,000 cells were 
transferred to the membrane of an Elispot plate. SCA controls were always seeded 
onto the same plate: non-infected or PrP-KD PK1 cells as negative controls and 
chronically RML prion-infected PK1 cells (iPK1) as positive controls (25,000 cells per 
well). Cells were seeded onto the membrane by applying a vacuum and drying them 
onto the membrane in a 50oC oven in biocontainment boxes. PK concentration to 
digest PrPC was determined for each cell line. 50 µl of PK (0.5 µg/ml, Roche) diluted 
in lysis buffer was added to each well for 30 minutes at 37oC before it was aspirated. 
The plate was washed twice with PBS, exposed to 160 µl per well of 1 mM PMSF for 
10 minutes to inhibit the action of the PK, washed once with PBS before incubation 
with 120 µl of 3 M GCSN in 10 mM Tris-HCL (pH 8.0) for 10 minutes to expose the 
PrPSc epitopes. GCSN was discarded into 2 M NaOH and the wells washed five times 
with PBS. 
For immunoprobing of PrPSc, 120 µl per well superblock buffer (Pierce) was 
added to plates for 1 hour and aspirated. 60 µl per well anti-PrP ICSM18 monoclonal 
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antibody was added at 0.6 µg/ml in 1 X TBST with 1 % non-fat milk powder (Marvel, 
Premier Brands, UK) and incubated for 1 hour at RT. The primary antibody was 
discarded into 2 M NaOH and the wells were washed seven times with 1 X TBST. 60 
µl per well of alkaline phosphatase (AP)-conjugated secondary antibodies diluted in 
TBST/1 % non-fat milk powder was added and plates were incubated for 1 hour. Anti-
IgG1 antibody was used as a secondary antibody for anti-PrP ICSM18 antibody. 
Appropriate dilution was established for each new vial of secondary antibody by 
titration.  
54 µl per well AP-conjugated substrate (prepared as recommended by Bio-Rad) 
was added until there was a clear colour change in the positive controls (approximately 
15 minutes). The AP-substrate was discarded and the plates were washed twice with 
de-ionised water before being dried under airflow. Plates were stored in the dark at - 
20oC until analysed. PrPSc-positive cells were counted using the Zeiss KS Elispot 
system and each well was assigned a SCA value. Stemi 2000-C stereo microscope 
equipped with a KL 1500 LCD scanner, Hitachi HV-C20A colour camera and 
WELLSCAN software from Imaging Associates (Bicester, UK) was used for analysis. 
Detection settings were optimised to give a maximal signal to noise ratio (PrPSc-
positive sample counts). Parameters were adjusted by using the training feature of the 
software program according to the manufacturer’s instructions. RML prion-infected 
wells were defined as those for which SCA value (counts per well) was significantly 
greater than background.  
2.6 Statistical analysis 
Data were expressed as mean plus standard error of the mean (SEM) unless 
otherwise stated. Data were compared by 2-tailed t-tests and considered significantly 
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different when P < 0.05. Degree of significance was expressed as follows: * P < 0.05; 
** P < 0.01; *** P < 0.001, unless otherwise specified. 
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3 Isolation of prion susceptible cell lines 
expressing tagged mouse PrP  
3.1 Background 
According to the widely accepted ‘protein-only’ hypothesis, PrPSc is the 
principal component that is responsible for disease transmission (Bolton et al., 1982; 
Prusiner, 1982). Specifically, PrPSc impresses its abnormal conformation on PrPC, 
thereby generating additional molecules of PrPSc in an autocatalytic reaction (Prusiner, 
1998a; Weissmann, 1994; Caughey and Chesebro, 1997). A widely accepted model of 
prion formation and replication proposes that direct interaction of endogenous PrPC 
with the pathogenic PrPSc template is required to drive conversion to the infectious PrP 
conformers (Weissmann, 1994; Caughey and Chesebro, 1997). However, there is little 
consensus on the molecular details of the process by which PrPC is converted into 
PrPSc. Likewise, the chain of events emanating from prion infections and leading to 
neurodegenerative changes and clinical signs are unknown.  
Studies in prion infected animals and tissue culture cells indicate that sequence 
compatibility between PrPC and PrPSc molecules is necessary for efficient PrPSc 
formation (Prusiner et al., 1990; Priola et al., 1994; Scott et al., 1992; Come and 
Lansbury, 1994; Goldfarb et al., 1993). The structure of PrPC has been extensively 
studied in neuroblastoma cells persistently infected with prions and in transgenic mice 
expressing mutant PrP in order to understand the regions of PrPC that are indispensable 
for PrPSc formation and prion propagation. Several lines of evidence have shown that 
the extreme N-terminal region of PrPC (from aa 23 to aa 32) modulates prion 
propagation (Fischer et al., 1996; Flechsig et al., 2000; Supattapone et al., 1999). 
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However, studies have also demonstrated that the region between aa 32 and 90 is not 
essential for production of PrPSc and propagation of prions (Flechsig et al., 2000; 
Legname et al., 2005; Muramoto et al., 1996; Zulianello et al., 2000). The residues 
114 to 121 comprise the most amyloidogenic region of PrP and they are essential for 
conversion of PrPC into PrPSc (Hölscher et al., 1998; Norstrom and Mastrianni, 2005). 
A deletion mutant of PrPC lacking residues 23 to 88 and 141 to 176 can convert into 
PrPSc and support prion propagation in transgenic mice, suggesting that the residues 
141 to 176 are not essential for prion propagation (Muramoto et al., 1996; Supattapone 
et al., 1999). Moreover, the cysteine residue at 178 that forms an intramolecular 
disulfide bond with another cysteine residue at 213 is essential for PrPSc formation 
(Muramoto et al., 1996). Additionally, amino acid substitutions at 167 and 218 prevent 
PrPSc formation and show dominant-negative effect on prion propagation (Kaneko et 
al., 1997b; Perrier et al., 2002). Taken together, these studies indicate that the primary 
structure of PrPC is essential in the conversion process and small amino acid changes 
may interrupt the formation and propagation of PrPSc.  
The cell biology of the disease process, both in terms of the toxic mechanism 
associated with PrPSc formation, and on the details of the misfolding of PrP into its 
abnormal conformation are poorly understood. This is due to the difficulties involved 
in discriminating the exogenous and endogenous PrP in transgenic mouse models and 
cell culture systems, as well as in cell free conversion experiments. In addition, there 
are no antibodies specific to PrPSc. Therefore, different epitope tags, for which high-
affinity antibodies are available, have been rationally designed into the PrP molecule 
as an instrument to study prion infection. However, the generation of true infectious 
prions containing an epitope tag has not yet been convincing in cells and animals. This 
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is probably because the sequence sensitivity of the conversion process prevents the 
misfolding of most tagged PrPC molecules (Moore et al., 2005).  The sequence 
sensitivity is such that the prion seed (exogenous PrPSc) and PrPC substrate 
(endogenous cellular PrPC) must have homologous primary structures for efficient 
conversion to take place, particularly in certain key regions of the PrP molecule 
(Caughey, 2001; Priola et al., 1994). Hence, previous attempts to produce PrP 
constructs with GFP reporter inserts or epitope tags have not generated PrP chimerae 
capable of prion conversion (Barmada and Harris, 2005; Rutishauser et al., 2009). 
Several recent studies have used epitope-tagged PrP such as MYC-, FLAG- and 3F4-
tagged PrP molecules to study prion susceptibility and propagation in vivo, purify PrP, 
identify proteins interacting with PrP or examine PrPSc uptake in mouse neuronal and 
fibroblast cells (Vorberg et al., 2004b; Rutishauser et al., 2009; Greil et al., 2008; 
Magalhaes et al., 2005; Raeber et al., 1992). However, no one has yet described using 
tagged PrP to examine the initial events of infection.    
3.1.1 Aims 
The aim of this study was to generate a cell line that can produce epitope-
tagged PrPSc molecules in a PrP-knock down (KD) neuroblastoma cell line. This 
would allow for the use of anti-tag antibodies to specifically detect the production of 
cellular de novo PrPSc (without detecting PrPSc in the inocula), allowing the earliest 
events in prion infection to be analysed. 
3.2 Methods 
Immunoblotting was used for detection of PrP expression (Section 2.3) in 
collaboration with Dr Rob Goold (Department of Neurodegenerative Disease, UCL 
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Institute of Neurology). Immunofluorescence analysis was undertaken for detection of 
PrPC and misfolded PrP expression (Section 2.4.2). Mouse 3F4-tagged Prnp was 
generated by Dr Mark Kristiansen (MRC Prion Unit, UCL Institute of Neurology). 
Mouse FLAG- and MYC-tagged Prnp were generated by Dr Dave Emery (Henry 
Welcome Laboratories for Integrated Neuroscience) (Section 2.2.2). The scapie cell 
assay (SCA) was used to isolate RML prion-susceptible cell lines expressing tagged-
PrP (Section 2.5). Biochemical and histological analysis was done to assess the 
infectivity of misfolded MYC-tagged PrP on the brains of Tg20 mice inoculated with 
RML prion-infected lysates of cells expressing MYC-tagged PrP (Section 2.3.1 and 
Section 2.3.3). Histology experiments were performed by Miss Caroline Powell (MRC 
Prion Unit, UCL Institute of Neurology) and Miss Julie Moonga (Department of 
Neurodegenerative Disease, UCL Institute of Neurology).  
3.3 Results 
3.3.1 Analysis of prion protein expression in knock down mouse 
PK1 cells  
The mouse neuroblastoma PK1 cell line (Section 2.1.1), which is highly-
susceptible to mouse-adapted prions (Klohn et al., 2003), was used throughout the 
experiments in this chapter. In order to generate a cell system to study prion infection 
in cells expressing tagged PrP without interference from the host wild-type PrPC, PK1 
cells were depleted of endogenous PrP using gene silencing. The inhibition of PrPSc 
formation by non-homologous PrPC molecules has been observed in transgenic mouse 
models, cell cultures and cell-free conversion assays and considerable data suggest this 
is due to ‘dominant negative’ inhibition of non-homologous prion propagation by 
endogenous mouse PrPC (Prusiner et al., 1990; Bueler et al., 1993; Priola et al., 1994; 
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Telling et al., 1994; Telling et al., 1995; Collinge et al., 1995; Horiuchi et al., 2000; 
Perrier et al., 2002). The basis for this inhibitory phenomenon of PrPSc formation is 
thought to be that non-homologous PrPC molecules readily interact with PrPSc but 
cannot be converted (Horiuchi et al., 2000). Therefore, in this study, to eliminate the 
inhibition of tagged-PrPSc formation and propagation by endogenous mouse PrPC in 
PK1 cells, the mouse Prnp gene was specifically silenced. RNAi, using the 
pSUPERretro system, was exploited to stably knock down the host mouse Prnp in PK1 
cells (courtesy of Professor Parmjit Jat, MRC Prion Unit, UCL Institute of Neurology, 
unpublished data, Section 2.2.1). Stable cell lines were isolated and analysed for PrP 
expression and prion susceptibility. Immunofluorescence analysis (Figure  3-1 A) and 
immunoblotting (Figure  3-3) on PrP-KD PK1 cells (P8(11)4.5 and PK1-10Si8) 
demonstrated effective Prnp silencing with PrP levels reduced by approximately 90-95 
% in the cell lines selected for further study. The scrapie cell assay was used to test the 
susceptibility of these PrP-KD cells to prion infection (Section 2.5). This assay 
measures the number of cells containing detectable levels of PK-resistant PrP (PrPSc) 
following 72 hours exposure to RML prions and three cell passages.  It can be used as 
a measure of the level of prion infection in a given cell culture (Klohn et al., 2003). 
The SCA showed that the cells were unable to propagate prions, as expected (Figure 
 3-1 B).  
Dr Liza Sutton (MRC Prion Unit, UCL Institute of Neurology) reconstituted 
PrP-KD PK1 cells with mouse PrPC to determine if siRNA expression affected the 
innate susceptibility of PK1 cells to RML prions. It was observed that mouse PrPC 
expression can be reconstituted in the PrP-KD cell lines to levels equivalent or greater 
than wild type cells. Moreover, it was demonstrated that reconstitution of mouse PrPC 
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in PrP-KD PK1 cells restored susceptibility to RML prions (Dr Liza Sutton, 
unpublished data). 
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Figure 3-1 Mouse PrP-KD PK1 cells do not express prions 
(A) Confocal images of PK1 cells, PrP-KD P8(11)4.5 and PK1-10Si8 cells stained with anti-
PrP antibody (green; ICSM18). Note PrPC is expressed in PK1 cells, but not in PrP-KD 
P8(11)4.5 and PK1-10Si8 cells. Nuclei were stained with DAPI (blue). Scale bar = 15 µm. (B) 
PK1, PrP-KD P8(11)4.5 and PK-10Si8 cells were exposed to 0.1 % RML prion-infected 
mouse brain homogenate for 72 hours and then passaged at 1:8 splits three times to clear the 
prion inocula. Cells were analysed for their prion-susceptibility by the SCA using ICSM18 
anti-PrP antibody. No detectable PK-resistant PrP (PrPSc) was seen in PrP-KD cells. The mean 
+ SEM of six wells are shown.   
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3.3.2 Generating a panel of nine differentially tagged mouse PrPC 
molecules 
To generate a tagged mouse PrPC construct able to support efficient prion 
protein conversion and replication a panel of novel PrPC molecules was designed with 
3F4, FLAG or MYC tags inserted at various points within the PrP sequence (Figure 
 3-2). In the 3F4 construct, the mouse Prnp was modified to express Methionine 108 
and 111 (PrPL108M/V111M). This allows it to be specifically recognised by the 3F4 
antibody, which although able to bind to hamster and human PrPC, is not able to bind 
to the mouse homolog. Inserting the 3F4 epitope does not impair the folding of PrPC as 
it undergoes conversion to PrPSc following RML infection in both neuronal cells 
(Atarashi et al., 2006) and mice (Telling et al., 1995). 
 As well as the 3F4 construct, PrP constructs tagged with the FLAG peptide 
sequence, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys, and MYC peptide sequences, Glu-
Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu, were also produced (Figure  3-2). They were 
used largely because the 3F4 construct cannot be used for detailed ultra-structural 
studies without antigen retrieval since the epitope is buried into the native protein 
(Peretz et al., 1997; Safar et al., 1998; Safar et al., 2005; Yuan et al., 2005). The MYC 
tag was chosen as they are small and are unlikely to affect the tagged prion’s 
biochemical properties. The MYC tag has also been used widely to detect cellular 
localisation of tagged-proteins by immunofluorescence analysis and there are excellent 
antibodies against the MYC epitope. The FLAG tag was chosen as it is relatively 
hydrophilic as compared to other common protein tags, and therefore the least likely to 
become buried within the core of the folded protein. Furthermore, this approach has 
been validated by Telling and colleagues using FLAG-tagged PrP at positions 22 and 
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88 of mouse PrPC, demonstrating conversion of PrPSc in transgenic mice following 
prion infection (Telling et al., 1997). Both MYC and FLAG tags were placed in the 
unstructured regions of the PrP (Figure  3-2). These sites are thought not to impinge on 
any regions suggested to be of importance in the binding of PrPC to PrPSc and therefore 
they are less likely to interfere with PrPSc formation (Horiuchi and Caughey, 1999; 
Caughey, 2001). 
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Figure 3-2 Schematic representation of the domain structure of murine PrP 
Substitution of leucine 108 and valine 111 to methionine generates the 3F4 epitope in the 
mouse PrP molecule. FLAG and MYC epitope tags have been positioned in unstructured 
regions of PrP not thought to be involved in the conformational rearrangement of PrP. 
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3.3.3 Mouse 3F4-tagged PrPC expression in PrP-KD PK1 cells 
Mouse 3F4-tagged Prnp was cloned into the retroviral expression vector, 
pLNCX2, and packaged into the PhiNX-eco retroviral producer cell line (Section 
2.2.3). Ecotropic virus was harvested and used for retroviral transduction of two PrP-
KD PK1 cell lines (P8(11)4.5 and PK1-10Si8) with the mouse 3F4-tagged PrPC 
construct (moPrPC.3F4). Successfully transduced cells were isolated by appropriate 
antibiotics as described in section 2.2.3 and mixed clones stably expressing mouse 
3F4-tagged PrPC were established. Immunoblotting of lysates from transduced cells, 
using anti-PrP ICSM35 and the 3F4 antibody, confirmed reconstitution of PrP-KD 
cells with 3F4-tagged PrPC (Figure  3-3, middle blot, lanes 2 and 3). Furthermore, 
immunofluorescence analysis in the transduced cells demonstrated the expression of 
moPrPC.3F4 (Figure  3-4, panels b and d), confirming the immunoblotting results. Non-
transduced cells did not express any detectable PrPC and were used as negative 
controls (Figure  3-3, lanes 4 and 5, Figure  3-4, panels a and c). The 3F4 antibody 
could not be used to detect prion protein without antigen retrieval, since the 3F4 
epitope is buried in the native protein (Peretz et al., 1997; Safar et al., 1998; Safar et 
al., 2005). Therefore, well characterised ICSM18 anti-PrP antibody was used in 
immunofluorescence analysis to detect 3F4-tagged PrPC expression in transduced cells. 
Taken together, these results indicate that the transduction of the moPrPC.3F4 
construct was successful, but the level of tagged-PrPC expression varies across the cell 
population (Figure  3-4, panels b and d). 
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Figure 3-3 Transduced PK1-10Si8 and P8(11)4.5 mixed clones express moPrPC.3F4 
Lysates from PK1, PK1-10Si8 and P8(11)4.5, as well as from PK1-10Si8.3F4 and 
P8(11)4.5.3F4 mixed clones were analysed by SDS-PAGE electrophoresis and immunoblotted 
with anti-PrP ICSM35 (top blot) and the 3F4 (middle blot) antibodies. MoPrPC.3F4 was 
detected in the 3F4 transduced cells (PK1-10Si8.3F4 and P8(11)4.5.3F4, lanes 2 and 3), 
however no 3F4 tagged-PrPC was noticed in PK1, PK1-10Si8 and P8(11)4.5 cells when the 
3F4 antibody was used (bottom blot, lanes 1, 4 and 5). Imunoblotting of β-actin confirmed 
equal protein loading (bottom blot). Quantitative densitometry of similar blots showed PrP 
expression was reduced by 90-95 % in PrP-KD cells.  
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Figure 3-4 Expression of moPrPC.3F4 in transduced PK1-10Si8 and P8(11)4.5 mixed 
clones 
MoPrPC.3F4 (green; ICSM18) is expressed in the P8(11).4.5.3F4 and PK1-10Si8.3F4 cells, as 
showing by confocal images. Note the predominant membrane expression of MoPrPC.3F4 in 
the transduced cells. P8(11)4.5 and PK1-10Si8 cells were used as negative controls. Nuclei 
were stained with DAPI (blue). Scale bar = 15µm. 
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3.3.4 Conversion of MoPrPC.3F4 into misfolded PrP 
In order to determine whether PrP-KD PK1 cells reconstituted with 
moPrPC.3F4 were susceptible to RML prions, P8(11)4.5.3F4 and PK1-10Si8.3F4 
mixed clones were infected with 0.1 % RML prion-infected mouse brain homogenate. 
Prion infection was assessed by the SCA, however, no detectable levels of the disease-
related isoform were found (Figure  3-5).   
 
Figure 3-5 PK1-10Si8.3F4 and P8(11)4.5.3F4 mixed clones are not susceptible to RML 
prions 
Non-infected and RML prion infected PK1-10Si8.3F4 and P8(11)4.5.3F4 were analysed for 
their susceptibility to RML prions by the SCA. No measurable level of RML prion infection 
was detected in the MoPrPC.3F4 expressing mixed clones using ICSM18 anti-PrP antibody. 
Non-infected, and RML prion infected PK1 cells were used as positive controls. The mean + 
SEM of six wells are shown.   
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Isolation of moPrPC.3F4 prion-susceptible single cell clones 
To find the rare clones susceptible to RML prions, a clonal selection strategy 
was developed (Section 2.2.4). Two hundred single cell clones were picked of each of 
the moPrPC.3F4 transduced P8(11)4.5 and PK1-10Si8 cell lines and grown in culture. 
Clones were then infected with 0.1 % RML prion-infected mouse brain homogenate 
and each clone was screened for RML prion-infectivity by scrapie cell assay (Section 
2.5) at every passage up to passage six. The twenty four most susceptible clones from 
each of the cell lines (P8(11)4.5.3F4 and PK1-10Si8.3F4) were selected for expansion. 
They were then assayed by the SCA and immunofluorescence analysis. These forty 
eight highly-susceptible single cell clones were analysed further to isolate the seven 
most susceptible ones. Non-infected master clones of seven selected cell clones were 
expanded and studied further. 
Immunofluorescence analysis was done on the selected cell clones to confirm 
that they express moPrPC.3F4, using an anti-PrP antibody, ICSM18, (Figure  3-6). 
MoPrPC.3F4 was detected in each of the isolated prion-susceptible clones, 
predominantly on the plasma membrane (Figure  3-6). Immunoblotting of lysates of the 
susceptible clones, using anti-PrP ICSM35 and the 3F4 antibodies, confirmed 
expression of moPrPC.3F4 (Figure  3-7, lanes 3-5 and lanes 7-10), but the expression 
levels varied across the different clones. PK1 cells were used to show the physiological 
expression of wild type PrPC (positive control). PK1-10Si8 and P8(11)4.5 cells were 
used as negative controls since they do not express significant levels of PrPC (Figure 
 3-6 and Figure  3-7).   
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Figure 3-6 moPrPC.3F4 expression in PK1-10Si8.3F4 and P8(11)4.5.3F4 single cell clones 
Immunofluorecence staining showed moPrPC.3F4 expression (green) in seven susceptible 
single cell clones, using an anti-PrP antibody (ICSM18). Nuclei were stained with DAPI 
(blue). Note the predominant expression of 3F4-tagged mouse PrPC on the plasma membrane. 
PK1 and parental PrP-KD cells were used as positive and negative controls, respectively. Scale 
bar = 15 µm  
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Figure 3-7 Detection of moPrPC.3F4 expression in PK1-10Si8.3F4 and P8(11)4.5.3F4 
single cell clones by immunoblotting 
Lysates of single cell clones from PK1-10Si8.3F4 (C9.1, D7.1, C5.2) and P8(11)4.5.3F4 (B9.2, 
D8.2, F6.2, H6.2) cells were analysed by SDS-PAGE electrophoresis for the expression of 
3F4-tagged mouse PrPC. Mouse monoclonal anti-PrP antibody (ICSM35; top blot) and mouse 
monoclonal 3F4 antibody (middle blot) were used for immunoblotting. PrPC runs between 30-
50 kDa in its three glycosylation states (di-glycosylated, mono-glycosylated, and un-
glycosylated), as seen in PK1 cells and moPrPC.3F4 reconstituted single cell clones but not in 
PrP-KD cell lines. MoPrP3F4 expression is shown in the single cell clones from the 
reconstituted cells.  PK1 lysates are included to indicate physiological expression of PrPC. 
Lysates from PrP-KD cells, which do not express substantial levels of PrPC, are included as 
negative controls. Levels of an endogenous mouse protein, β-actin, were assessed by 
immunoblotting to confirm equal protein loading (bottom blot). 
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Misfolded moPrP.3F4 propagation in prion-susceptible single cell 
clones 
The seven susceptible single cell clones were analysed in more details. Clones 
were exposed to 0.1 % RML prion-infected mouse brain homogenate, following which 
they were screened for their susceptibility to prion infectivity by the SCA and 
immunofluorescence analysis (Figure  3-8, Figure  3-9 A and B). The SCA analysis of 
the susceptible single cell clones showed that of the RML prion-infected PK1-
10Si8.3F4 cells, D7.1 single cell clone contained the highest amount of misfolded 
moPrP.3F4. The RML prion-infected P8(11)4.5.3F4 single cell clones had similar spot 
numbers, but it was found that P8(11)4.5.3F4;H6.2 single cell clone displayed a 
consistent level of infectivity in repeated experiments as compared to the other 
P8(11)4.5.3F4 clones (Figure  3-8). 
The susceptibility of selected single cell clones to RML prions were also assessed with 
Immuno-fluorescence analysis, using a mouse monoclonal 3F4 antibody following five 
minutes formic acid treatment. Due to the lack of antibodies specific for PrPSc, it is 
necessary to treat cells post-infection to remove detectable PrPC, leaving PrPSc 
available for immunodetection. Five minutes treatment of RML prion-infected cells 
with 98 % formic acid has been shown to hydrolyse PrPC and reveal PrPSc (Kristiansen 
et al., 2005). Formic acid was also used to expose the 3F4 epitope. To determine the 
percentage of cells producing misfolded moPrP.3F4, pictures of the stained cells were 
taken using a fluorescent microscope and the number of 3F4 positive cells was counted 
(Figure  3-9 A). The results for the PK1-10Si8.3F4 cells corroborated the SCA results, 
but, counts for P8(11)4.5.3F4 single cell clones showed that P8(11)4.5.3F4;B9.2 clone 
had the highest percentage of 3F4 positive cells. Therefore, experiments were 
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continued using the P8(11)4.5.3F4;H6.2 clone as it showed more consistent infectivity 
by both immunofluorescence and the SCA analysis. The P8(11)4.5.3F4;H6.2 clone 
was also the only single cell clone that significantly over-expressed moPrP.3F4 as 
compared to wild type PK-1 cells (Figure  3-7, lane 10). Therefore, P8(11)4.5.3F4;H6.2 
as well as PK1-10Si8.3F4;D7.1 clones (henceforth termed H6.2 and D7.1 cells, 
respectively) were expanded for use in experiments. Confocal images of RML prion-
infected D7.1 and H6.2 cells showed the presence of intracellular and plasma 
membrane formic acid-resistant moPrP.3F4 in the cells (Figure  3-9 B).  
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Figure 3-8 Misfolded moPrP.3F4 propagation in seven RML prion-infected single cell 
clones 
P8(11)4.5.3F4 and PK-10Si8.3F4 single cell clones, parental PrP-KD lines and PK1 cells were 
exposed to 0.1 % RML prion-infected mouse brain homogenate for 72 hours and then 
passaged at 1:8 splits three times to clear the prion inocula. Cells were analysed for their prion-
susceptibility by the SCA (ICSM18). i = RML prion-infected. The mean + SEM of six wells 
are shown. * P < 0.05, ** P < 0.01.  
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Figure 3-9 Seven moPrP.3F4 single cell clones infected with RML prions propagate 
misfolded PrP 
(A) Non-infected and RML prion-infected cells were treated with formic acid for five minutes 
prior to staining with the 3F4 antibody. The percentage of cells positive for 3F4 staining was 
counted. PrP-KD cells, which do not express PrPC, were used as negative controls. i = RML 
prion-infected. The mean + SEM of 20 fields of view are shown. ** P < 0.01. (B) Confocal 
images of the non-infected (- RML prions) and RML prion-infected (+ RML prions) H6.2 and 
D7.1 clones stained with mouse monoclonal 3F4 antibody (green) following five minutes 
formic acid treatment. Residual 3F4 staining (white arrows) indicates that some of the cells 
contain formic acid-resistant PrP, which corresponds to misfolded PrP. Nuclei were stained 
with DAPI (blue). Scale bar = 15 µm.  
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3.3.5 FLAG- and MYC-tagged mouse PrPC expression in PrP-KD 
PK1 cells 
Mouse FLAG- and MYC-tagged Prnp (Appendix I and Appendix II) were 
generated by Dr Dave Emery (Henry Wellcome Laboratories for Integrated 
Neuroscience) and were cloned into the retroviral expression vector, pLNCX2, 
(Appendix III) using the following cloning strategy (Figure  3-10). 
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Figure 3-10 Cloning strategy for inserting FLAG and MYC tag sequence in pLNCX2 
The PCR scheme has been adapted from that previously seen with the incorporation of an 
EcoR I site into the 5’ sequencing (flanking PCR) primer and an Xho I site into the 3’ primer. 
This cloning strategy was developed by Dr Dave Emery (Henry Wellcome Laboratories for 
Integrated Neuroscience). 
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pLNCX2 vectors expressing FLAG- and MYC- tagged PrP were packaged into 
the PhiNX-eco retroviral producer cell line and ecotropic viruses were harvested and 
used for retroviral transduction of PrP-KD PK1 cells as described in section 2.2.3. 
P8(11)4.5 cells were transduced with six different mouse FLAG-tagged PrP constructs 
and PK-10Si8 cells were transduced with two different mouse MYC-tagged PrP 
constructs. Successfully transduced cells were isolated by appropriate antibiotic 
selections (Section 2.2.3) and mixed clones stably expressing tagged mouse PrPC were 
generated. Cells were screened for FLAG- and MYC-tagged PrPC expression by 
immunoblotting and immunofluorescence analysis (Figure  3-11 A, B and Figure  3-12). 
Immunoblotting of stable transformants of P8(11)4.5 and PK-10Si8 cell lysates 
transfected with FLAG- and MYC-tagged mouse PrPC constructs, respectively, using 
anti-PrP ICSM35 and anti-tag antibodies showed that the inclusion of the FLAG and 
MYC epitope in mouse Prnp does not prevent normal biosynthesis of PrPC (Figure 
 3-11 A, lanes 3-8, B, lanes 3 and 4). SDS-PAGE analyses showed a slightly decreased 
mobility of PrP-95ThrFLAG, PrP-143ThrFLAG, PrP-168ThrFLAG and PrP-
124GlyMYC construct when compared to N-terminal FLAG-tagged PrP (PrP-
22CysFLAG and PrP-30GlyFLAG), C-terminal MYC-tagged PrP (PrP-224AlaMYC) 
and wild type PrP (Figure  3-11 A, B). This was assumed to be due to conformational 
affects that result in a reduced migration. Detection of PrPC expression in PrP-
95ThrFLAG cells (Figure  3-11 A, top blot, lane 5) using anti-PrP ICSM35 antibody 
was failed by immunoblotting, since the 95ThrFLAG tag had been inserted into the 
same position as the epitope detected by the anti-PrP ICSM35 antibody (amino acid 
residues 93-105 on the N-terminal region of Prnp). Figure  3-11 A and B show that in 
comparison to non-transfected PK1 cells (top blots, lane 1), all the cells transduced 
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with FLAG- and MYC-tagged PrPC are expressing PrPC to different levels. In 
particular PrP-30GlyFLAG cells are heavily over-expressing FLAG-tagged PrPC 
(Figure 3-11 A, lane 4). Furthermore, the molecular weight of PrPC in the transfected 
cells appears slightly different from the endogenous PrPC produced in PK1 cells due to 
the insertion of the FLAG and MYC tag into Prnp. 
Immunofluorescence analysis of P8(11)4.5.FLAG and PK-10Si8.MYC cells 
demonstrated that the cellular distribution of FLAG- and MYC-tagged PrPC were 
similar to that of wild type PrPC in PK1 cells, predominantly on the plasma membrane, 
(Figure  3-12). Therefore, the presence of FLAG and MYC tag in Prnp does not seem 
to affect the normal physiological distribution of PrPC.  PrPC expression could not be 
detected in cells expressing PrP-143Asn FLAG, as the tag has been inserted in the 
epitope recognised by the ICSM18 anti-PrP antibody (amino acid residues 142–153).  
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Figure 3-11 Transduced P8(11)4.5 and PK-10Si8 mixed clones express Mouse FLAG- 
and MYC-tagged PrPC  
Lysates of the P8(11)4.5 and PK-10Si8 cell lines reconstituted with FLAG- and MYC-tagged 
PrP constructs were analysed by SDS-PAGE electrophoresis using mouse monoclonal anti-PrP 
antibody (ICSM35; top blot; A and B) and mouse monoclonal anti-FLAG (M2) and anti-MYC 
(9B11) antibody (middle blot; A and B). PK1 lysate is included to indicate physiological 
expression of PrPC (lane 1; A and B) and parental PrP-KD cell lines, P8(11)4.5 (lane 2; A) and 
PK-10Si8 (lane 2; B), were used as negative controls. Immunoblotting of β-actin, confirmed 
equal protein loading (A and B). (A) Expression of FLAG-tagged PrPC in the reconstituted 
cells was shown (lanes 3 to 8). Cells reconstituted with FLAG tag inserted in different position 
of Prnp express PrPC in different levels. PrP-30GlyFLAG cells are heavily over-expressing 
FLAG-tagged PrPC (lane 4). No PrPC expression was detected in PrP-95ThrFLAG cells (lane 
5) since the 95ThrFLAG tag has been inserted in the ICMS35 epitope (aa 96 and 109). (B) 
Immunoblotting analysis of MYC-tag reconstituted cells showed that MYC epitope in mouse 
Prnp does not prevent normal biosynthesis of PrPC (lanes 3 and 4). 
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Figure 3-12 Expression of FLAG- and MYC-tagged PrPC in reconstituted mixed clones 
Immunofluorescence staining was performed on reconstituted mixed clones expressing FLAG- 
and MYC-tagged PrPC using an anti-PrP antibody (Green; ICSM18). PrPC was dominantly 
expressed on the plasma membrane of the cells.  Note that PrPC expression levels vary depends 
on where the FLAG and MYC tags are inserted. Nuclei were stained with DAPI (blue). PK1 
and PrP-KD cells were used as positive and negative controls, respectivel. Scale bar = 30 µm.  
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3.3.6 Conversion of FLAG- and MYC-tagged mouse PrPC into 
misfolded PrP in reconstituted P8(11)4.5 and PK1-10Si8  
cells 
To check whether FLAG- and MYC-tagged PrP expressing cells were 
susceptible to prion infection, mixed clones were exposed to 0.1 % RML prion-
infected mouse brain homogenate and their infectivity levels were analysed (Figure 3-
13 and Figure 3-14). The SCA analysis demonstrated that PrP constructs with FLAG- 
tag inserted near the N-terminus of the protein (22CysFLAG, and particularly 
30GlyFLAG) reconstituted prion propagation very efficiently and contained high 
levels of PK-resistant PrP (Figure  3-13 A). Cells expressing molecules with tags 
inserted centrally within the PrP sequence did not support prion propagation (Figure 
 3-13 A and B). However, cells expressing MYC-tagged PrP with the tag inserted near 
the C-terminus (224AlaMYC) were found to propagate prions robustly and 
reproducibly (Figure  3-13 B). 
This finding was corroborated by immunoblotting on the PK-digested cell 
lysates of RML prion-infected P8(11)4.5-FLAG and PK1-10Si8-MYC cells (Figure 
 3-14 A and B). RML prion-infected PrP-22CysFLAG contained PK-resistant prion 
protein, a characteristic feature of PrPSc, to a similar level as wild type PK1 cells 
(Figure  3-14 A, lane 3). RML prion-infected PrP-224AlaMYC cell extracts contained 
low levels of PK-resistant PrP consistent with the SCA data (Figure  3-14 B, lanes 8, 9 
and 12). Finally, RML prion-infected PrP-30GlyFLAG cells heavily over-expressed 
PK-resistant PrP (Figure  3-14 A, lane 4). No significant levels of PK-resistant PrP 
were found in cells expressing the other FLAG (Figure  3-14 A, lanes 5-8) and MYC 
(data not shown) constructs. RML prion-infected PK1 cells were used as positive 
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controls to show the PK-resistant band in prion-infected cells and RML prion-infected 
PrP-KD PK1 cells were used as negative controls (Figure  3-14 A, lanes 1 and 2, B, 
lanes 1-5). Single cell cloning of FLAG- and MYC-tagged reconstituted PK1 cells was 
deemed unnecessary since the mixed clones were able to propagate misfolded tagged 
PrP.  
As aforementioned, PrP-30GlyFLAG cells were heavily over-expressing 
FLAG-tagged PrPC. Therefore to confirm that the PK-resistant PrP seen in the 
immunoblotting and the SCA analysis is true misfolded PK-resistant PrP molecules 
and not partially digested PrPC molecules, immunoblotting was performed on the 
lysates of non-infected and RML prion-infected PrP-30GlyFLAG cells (Figure  3-15). 
Expression of PrP in non-infected and RML prion-infected PrP-30GlyFLAG cells was 
shown respectively in figure  3-15, lane 1 and 2. Treatment of non-infected PrP-
30GlyFLAG cells with PK for 30 minutes at 37°C was sufficient to digest PrPC 
completely as no bands were seen on the blot (Figure  3-15, lane 3). Therefore, this 
demonstrates that the PK-resistant PrP of prion-infected PrP-30GlyFLAG cells seen on 
the SCA and immunoblots are not due to the partial digestion of PrPC. In addition, 
lower molecular bands were seen in the non-PK digested, RML prion-infected PrP-
30GlyFLAG cell lysates similar to the expected PrPSc signal in their PK-digested 
counterparts. This result follows the finding from Caughey and his colleagues that 
misfolded PrP are partially proteolysed within neuroblastoma cells (Caughey et al., 
1991). 
Taken together, N-terminally FLAG- and C-terminally MYC-tagged PK1 cells 
were able to propagate misfolded FLAG- and MYC-tagged PrP after exposure to RML 
prions and among those N-terminally FLAG-tagged cells, PrP-30GlyFLAG cells were 
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highly propagating the misfolded PrP. However, it became apparent during the course 
of my study that the N-terminal FLAG tag was readily cleaved during cellular 
processing such that a proportion of the tagged PrPSc in the cells was not detected by 
the anti-FLAG antibodies, making them unsuitable for this study. Therefore PrP-
224AlaMYC cells were expanded for further analysis and use in future experiments. 
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Figure 3-13 Misfolded PrP detection in P8(11)4.5.FLAG and PK-10Si8.MYC cells 
Susceptibility of RML prion-infected FLAG- and MYC-tagged PrP reconstituted cells to prion 
infection was analysed by the SCA at passage four using a mouse monoclonal anti-PrP 
antibody (ICSM18). (A) The SCA showed presence of PK-resistant PrP in P8(11)4.5 cells 
expressing 22CysFLAG and 30GlyFLAG constructs. RML prion-infected PK1 and parental 
PrP-KD cells were used as positive and negative controls, respectively. i = RML prion-
infected. The mean + SEM of six wells are shown. (B) The SCA data showed the relative prion 
susceptibility of cell lines expressing MYC-tagged PrP constructs compared with PrP-KD 
cells. PrP molecules with the MYC tag inserted near the C-terminus at Ala224 support prion 
propagation. RML prion-infected PrP-124GlyMYC cells and PrP-KD cells do not contain PK-
resistant PrP. i = RML prion-infected. The mean + SEM of six wells are shown.  
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Figure 3-14 PK-resistant detection in P8(11)4.5.FLAG and PK1-10Si8 cell lysates by 
immunoblotting 
(A) Western blot analysis of RML prion-infected P8(11)4.5-FLAG cells, demonstrated similar 
results as the SCA. Lysates were Immunoblotted with a mouse monoclonal anti-PrP antibody 
(ICSM35). RML prion-infected PK1 cells were included as a positive control (lane 1) and 
parental PrP-KD cell line, P8(11)4.5, was used as a negative control for PK-resistant PrP 
expression (lane 2). i = RML prion-infected (B) Western blots developed with anti-PrP and 
anti-MYC antibodies showing levels of PK-resistant PrP in control and RML prion-infected 
PK1, PrP-KD and PrP-224AlaMYC cell extracts. The cell extracts were harvested after 
passage five and analysed undigested or subjected to PK digestion by the indicated 
concentrations of PK prior to SDS-PAGE. RML Prion-infected PK1 cells contain PK-resistant 
fragments characteristic of PrPSc (lane 3) whereas non-infected cells do not (lane 2). PrP-KD 
cells exposed to prions do not contain PK-resistant PrP demonstrating that no residual inocula 
derived PrPSc remains in the cells (lane 5). Consistent with the SCA data RML prion-infected 
PrP-224AlaMYC cell extracts contained low levels of PK-resistant PrP such that the most 
abundant PK-resistant fragment in RML prion-infected cells was detected (lane 8). No PK 
resistant fragments were detected in non-infected cells treated in the same way (lane 7). 
Reducing the PK concentration increased the levels of MYC-tagged PK-resistant PrP (lane 9) 
and allowed detection with anti-MYC antibodies (lane 12). 
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Figure 3-15 PrP-30GlyFLAG cells produce PK-resistant PrP following RML prion 
exposure  
Lysates from non-infected and RML prion-infected PrP-30GlyFLAG cells were analysed by 
SDS-PAGE electrophoresis and were immunoblotted with a mouse monoclonal anti-PrP 
antibody (ICSM35). Expression of PK-resistant PrP was detected in RML prion-infected PrP-
30GlyFLAG cells (lanes 2 and 4). PrPC runs between 30-50 kDa in its three glycosylation 
states (di-glycosylated, mono-glycosylated, and un-glycosylated). Following PK treatment, 
which distinguishes between the PrPC and PrPSc, PrP bands shift to lower molecular weight in 
RML prion-infected PrP-30GlyFLAG cells (lane 4). Note PK digested PrPC completely in PrP-
30GlyFLAG cells (lane 3).  
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PrP-224AlaMYC molecules generate true infectious prions 
As novel PrP molecules, the infectious and pathological properties of 
misfolded PrP-224AlaMYC protein generated by prion exposure are untested. 
Therefore, to confirm that the infected PrP-224AlaMYC cells were generating bona-
fide prions, Tg20 mice, a transgenic mouse line that over-expresses PrP, were 
inoculated intracerebrally with extracts from RML-prion infected and non-infected 
PrP-224AlaMYC cells. PK1 and PrP-KD cells infected in parallel with these cultures 
were used as positive and negative controls, respectively.  As expected, inoculation of 
mice with RML prion-infected PK1 cell extracts resulted in prion disease in the mice 
(Table 3-1, Figure 3-16 and Fiure 3-17). In contrast, inoculation of extracts from RML 
prion treated PrP-KD cells, which do not propagate prions, did not result in prion 
diseases (Table 3-1, Figure 3-16 and Fiure 3-17), confirming that the cells at this stage 
(Passage five after RML prion exposure) do not contain residual inocula-derived RML 
prions. Inoculation of mice with RML prion-infected PrP-224AlaMYC cell extracts 
resulted in early clinical signs of scrapie, whereas, non-infected cell extracts from PrP-
224AlaMYC cultures not exposed to prions did not (Table 3-1). 
Mice inoculated with RML prion-infected PrP-224AlaMYC and PK1 cells 
were diagnosed with prion disease at an average of 67 days post-inoculation showing 
that the amount of PrPSc and presence of the tagged sequence in the misfolded PrP is 
not affecting the incubation time (Table 3-1). Biochemical analysis of the brains of the 
scrapie-affected mice showed that they contained PK-resistant PrP with a band pattern 
similar to that seen with RML prions (Figure 3-16, lanes 2 and 8). Histological 
analysis revealed classical prion neuropathology with PrPSc deposition, neuronal loss, 
spongiosis and gliosis (Figure 3-17). Control animals culled in parallel with scrapie-
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affected mice did not contain PrPSc or show any pathologic features (Figure 3-17). 
These experiments demonstrated that cells expressing PrP-224AlaMYC propagate true 
infectious tagged prions following RML prion exposure and cause diseases identical 
from that caused by RML prions expressed in wild type PK1 cells.   
 
Table 3-1 In vivo bioassay of the infectious and pathological properties of the novel 
tagged PrP molecules generated in PrP-224AlaMYC cells 
RML prion-infected PrP-224AlaMYC cells were screened for their infectivity by the SCA at 
passage five before they were injected intracerebrally into Tg20 mice (the mean from six 
replicates is shown). Non-infected PrP-224AlaMYC cells and RML prion-infected PK-10Si8 
PrP-KD cells were used as negative controls. RML prion-infected PK1 cells were used as 
positive controls. Pathological and biochemical analysis showed that inoculation of mice with 
RML prion-infected PrP-224AlaMYC cell extracts result in prion disease, however, mice 
inoculated with RML prion-infected PK-10Si8 PrP-KD cells and non-infected PrP-
224AlaMYC cells were not diagnosed with prion disease. Pathological and biochemical 
analysis were performed on the indicated number of animals from each group. Note the disease 
incubation time was similar in mice inoculated with RML prion-infected PrP-224AlaMYC 
cells and RML prion-infected PK1 cells. The mean ± SD of four independent experiments are 
shown.   
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Figure 3-16 Tg20 mice inoculated intracerebrally with extracts of RML prion-infected 
PrP-224AlaMYC cells develop prion disease (Biochemical analysis) 
(A) Western blots developed with anti-PrP ICSM35 antibody showed that Tg20 mice 
inoculated with extracts of RML prion-infected PK1 and PrP-224AlaMYC cells generate PK-
resistant PrP (PrPSc) with a triplet band pattern similar to RML prions (lanes 2 and 8), a 
diagnostic biochemical feature of prion disease. Inoculations with control cell extract (non-
infected PrP-224AlaMYC cells) or extracts from PrP-KD cells exposed to RML prions do not 
produce PK-resistant PrP (lanes 4 and 6).  
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Figure 3-17 Tg20 mice inoculated intracerebrally with extracts of RML prion-infected 
PrP-224AlaMYC cells develop prion disease (Histological analysis) 
Histological analysis of Tg20 mice brains inoculated intracerebrally with extracts of RML 
prion-infected PK1 cells (panels a–c) and PrP-224AlaMYC cells (panels g–i) revealed 
classical prion neuropathology with PrPSc deposition (ICSM35 immunostaining), neuronal loss 
and spongiosis (hematoxylin and eosin (H&E) staining) and gliosis (GFAP immunostaining). 
Brains from animals inoculated with extracts of RML prion-infected PrP-KD cells (panels d–f) 
or control non-infected PrP-224AlaMYC cells (panels j–l) did not contain PrPSc or show other 
diagnostic features. i = RML prion-infected. Scale bar = 80 μm on the H&E stained sections 
(panels a, d, g, j) and 160 μm for all other panels. Histology experiments were performed by 
Miss Caroline Powell (MRC Prion Unit, UCL Institute of Neurology) and Miss Julie Moonga 
(Department of Neurodegenerative Disease, UCL Institute of Neurology). 
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3.4 Discussion  
At present, little is known about the site of conversion of PrPC to PrPSc, and the 
details of cellular PrPSc trafficking.  This is particularly true of the initial stages of 
infection when prions are first applied to previously non-infected cells.  This is mostly 
due to the difficulties involved in differentiating de novo produced PrPSc from 
endogenous cellular PrPc and the PrP forms present in the inocula. Studies have shown 
that proteasome inhibition in prion-infected cell lines and mouse brain leads to the 
formation of PrPSc-containing aggresomes, which in turn activate caspase 3 and 8 and 
subsequently leads to cell death (Kristiansen et al., 2005; Dron et al., 2009). It has also 
been reported that disease-associated PrP specifically inhibits the proteolytic β 
subunits of the 26S proteasome in prion-infected cells and mice (Kristiansen et al., 
2007), indicating that misfolded PrP must have access to the cytosol. The site of 
conversion of PrPC to PrPSc has been suggested to be at the plasma membrane 
(Caughey and Raymond, 1991), or at the endolysosomal system (Campana et al., 
2005; Arnold et al., 1995). Hence, the development of experimental tools to study the 
early events of prion infection and investigate how PrPSc traffic around the cell and 
access the cytosol to interact with the UPS is important. 
To this end, PrP-KD PK1 cells were reconstituted with several differently 
tagged mouse PrP constructs, which were subsequently infected with RML mouse-
adapted prions to ascertain if the tagged PrP can be converted into PrPSc. The use of 
tagged PrPSc allows for differentiation between newly formed PrPSc (de novo 
production) and PrPSc already in the prion-containing inocula. This will also allow the 
study of the early temporal and spatial events in prion infection as well as PrPSc 
trafficking around the cell. Various forms of tagged PrP have been used in prion 
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research, including mouse PrP mutated to contain the commonly used 3F4 epitope and 
GFP, MYC and FLAG fusion proteins, however, most of them do not convert into 
PrPSc or have been expressed in a cell background where endogenous PrP is present 
(Rutishauser et al., 2009; Vorberg et al., 2004b; Greil et al., 2008; Magalhaes et al., 
2005; Raeber et al., 1992). Hence, generating an epitope-tagged PrPC chimera that 
supports prion conversion and generates an infectious tagged PrPSc is challenging. A 
C-terminal GFP tagged PrPC construct produced by Barmada and Harris failed to form 
PrPSc (Barmada and Harris, 2005), and even the insertion of a small ten amino acid 
MYC tag at position 230Ser of murine PrP abrogated prion conversion when expressed 
in a PrPC knockout mouse background (Rutishauser et al., 2009). 
Furthermore, the inhibition of PrPSc formation by non-homologous PrPC 
molecules has been observed in transgenic mouse models and cell cultures where 
endogenous PrP is expressed. Human PrP transgenic mice with endogenous mouse 
Prnp expression are as resistant as wild type mice to sporadic CJD prions and require 
the ablation of Prnp to acquire susceptibility (Telling et al., 1994; Telling et al., 1995). 
Similarly, mice expressing both the hamster PrP transgene and endogenous mouse 
Prnp exhibit longer disease incubation period for hamster scrapie compared to those in 
which mouse Prnp has been ablated (Bueler et al., 1993; Race et al., 2000). This 
inhibitory phenomenon of PrPSc formation is thought to be that non-homologous PrPC 
molecules readily interact with PrPSc but cannot be converted due to ‘dominant 
negative’ inhibition by endogenous PrP (Prusiner et al., 1990; Priola et al., 1994; 
Collinge et al., 1995; Horiuchi et al., 2000; Perrier et al., 2002). Therefore, in the 
unique cell system presented in this chapter, tagged PrP is expressed in a PrP-KD 
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neuroblastoma cell line essentially devoid of endogenous PrP, at least in terms of prion 
propagation. 
In this study, the ability of 3F4-, MYC- and FLAG-tagged PrPC to convert into 
PrPSc in prion-infected PK1 cells was measured. PrP-KD PK1 cells reconstituted with 
FLAG-, MYC- and 3F4-tagged PrP constructs expressed PrPC at near physiological 
levels seen in wild type PK1 cells and showed a normal sub-cellular PrPC distribution. 
Therefore, insertion of the tags into the Prnp does not seem to impair the expression or 
processing of mouse PrPC.  
The data presented here illustrates that replacement of leucine (L) 108 and 
valine (V) 111 with methionine (M) in the mouse PrP sequence to generate 3F4 
epitope or insertion of the MYC sequence at amino acid position 224 of the Prnp do 
not impair the PrP conversion. However, the PrPC conversion efficiency was reduced 
in cells expressing 3F4-tagged PrP compare to wild type PrPC; these results are in 
agreement with previous studies (Priola et al., 1994; Safar et al., 1998; Safar et al., 
2005; Rutishauser et al., 2009; Geissen et al., 2009). The reduced ability of 3F4-tagged 
PrPC to convert to PrPSc might be due to a disruption of the process by which PrPC is 
converted into PrPSc. For instance, interactions between dissimilar PrPSc and PrPC 
molecules might reduce the aggregation and accumulation of PrPSc by interfering with 
the interactions between different PrP monomers (Bolton and Bendheim, 1988; Hope 
et al., 1986).  
It was also demonstrated that prion-infected PrP-KD PK1 cells expressing 
22CysFLAG and 30GlyFLAG produce PK- and formic acid-resistant PrP, whereas no 
misfolded PrP was detected in cells transduced with the FLAG-tag at positions Thr95, 
Asn143, Gln168 and Thr199, despite careful consideration of their positioning outside 
Isolation of prion susceptible cell lines expressing tagged mouse PrP 
133  
 
of the known structured regions of the PrP molecule (Caughey, 2001; Telling et al., 
1997). Therefore, it seems that the N-terminus of PrPC is not critical for the conversion 
process (Flechsig et al., 2000; Legname et al., 2005; Muramoto et al., 1996; Zulianello 
et al., 2000), whereas any changes in the central region of PrP will prevent PrPC 
conversion to PrPSc (Caughey, 2001; Priola et al., 1994). Hence, impairment of prion 
propagation by inserting the FLAG- and MYC-tag centrally within the PrP sequence 
highlights the significance of the hydrophobic region of PrPC for prion conversion, 
where only minor substitutions or insertions of a few amino acids can prevent the 
accumulation of PrPSc. This finding is consistent with previous reports on the 
importance of sequence conservation in this region for efficient conversion (Hölscher 
et al., 1998; Zulianello et al., 2000). 
Results shown here suggest that placement of a FLAG tag at amino acid 
positions 22 and 30 of the PrP sequence does not interfere with PrPSc formation; 
however such constructs cannot be used to study trafficking of newly synthesised PK-
resistant FLAG-tagged PrPSc as the FLAG tags are in the PK-sensitive region of PrPC 
(amino acid residues 22-88). Previous studies have shown that the protease-resistant 
core of PrPSc extends from amino acid residues 89-230 (Telling et al., 1997). 
Therefore, PK treatment of the FLAG-tagged PrP results in the loss of the FLAG 
epitope when inserted at residues 22 and 30 making them unsuitable for this study. An 
alternative method could be to detect PrPSc in RML prion-infected cells expressing N-
terminal FLAG-tagged PrP using the protease thermolysin (Owen et al., 2007; 
Wadsworth et al., 2008). This thermostable protease cleaves at the hydrophobic 
residues Leu, Ile, Phe, Val, Ala, and Met that are absent from the protease accessible 
N-terminal region of PrPSc. Therefore, although thermolysin readily digests PrPC into 
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small protein fragments, full-length PrPSc are resistant to such proteolysis. In addition, 
these results showed that the misfolded PrP species (PK-resistant PrP molecules) have 
lower molecular masses than the normal, protease-sensitive PrP species and are not 
affected by moderate PK treatment. Further studies have shown that that the PrPSc N-
terminus is readily cleaved by the proteases in neuroblastoma cells (Caughey et al., 
1991; Borchelt et al., 1992). Hence, albeit thermolysin can be used to expose full 
length PrPSc, the N-terminal site of the protein cannot be protected from the cellular 
proteases. Therefore, using any N-terminal tag to study trafficking of tagged PrPSc will 
be challenging. 
Furthermore, the mouse bioassay studies on the novel PrP molecules (PrP-
224AlaMYC) showed that presence of MYC-tag at amino acid position 224 of PrPSc 
does not diminish PrPSc infectivity and Tg20 mice inoculated with cell extracts of the 
prion infected PrP-224AlaMYC developed prion diseases. These results also showed 
that there is no correlation between the amount of cell-derived PrPSc that is inoculated 
into the animals and the disease incubation time as all the animals injected with RML 
prion-infected PK1 and PrP-224AlaMYC cell extracts, which each line produces 
different amount of cell-derived PrPSc, developed neurodegeneration in the similar 
time. This mouse bioassay clearly demonstrates that a high titre of infectivity is present 
in both RML prion-infected PrP-224AlaMYC and PK1 cell lines. However, to 
measure the difference in infectivity levels between the samples, the infectivity titre 
needs to be calculated.    
Collectively, the data presented here supported the view that changes in the N-
terminal and extreme C-terminal segment of PrP protein do not interrupt the prion 
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conversion efficiency. While any changes in the central region of PrPC impinge prion 
propagation confirming the importance of this region in prion protein conversion.  
3.5 Summary    
Work in this chapter describes the successful transduction of PrP-KD PK1 cells 
with different 3F4-, FLAG- and MYC-tagged PrP constructs and the isolation of cell 
lines that were able to propagate misfolded PrP. Importantly, these cell lines were 
shown to express PrPC at near physiological levels and demonstrated a normal sub-
cellular PrPC distribution. The N-terminal region of PrPC was demonstrated to not be 
indispensable for PrPSc formation and prion propagation, whereas the highly conserved 
hydrophobic segment and the C-terminal hydrophobic region of PrPC are important for 
conversion of PrPC to PrPSc. It was demonstrated that H6.2 and D7.1 cells (expressing 
moPrP.3F4), PrP-224AlaMYC, PrP-22CysFLAG and PrP-30GlyFLAG cells are 
susceptible to RML prions. PrP-30GlyFLAG cells were shown to produce N-terminal 
FLAG-tagged misfolded PrP to levels greater than wild type PK1 cells. Furthermore, it 
was demonstrated that MYC-tagged PrPSc are true infectious particles and inoculation 
of them into Tg20 mice cause prion disease.   
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4 Rapid de novo prion conversion revealed using 
a novel cell system  
4.1 Background 
Chronically prion-infected cells synthesise PrPSc over multiple serial passages 
following exposure to prion-infected brain homogenates, and these cell lysates can 
cause prion diseases when inoculated into experimental animals (Doh-ura et al., 2000; 
Gilch et al., 2001; Aucouturier et al., 2001). Indeed both neuronal and non-neuronal 
cells can become persistently infected following exposure to specific prion strains 
(Race et al., 1987; Butler et al., 1988; Baron et al., 2006). Much of what is currently 
understood, therefore, about the process of cellular infection and subsequent PrPSc 
formation has resulted from studies using such chronically infected cellular models. 
Therefore, little is known about the immediate events of infection following initial 
exposure of susceptible cells to prions, and fundamental questions such as the 
timescale of the infection process or where PrP conversion initially occurs have not yet 
been unequivocally established. Attempts to study these early events of prion infection 
are difficult for several reasons: i) only relatively few cell culture systems have been 
described that are susceptible to prion infection; ii) newly-formed, host synthesised 
PrPSc is immunologically indistinguishable from both the PrPC expressed by the 
recipient cell and various PrPSc species present in the prion-infected brain homogenate 
inoculum; and, iii) the amount of PrPSc produced in susceptible cell lines is often 
relatively low (Vorberg et al., 2004b).  
However, several recent in vitro studies have studied the earlier stages of prion 
infection, showing that mouse neuroblastoma cells as well as fibroblast cells produce 
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de novo PrPSc after only four hours of scrapie exposure (Vorberg et al., 2004a) and that 
72 hours exposure to prion-infected material is necessary for PrPSc production in 
neuroblastoma N2a cells (Klohn et al., 2003). In vivo studies conducted by Flechsig 
and colleagues have shown that prion-infected stainless steel wires need only be 
inserted in recipient brains for 30 minutes to induce infection (Flechsig et al., 2001). 
Still most of these earlier studies remained limited by the difficulty of specifically 
distinguishing PrPSc in the inoculums from newly synthesised PrPSc in the cell, which 
may help to explain the apparently conflicting results. To our knowledge, however, no 
one has yet utilised a cellular model in which epitope-tagged PrPSc molecules are 
produced following inoculation, allowing investigation of the earliest timescales of PrP 
conversion and prion propagation.   
4.1.1 Aims 
The aim of this part of my thesis work was to study the earliest events in prion 
infection of cells and subsequent PrP misfolding and to assess the timescale that PrPC 
is converted to PrPSc following exposure to exogenous RML prions. 
4.2 Methods 
Formic acid extraction, PK digestion and GdnHCl denaturation followed by 
immunofluorescence staining were used to hydrolyse PrPC and expose PrPSc for 
subsequent detection in RML prion-infected cells (Section 2.4.2). RML prion infected 
cells were quantified as described in chapter two (Section 2.4.2, ‘Quantification of 
RML prion infected cells’). Data in figure  4-3, figure 4-6 and figure 4-9 were 
generated in collaboration with Dr Rob Goold (Department of Neurodegenerative 
Disease, UCL Institute of Neurology).  
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4.3 Results 
4.3.1 Characterisation of prion infected cells  
Removal of PrPC and exposure of PrPSc in RML prion-infected cells 
In order to study the biology of prion infection in cells it is essential to 
differentiate de novo synthesised PrPSc from the host PrPC. As there are no available 
antibodies that are specific for PrPSc, it is necessary to treat cells post-infection to 
remove detectable PrPC, leaving PrPSc available for immunodetection. As mentioned in 
Section 3.2.4, formic acid extraction is one technique used routinely in our lab to 
hydrolyse PrPC and reveal PrPSc (Kristiansen et al., 2005). However, there are two 
other established methods for achieving this that utilise the biochemical differences 
between PrPC and PrPSc. These are proteinase K (PK) digestion and guanidinium 
hydrochloride (GdnHCl) denaturation (Taraboulos et al., 1995; Veith et al., 2008). To 
compare each method in detail, PrP-224AlaMYC cells were treated with formic acid, 
PK or GdnHCl and subsequently stained with anti-MYC antibodies (Figure  4-1 A and 
B). RML prion-infected PrP-224AlaMYC cells contained a moderate level of resistant 
MYC-tagged PrPSc when treated with formic acid or PK (~ 15 % and 22 %, 
respectively) (Figure  4-1 A and B, + RML prions), whereas only low levels of 
background immunostaining (~ 3 %) were detected in non-infected cells, indicating 
PrPC had been effectively removed by these treatments (Figure  4-1 A and B, - RML 
prions). The low background level of staining remaining in the non-infected cells was 
mostly attributable to clumps of cells to which access of the formic acid or PK was 
restricted. Confocal imaging of these RML prion-infected PrP-224AlaMYC cells 
showed that both PK- and formic acid-resistant PrPSc were distributed at the plasma 
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membrane and in the perinuclear compartment (PNC) (Figure  4-1 A, arrows), 
consistent with previous observations of the sub-cellular distribution of PrPSc (Section 
1.6.2). As compared to formic acid and PK treatment, however, GdnHCl denaturation 
was less effective at removing PrPC staining, as higher levels of background 
immunostaining were detected in non-infected PrP-224AlaMYC cells (~ 11 %) (Figure 
 4-1 A and B, - RML prions). Results obtained from PK, formic acid and GdnHCl 
treated PK1 cells were consistent with those from PrP-224AlaMYC cells. Non-tagged 
PrPSc, visualised in formic acid and PK treated RML prion-infected PK1 cells and 
immunostained with the ICSM18 anti-PrP antibody, had a very similar sub-cellular 
distribution (Figure  4-2 A and B, + RML prions). This indicates that the MYC-tagged 
PrPSc displays a physiologically relevant cellular localisation. 
 
 
 
 
 
 
 
 
 
 
 
 
Rapid de novo prion conversion revealed using a novel cell system 
140  
 
 
 
Figure 4-1 Comparison of the methods used to visualise PrPSc in RML prion-infected 
PrP-224AlaMYC cells 
(A) Non-infected PrP-224AlaMYC (top panel) or chronically RML prion-infected PrP-
224AlaMYC (passage five following RML prion exposure - bottom panel) were fixed and 
treated with formic acid, PK or GdnHCl prior to staining with anti-MYC antibodies (green). 
Non-infected PrP-224AlaMYC cells showed no green staining after formic acid and PK 
treatment indicating that the PrPC had been removed. However, some residual staining was 
observed in non-infected cells after GdnHCl treatment. A proportion of RML prion-infected 
cells contained formic acid- and PK-resistant PrP (PrPSc) with a characteristic plasma 
membrane/perinuclear compartment distribution (arrow). Nuclei were stained with DAPI 
(blue). Scale bar = 15 µm. (B) Quantification of randomly chosen cell fields after the indicated 
treatments. Approximately 20 % of PrP-224AlaMYC cells in cultures exposed to RML prions 
contained formic acid- and PK-resistant PrP (PrPSc). The background staining observed in the 
non-infected PrP-224AlaMYC cells after formic acid and PK treatment is mostly attributable 
to clumped cells where access to the PrPc is restricted. GdnHCl treatment was less effective at 
removing PrPC staining. The mean + SEM of 20 fields of view are shown.  
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Figure 4-2 Comparison of the methods to visualise PrPSc in RML prion-infected PK1 
cells  
(A) Non-infected PK1 cells (top panel) or iPK1 cells (from chronically RML prion infected 
cultures, bottom panel) were fixed and treated with 98 % formic acid, PK or GdnHCl prior to 
staining with ICSM18 anti-PrP antibody (green). Merged confocal images are shown. 
Uninfected cells showed no staining after formic acid and PK treatment indicating that the 
PrPC has been removed. Some residual staining was observed after GdnHCl treatment. RML 
prion-infected cells contained formic acid and PK resistant PrP (PrPSc) with a characteristic 
plasma membrane/perinuclear compartment distribution. Nuclei were stained with DAPI 
(blue). Scale bar = 15 µm (B) Quantification of randomly chosen cell fields after the indicated 
treatments.  Approximately half of the iPK1 cells contained PrPSc. The low level of 
background staining observed in the PK1 cells after formic acid and PK treatment was mostly 
attributable to clumped cells where access to the PrPC is restricted. GdnHCl treatment was less 
effective at removing PrPC staining. The mean + SEM of 20 fields of view are shown.  
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The effective removal of PrPC in non-infected cells, and the appearance of 
formic acid- and PK- resistant PrPSc in infected cells, indicates that both formic acid 
extraction and PK digestion are effective at revealing PrPSc in RML prion-infected 
cells. Therefore, the distribution of formic acid-resistant tagged PrPSc was analysed in 
detail in 3F4-, FLAG- and MYC-tagged PrP expressing cells by dual staining of formic 
acid treated cells with anti-tag and anti-PrP antibodies (Figure  4-3). Cellular 
localisation of formic acid-resistant PrPSc in PK1-10Si8.3F4;D7.1 cells (expressing 
3F4-tagged PrP) (Section 3.3.4) and PrP-224AlaMYC cells (expressing MYC-tagged 
PrP) was similar to that described above, with strong staining at the plasma membrane 
and PNC. Importantly, anti-3F4 and anti-MYC tag antibodies colocalised perfectly 
with the ICSM18 anti-PrP antibody (Figure  4-3 D, E, I and J) and non-infected cells 
showed only very low background levels of immunostaining (Figure  4-3 A and F). In 
contrast, the FLAG-tag antibody used to immunostain RML prion-infected PrP-
30GlyFLAG cells (expressing FLAG-tagged PrP) did not overlap exactly with the 
staining from the anti-PrP antibody (Figure  4-3 N and O), and it appeared to cross-
react with other naturally occurring FLAG-like epitopes within the cells. Furthermore, 
unlike 3F4- and MYC-tagged PrP expressing cells, non-infected PrP-30GlyFLAG cells 
also showed very high levels of background immunostaining (Figure  4-3 K). This is 
possibly attributable to the very high expression of FLAG-tagged PrP in these cells 
(Figure 3-11 A, lane 4), making the formic acid extraction process less efficient. 
Moreover, since the N-terminus of PrPSc is truncated by endogenous proteases in 
lysosomes (Caughey et al., 1991); (Borchelt et al., 1992), it is also likely that a 
proportion of the N-terminal FLAG-tagged PrPSc in PrP-30GlyFLAG cells could not 
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be detected (Section 3.3.6). Therefore, PrP-30GlyFLAG cells were not used for any 
further studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rapid de novo prion conversion revealed using a novel cell system 
144  
 
 
Figure 4-3 Characterisation of newly formed tagged PrPSc distribution in RML prion-
infected cells 
Chronically RML prion-infected PK1-10Si8.3F4;D7.1, PrP-224AlaMYC and PrP-30GlyFLAG 
cells were fixed and treated with 98 % formic acid prior to staining with anti-tag (green) and 
ICSM18 anti-PrP (red) antibodies. Single channels and merged confocal images are shown as 
indicated. The anti-3F4 and anti-MYC staining overlapped exactly with the PrP antibody 
staining (panels D and I). However, the anti-FLAG antibody did not colocalise perfectly with 
the ICSM18 anti-PrP antibody (panels N). Panels E, J and O are enlarged images of the 
regions indicated by red squares in panels D, I and N. Note formic acid extraction was less 
efficient in removing PrPC in non-infected PrP-30GlyFLAG cells (panel k). Nuclei were 
stained with DAPI (blue). Scale bar = 30 µm. 
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Colocalisation of tagged-PrPSc with intracellular organelles 
To better understand the molecular events involved in PrP conversion and 
prion propagation, and how PrPSc might transport to the cytosol, it is important to 
know which sub-cellular compartments are implicated in the trafficking of PrPSc. 
Formic acid extracted PrP-224AlaMYC cells were dual-stained with an anti-MYC 
antibody and antibodies directed against various intracellular compartments, including 
early endosomes, recycling endosomes, lysosomes, the Golgi stack, the trans-Golgi 
network and the proteasome (Figure  4-4 A). Formic acid-resistant MYC-tagged PrPSc 
was partially colocalised with each of compartments above consistent with previous 
reports (Caughey et al., 1991; McKinley et al., 1991b; Borchelt et al., 1992; 
Kristiansen et al., 2005; Marijanovic et al., 2009). Dual staining experiments were also 
done on prion susceptible 3F4-tagged PrP expressing cells (PK1-10Si8.3F4;D7.1) 
(Section 3.3.4) and identical results to PrP-224AlaMYC cells were obtained (Figure 
 4-4 B). 
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Figure 4-4 Intracellular localisation of tagged PrPSc in RML prion-infected cells 
Chronically RML prion-infected PrP-224AlaMYC (A) and PK1-10Si8.3F4;D7.1 (B) cells 
were fixed and treated with 98 % formic acid for 5 minutes. Cells were stained with the anti-
MYC and anti-3F4 antibodies (green) together with marker antibodies for various cell 
compartments (red). Partial colocalisation of MYC- and 3F4-tagged PrPSc with early 
endosomes (EEA-1), recycling endosomes (TfR), lysosomes (LAMP-1), the Golgi (GM130), 
the trans-Golgi network (TGN38) and proteasomes (20S) was observed. Nuclei were stained 
with DAPI (blue). Scale bar = 15 µm except PK1-10Si8.3F4;D7.1 stained with Tfr and TGN38 
has the scale bar of 30 µm. 
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4.3.2 Cellular prion infection is a rapid process 
In order to further understand the details of PrP misfolding into its abnormal 
conformation; it is necessary to understand when the initial conversion of PrPC to PrPSc 
occurs in cells. The novel cell system expressing tagged PrP molecules in a prion 
susceptible environment, combined with effective PrPC removal by formic acid 
extraction allows de novo produced PrPSc to be clearly distinguishable from the PrPSc 
within the inoculum. This makes it possible to do a detailed temporal and spatial study 
of the earliest stages of prion infection for the first time.  
My initial experiments were focused on the time-course of RML prion 
infection. Previous work in the field suggests that 72 hours exposure to prion infected 
material is necessary to fully infect susceptible cells (Klohn et al., 2003). Hence, prion 
susceptible 3F4-tagged PrP expressing single cell clones PK1-10Si8.3F4;D7.1 (D7.1) 
and P8(11)4.5.3F4;H6.2 (H6.2) (Section 3.3.4) as well as PrP-224AlaMYC cells were 
first infected with 0.1 % RML prion-infected mouse brain homogenate for three days, 
and they were fixed either immediately or passaged in fresh media for up to 20 days 
prior to fixation. Non-infected D7.1, H6.2 and PrP-224AlaMYC were also fixed as 
negative controls. Following formic acid extraction and anti-tag antibody staining, 
immunofluorescent images were taken at each time-point (3 days, 4 days, 5 days, 6 
days and 14 days) and the number of 3F4- or MYC-tagged positive cells was counted. 
As mentioned previously, formic acid extraction does not necessarily hydrolyse all of 
the PrPC and some residual PrPC staining is almost always seen in formic acid 
extracted non-infected cells. Therefore, to ensure that the residual PrPC is not detected 
instead of PrPSc, the number of 3F4 and MYC positive cells in non-infected cultures 
with remaining PrPC were counted and subtracted from the number of positive cells in 
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those cultures infected with RML prions (Figure  4-5). Such quantification 
demonstrated that both RML prion-infected D7.1 and PrP-224AlaMYC cells have 
their highest percentage of cells producing RML prion-infected tagged PrPSc (~ 15 % 
and 28 %, respectively) after six days post-infection (Figure  4-5, red and blue) and 
stable prion propagation in a proportion of the cells was observed up to 20 days post 
infection (5th passage, data shown up to 14 days post-infection in Figure  4-5). In 
contrast, H6.2 cell cultures had their maximum numbers of RML prion-infected cells 
(~ 18 %) after four days post-infection, but the cells had lost their infectivity by 14 
days post-infection (Figure  4-5, green). Moreover, a significant proportion of D7.1, 
H6.2 and PrP-224AlaMYC cells already contained tagged PrPSc after three days RML 
prion exposure (Figure  4-5). This led, therefore, to examination in more detail of the 
first 72 hours of RML prion exposure. Since the prion infectivity of H6.2 cells was 
transient and D7.1 cells had lower levels of PrPSc expression, further experiments were 
performed on PrP-224AlaMYC cells reproducibly infected with RML prions.  
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Figure 4-5 3F4- and MYC-tagged PrPSc propagation in RML prion-infected cells 
D7.1, H6.2 and PrP-224AlaMYC cells were exposed to RML prions for 72 hours then fixed 
immediately or washed and cultured in fresh media (without RML prions) for the indicated 
times prior to fixation and formic acid extraction. Non-infected D7.1, H6.2 and PrP-
224AlaMYC were also fixed, formic acid extracted and immunostained at each time point as 
negative controls. Total numbers of non-infected cells staining positive using anti-3F4 or anti-
MYC antibodies were counted and subtracted from the number of 3F4- and MYC-positive 
cells in RML prion-infected H6.2, D7.1 and PrP-224AlaMYC cells. D7.1, H6.2 and PrP-
224AlaMYC cells contained formic acid-resistant PrP (PrPSc) after 72 hours RML prion 
exposure. At 14 days post-infection H6.2 cells lost their infectivity, whereas D7.1 and PrP-
224AlaMYC cells remained infected. The mean ± SEM of four independent experiments are 
shown.   
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Figure  4-6 A shows the proportion of infected cells over the first 72 hours of 
exposure of PrP-224AlaMYC cells to RML prions, revealing that they produce PrPSc 
very early in the time-course. Prior to RML prion exposure (0 hour), very few formic 
acid-resistant cells were detected, but subsequent RML prion exposure caused the 
rapid build up of formic acid-resistant PrPSc. MYC-tagged PrPSc positive cells were 
clearly detectable after two hours, and the maximum number of PrPSc positive cells 
was observed between three and four hours (~ 21 %). The number of RML prion-
infected cells then declined slightly to under 15 % at 72 hours (Figure  4-6 A). This was 
consistent with the number of RML prion-infected cells observed after three days post 
infection in the initial experiments (Figure  4-5). No MYC-tagged PrPSc was detected in 
RML prion-infected PrP-KD cells confirming that the anti-MYC antibody is specific 
in detecting only MYC-tagged PrPSc (Figure  4-6 A). These observations suggest that 
cellular prion infection is a dynamic process and occurs far more quickly than 
previously thought. Therefore, the first few minutes of prion exposure (0- 32 minutes) 
was examined in further detail. PrP-224AlaMYC cells were exposed to 0.1 % RML 
prions for short periods prior to rapid washing and fixation. A significant proportion of 
the cells showed clearly detectable levels of formic acid-resistant MYC-tagged PrPSc 
after as little as one minute exposure to RML prions (Figure  4-6 B), the shortest time 
period technically and reproducibly possible within the limits of the experimental 
system. Of note also was that the number of infected cells rose steeply in the first two 
minutes following exposure to RML prions indicating that this is when most cells first 
begin to synthesise de novo PrPSc. Figure  4-7 shows the confocal images of PrP-
224AlaMYC cells from 0 to 72 hours post-RML prion exposure. Formic acid-resistant 
MYC-tagged PrPSc were clearly detectable at the plasma membrane and in the PNC of 
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prion-exposed cells exposed to RML for less than 72 hours, consistent with them being 
stably infected cultures. Similar experiments using PK digestion confirmed the 
generation of protease resistant MYC-tagged PrPSc after very short periods of prion 
exposure (Figure  4-7, bottom panel). These studies were replicated by two independent 
investigators and analysed blinded by a third. 
Taken together, these time-course studies demonstrate that prion infection is a 
rapid process and cells exposed to RML prions start to produce newly formed PrPSc as 
early as one minute after infection. Seventy two hours exposure to RML prions is not, 
therefore, an absolute requirement for the infection of susceptible cell lines, with much 
shorter periods of time proving sufficient.  
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Figure 4-6 MYC-tagged PrPSc is synthesized rapidly following RML prion exposure 
(A) PrP-224AlaMYC cells were exposed to RML prions for 0 – 72 hours then fixed and 
formic acid extracted. The proportion of anti-MYC positive (RML prion-infected) cells fixed 
at the indicated times was quantified (red). As a control PrP-KD cells were exposed to RML 
prions and processed in parallel (blue). Note that PrP-224AlaMYC cells contain formic acid-
resistant PrP (PrPSc) as early as two hours RML prion exposure whereas PrP-KD cells do not 
stain significantly. The mean ± SEM of eight independent experiments are shown. (B) PrP-
224AlaMYC cells were exposed to RML prions for 0 – 32 minutes prior to fixation and formic 
acid extraction. The proportion of anti-MYC positive (RML prion infected) cells fixed at the 
indicated times was quantified. The number of infected cells rises steeply in the first two 
minutes after RML prion addition indicating that this is when most cells first begin to 
synthesize de novo PrPSc. The 4, 8 and 32 minute time points are the mean ± SEM of four 
independent experiments, whereas the 0, 1 and 2 minute time points are the mean ± SEM of 8 
independent experiments. * P < 0.05, ** P < 0.01. 
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Figure 4-7 Formic acid- and PK- resistant tagged PrPSc is synthesized rapidly following 
RML prion exposure 
Confocal images of RML prion-infected PrP-224AlaMYC cells fixed and formic acid 
extracted and PK digested prior to staining with anti-MYC antibodies (green). Formic acid-
resistant MYC tagged PrP positive cells were found as early as one minute post-RML prion 
exposure. PK digested PrP-224AlaMYC cells exposed to RML prions for two minutes 
contained PK-resistant PrPSc (bottom panel). Nuclei were stained with DAPI (blue). Scale bars 
= 15 µm.  
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4.3.3 Two minutes exposure to RML prions is sufficient to cause 
stable prion propagation  
To determine whether acute exposure to RML prions is sufficient to cause long 
term PrPSc propagation, PrP-224AlaMYC cells were exposed to 0.1 % RML prion-
infected mouse brain homogenates for two minutes, after which the cells were 
immediately fixed or washed thoroughly with fresh media and cultured for a further 48 
hours in the absence of the RML inocula. This demonstrated that approximately 22 % 
of the cells contained MYC-tagged PrPSc after two minutes RML prion exposure 
(Figure  4-8, 2 min). This level was maintained for 48 hours in the absence of RML 
prions (Figure  4-8, 2 min + 48 hr), showing that two minutes of prion exposure was 
sufficient to generate cells that stably propagate PrPSc. 
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Figure 4-8 Short RML prion exposure is sufficient to cause stable prion propagation 
PrP-224AlaMYC cells were exposed to RML prions for 2 minutes and fixed immediately or 
washed and cultured in fresh media (without RML prions) for 48 hours prior to fixation and 
formic acid extraction. The proportion of anti-MYC positive (RML prion-infected) cells fixed 
at the indicated times was quantified. Non-infected PrP-224AlaMYC cells (0 minute) were 
also fixed, formic acid extracted and immunostained in parallel to RML prion-infected PrP-
224AlaMYC cells as negative controls. Note cells exposed to RML prions for only 2 minutes 
maintained their infectivity for at least 48 hours. The mean + SEM of three independent 
experiments are shown.   
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4.3.4 Cellular PrPSc interaction is not sufficient to induce PrPSc 
propagation 
In analysing the presence of PrPSc in prion-infected cells, co-staining using 
anti-PrP and anti-MYC antibodies clearly showed that some cells stained positive at 
the plasma membrane for PrPSc, but not, for example, the MYC tag (Figure 4-9, 
arrows). This demonstrates that the PrPSc-staining in some cells can only be derived 
from the inoculum, as the absence of positive co-staining for the MYC tag after formic 
acid extraction indicates that it has not been synthesised by the cell. Therefore, these 
data demonstrate that the binding of RML prions alone to the plasma membrane of the 
cells and/or the internalisation of exogenous PrPSc is not necessarily sufficient to 
catalyse the conversion of endogenous PrPC to PrPSc, suggesting that other unknown 
factors are also required. They also suggest that the formic acid- and PK-resistant PrP 
(PrPSc) seen in cells shortly after exposure to RML prions is not merely due to 
detecting tagged-PrPC protected from formic acid treatment or PK digestion by a tight 
association with PrPSc from the inoculum. If tagged-PrPC and exogenous PrPSc were 
associating in this manner, it would be expected that all cells showing formic acid- or 
PK-resistant PrP would co-stain for both PrP and the MYC tag. That this is not the 
case indicates that those cells (~ 20 %) that do demonstrate co-localised PrP and MYC 
must be doing so as a result of producing de novo PrPSc.  
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Figure 4-9 Cellular PrPSc interaction is not sufficient to induce PrPSc propagation 
PrP-224AlaMYC cells exposed to RML prions for six hours were fixed and treated with 98 % 
formic acid prior to staining with ICSM18 anti-PrP (red) and anti-MYC (green) antibodies. 
Single channels and merged confocal images are shown as indicated. Note that some of the 
cells do not have newly synthesised PrPSc, albeit the RML prions are associated with their 
plasma membrane and/ or is internalised in those cells (arrows). Nuclei were stained with 
DAPI (blue). Scale bar = 15 µm. 
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4.4 Discussion  
Temporal analysis of the events immediately following cellular exposure to 
prion infected material has previously proven difficult, as newly formed PrPSc is 
immunologically indistinguishable from both the PrPC expressed by the recipient cells 
and PrPSc species in the brain homogenate inocula. The unique cell system generated 
here in which MYC epitope tagged-PrPSc is produced, combined with effective 
protocols to remove PrPC, allowed examination of PrP misfolding when prions initially 
contact and infect susceptible cells; this is the first time such an analysis has been 
possible.  
In view of the close similarity between the structures of PrPC and PrPSc, and the 
lack of antibodies specific for PrPSc, pre-treatments have been devised for 
immunostaining of PrPSc (Diedrich et al., 1991; Bell and Ironside, 1993). These are 
intended to exploit differing protease and detergent sensitivities, thereby destroying 
PrPC whilst retaining or enhancing the antigenicity of the pathogenetic isoforms. To 
immunostain disease-associated PrPSc, a variety of pre-treatments have been 
previously employed including incubation in formic acid (Kitamoto and Tateishi, 
1988; Lantos et al., 1992; Kristiansen et al., 2005), guanidine thiocyanate (Bell and 
Ironside, 1993; Ironside et al., 1993; Veith et al., 2008), and proteinase K (Taraboulos 
et al., 1990b; Fevrier et al., 2004; Veith et al., 2008). These studies have generally 
shown positive staining for PrPSc at the plasma membrane and in the perinuclear 
compartments (Caughey and Raymond, 1991; Arnold et al., 1995). In contrast, PrPC is 
fully hydrolysed by these treatments (Kristiansen et al., 2005; Veith et al., 2008). In 
agreement with these findings, results presented in this chapter revealed that formic 
acid and PK treatment were very efficient in removing PrPC and exposing PrPSc in 
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RML prion-infected PrP-224AlaMYC and PK1 cells. Previous studies have shown that 
the immunoreactivity of PrPC is lost when the normal isomer of PrP is exposed to 6 M 
GdnHCl (Thackray et al., 2007). This reflects the loss of surface exposed PrP epitopes 
within PrPC as a consequence of chaotropic agent-induced denaturation. In contrast, 
the immunoreactivity of disease-associated PrP is increased upon exposure to 6 M 
GdnHCl, which reflects the exposure of previously buried epitopes within PrPSc that 
are no longer accessible in denatured PrPC (Hilmert and Diringer, 1984; McKinley et 
al., 1991a). However, the data presented here shows that although GdnHCl was 
effective in denaturing of PrPC, it was not as efficient as formic acid and PK treatment 
in exposing PrPSc.  
Studies on persistently prion-infected cells reported the accumulation of PrPSc 
at the cells surface (Vey et al., 1996), and in association with the Golgi (Barmada and 
Harris, 2005), early endosomes (Godsave et al., 2008), late endosomes, lysosomal 
compartments (Arnold et al., 1995; Veith et al., 2008) and recycling vesicles (Godsave 
et al., 2008). Characterisation of susceptible cell lines producing tagged-PrPSc showed 
that formic acid-resistant 3F4- and MYC- tagged PrPSc has an identical cellular 
distribution to that reported previously for PrPSc that is not tagged. These data, 
therefore, confirm that the presence of the 3F4 and MYC tag does not affect the sub-
cellular localisation of PrPSc and further supported the use of formic acid treatment to 
reveal PrPSc in cultured cells. 
Earlier reports on the cell biology of prion infection indicate that cells take up 
inocula-derived PrPSc slowly (i.e. over days) and, several days of exposure to prions 
are necessary for susceptible cell lines to become infected (Magalhaes et al., 2005; 
Bergstrom et al., 2006). Conversely, however, data presented here shows that the 
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infection of cells is far quicker than previously supposed. This finding is supported by 
a previous study in which prions were immobilised on stainless steel metal rods that 
were then used to infect mice, showing that 30 minutes exposure or less was sufficient 
to generate prion infection in vivo (Flechsig et al., 2001). Another study has 
demonstrated the rapid endocytosis of semi-purified prions within minutes of 
application, suggesting that prion cell interactions may be very rapid (Jen et al., 2010). 
However, neither of these studies analysed de novo cellular prion conversion itself. 
The results presented here clearly show an accumulation of de novo cellular PrPSc as 
early as one minute exposure to RML prions. This is similar to an earlier study 
showing that PrPSc can be formed almost immediately following exposure to infectious 
scrapie inoculums; however, in this case, acute exposure to scrapie agents resulted for 
the most part in the transient formation of PrPSc (Vorberg et al., 2004b). In contrast, 
here it is demonstrated that only two minutes exposure to RML prion brain 
homogenate is sufficient to generate cells that continue to produce PrPSc in the absence 
of further prion exposure and the similarity in the appearance of PrPSc in these cells to 
persistently infected cells suggest that stable prion infection can become established 
over a very short time period.  
Interestingly, the data presented here show that association of RML-derived 
PrPSc to the plasma membrane of the cells and/or its internalisation, does not always 
necessarily lead to prion conversion. This confirms that the MYC-tagged PrPSc 
detected in cells shortly after RML exposure is true de novo PrPSc, rather than the 
MYC-tagged PrPC tightly bound to inocula-derived PrPSc. These findings are also 
supported by data presented in the previous chapter (Chapter 3), whereby it was 
demonstrated that insertion of FLAG or MYC tags into the hydrophobic segment or at 
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the C-terminal hydrophobic region of Prnp (Section 3.3.6) prevent PrPC conversion to 
PrPSc. This suggests that if the tagged-PrPSc detected in the susceptible cell lines was 
due to the binding between the tagged-PrPC and PrPSc in the inoculum, tagged PrPSc 
would be also detected in cells with the tag inserted in any regions of their Prnp.   
Several reasons can be attributed to a lack of PrP conversion in some cells that 
are associated and in contact with inocula-derived PrPSc molecules. The first 
possibility is that some cells are inherently slower in their conversion of PrPC to PrPSc 
and that the individual cells that were analysed may have gone on to demonstrate de 
novo PrPSc at some point after their fixation. Another possibility is that the 
reconstitution of PrP-KD cells with tagged PrPC does not have full penetrance. 
Therefore, there could always be some cells in the culture that do not express the PrPC 
that is essential for conversion (Bueler et al., 1993) to PrPSc. Hence, an association of 
prions with these cells would not result in the production of PrPSc without any PrPC to 
nucleate the conversion process. And finally, it is also possible these cells lacked prion 
susceptibility factors, as yet unknown, other than RML and PrPC expression that are 
required for the prion conversion process to take place.  
In conclusion, the unique cell system utilised here allowed the study of the 
earliest events in cellular prion conversion. The data presented in this chapter showed 
that cellular prion infection is a dynamic process that occurs within one minute of 
prion exposure. These results have important implications for understanding of the 
conversion and spread of prions in vivo. Once a sufficient of seed of infectious prions 
has been established in the brain, it is possible that prion cellular spread is likely to 
proceed far more rapidly than previously thought. These data cast new light on why 
prion infection can be very aggressive in vivo and affect the whole neuronal axis in a 
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few weeks. They suggest also that prion disease therapeutics aimed at preventing the 
conversion process itself by stabilising PrPC are likely to be more effective than 
strategies aimed at cleaning infectious prions once the disease is established. 
4.5 Summary 
The work in this chapter revealed that formic acid extraction and PK digestion are 
better than GdnHCl for hydrolysing PrPC and exposing PrPSc in RML prion infected 
PrP-224AlaMYC and PK1 cells. It was shown that formic acid-resistant tagged PrPSc 
accumulated mostly at the cell surface and perinuclear region of RML prion infected 
cells. Most importantly, study of the early events of prion infection showed that 
conversion of PrPC to PrPSc is very dynamic and it occurs as early as one minute 
exposure to RML scrapie prions. The data also demonstrated that two minutes of prion 
exposure is sufficient to generate cells that continue to stably propagate PrPSc in the 
absence of RML and finally it was demonstrated that association of RML prions with 
cells does not always lead to prion infection.       
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5 Cellular sites of de novo PrPSc formation and its 
intracellular trafficking  
5.1  Background 
Conversion of PrPC to PrPSc is the central event in the pathogenesis of 
transmissible prion diseases. In the established model of prion formation and 
propagation, direct interaction of endogenous PrPC with the pathogenic PrPSc template 
is required to drive conversion to the infectious PrP conformers (Weissmann, 1994; 
Caughey and Chesebro, 1997). Despite decades of research, however, there is little 
consensus as to the precise mechanism(s) of prion conversion, the location in the cell 
where this process occurs and the means of toxicity associated with the formation of 
PrPSc. 
A number of studies have already attempted to identify the intracellular site of 
prion conversion, mostly by analysing the sub-cellular localisation of PrPC and PrPSc in 
primary neurons (Shyng et al., 1993; Sunyach et al., 2003; Galvan et al., 2005), the 
brains of infected animals (Jeffrey et al., 1994; Grigoriev et al., 1999; Fournier et al., 
2000; Barmada and Harris, 2005; Godsave et al., 2008) and in infected cell lines 
(Borchelt et al., 1992; Beranger et al., 2002) using different techniques. However, 
these results remain controversial and the evidence for the involvement of any specific 
cellular compartment is not unequivocal.  
Characterising the precise cellular localisation of PrPC and PrPSc is essential to 
yield insights as to the site of prion conversion and the mechanisms that underlie prion 
formation. PrPC is a cell surface GPI-anchored protein which is synthesised in the 
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rough ER and travels to the membrane through the Golgi apparatus. PrPC has been 
shown to localise to different compartments depending on the cell type (Section 1.6.1), 
but it is generally found at the cell surface membrane associated with cholesterol-rich 
microdomains called lipid rafts (Turk et al., 1988; Caughey and Raymond, 1991; Vey 
et al., 1996), in the Golgi apparatus (Caughey et al., 1991; McKinley et al., 1991b; 
Borchelt et al., 1992), in early endosomes (Godsave et al., 2008), and in the endosomal 
recycling compartments (ERC) (Marijanovic et al., 2009). In primary neurons and N2a 
neuroblastoma cells, PrPC is internalised and then recycled back to the cell surface, 
with some being sent for degradation in lysosomes (Shyng et al., 1993; Sunyach et al., 
2003). 
In contrast to PrPC, the sub-cellular localisation of PrPSc is less well described. 
This is mainly due to the lack of antibodies that are specific to PrPSc. However, studies 
to date suggest a wide cellular distribution, in particular at the cell plasma membrane, 
in the Golgi and the endolysosomal compartment (McKinley et al., 1991b; Caughey 
and Raymond, 1991; Jeffrey et al., 1992; Arnold et al., 1995) (Section 1.6.2).  
Several studies indicate that PrPSc formation itself occurs either at the plasma 
membrane, where the initial contact between endogenous PrPC and exogenous PrPSc is 
likely to occur, or immediately after its internalisation in the endolysosomal 
compartments (Campana et al., 2005). Blocking PrPC endocytosis has been revealed to 
inhibit PrP conversion (Borchelt et al., 1992). Conversely, expression of dominant-
negative mutants of Rab 4, which inhibits recycling to the plasma membrane, results in 
an accumulation of PrPSc (Beranger et al., 2002). This suggests that PrPSc formation 
does not require recycling of PrPC to the cell surface and occurs at the initial contact 
between PrPC and PrPSc at the cell surface or within an intracellular compartment. 
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Indeed, a variety of evidence suggests that plasma membrane lipid rafts are the site of 
conversion, as both PrPSc and PrPC can be found in these rafts (Taraboulos et al., 1995; 
Vey et al., 1996; Naslavsky et al., 1997; Baron et al., 2002; Botto et al., 2004), 
however, Marijanovic et al. showed evidence that the ERC are the likely site of prion 
conversion (Marijanovic et al., 2009) (Section 1.6.2).  
Proteins can enter the cell through several different routes (Mayor and Pagano, 
2007). However, regardless of the means of internalisation, endocytosed proteins are 
first delivered to early endosomes. At this level, proteins to be recycled are returned to 
the cell surface either by a fast-recycling pathway, directly from early endosomes, or 
they are transported first to the ERC and then to the cell surface. In contrast, cargo 
destined for degradation is sorted to multi-vesicular late endosomes and finally to 
lysosomes, where degradation occurs (Gruenberg and Maxfield, 1995; Maxfield and 
McGraw, 2004). Using anti-MYC antibodies in the PrP-224AlaMYC cells in 
conjunction with methods presented in chapter four to remove PrPC, and to specifically 
detect newly formed PrPSc (i.e. pre-treatment with formic acid or proteinase K) the 
intracellular trafficking of de novo PrPSc can be tracked to answer some of the 
questions described above. 
5.1.1 Aims 
The aims of the current study were to identify the initial cellular site of PrPSc 
production and examine how trafficking impairment of PrPSc affects the PrP 
conversion and prion propagation.  
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5.2 Methods 
Treatment of PrP-224AlaMYC and iPK1 cells with pharmacological agents 
were undertaken as described in section 2.4.5 and section 5.3. Formic acid extraction 
followed by immunofluorescence staining was used to hydrolyse PrPC and expose 
PrPSc for subsequent detection in RML prion-infected cells (Section 2.4.2). RML prion 
infected cells were quantified as described in chapter two (Section 2.4.2, 
‘Quantification of RML prion infected cells’) unless otherwise specified. Confocal 
images and Orthogonal projections were generated as described in chapter two 
(Section 2.4.2, ‘Image acquisition’). For cell phenotypic analyses, z stacks 
encompassing the entire cell were obtained and cells were grouped into one of three or 
one of seven categories based on the localisation of MYC-tagged PrPSc; three 
categories are exclusively plasma membrane, plasma membrane/diffuse intracellular 
and plasma membrane/prinuclear. Seven categories are plasma membrane/prinuclear, 
perinuclear, diffuse perinuclear, plasma membrane/diffuse perinuclear, peripheral, 
plasma membrane/peripheral, exclusively plasma membrane. In each experiment, at 
least 50 cells were analysed for each condition. Immunoblotting was performed by Dr 
Rob Goold (Department of Neurodegenerative Disease, UCL Institute of Neurology) 
for detection of PrPSc expression in chronically infected PK1 cells (iPK1) treated with 
different pharmacological agents or incubated at different temperatures (Section 2.3.5 - 
2.3.8). Quantitative densitometry of iPK1 blots were performed as described in section 
2.3.10. Data presented in this chapter for naive cells were generated in collaboration 
with Dr Rob Goold (Department of Neurodegenerative Disease, UCL Institute of 
Neurology).  
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5.3 Results 
Sub-cellular trafficking of PrP is likely to play an important role in the 
mechanism that catalyses PrP misfolding, leading to the formation of PrPSc. The 
unique cell system described previously (Chapters 3 and Chapter 4), in which MYC-
tagged PrPC is able to convert to misfolded MYC-tagged PrPSc, allows the study of 
PrPSc trafficking, and analysis of the sites of PrPC conversion to PrPSc when the cells 
are exposed to infectious prions. To study the site of prion conversion, naive PrP-
224AlaMYC cells (i.e. cells not previously exposed to RML prions) were treated with 
different pharmacological agents (Section 2.4.1) or incubated at different temperatures 
for 30 minutes, and then were exposed to RML prions for a further four hours still in 
the presence of the agent or remaining at the set temperature. These pharmacological 
treatments or temperature shifts were also used on stable RML prion-propagating PrP-
224AlaMYC cells (i.e. cells that had been propagating PrPSc for four days). Texas-red 
labelled transferrin, widely used to characterise trafficking through endocytosis 
compartments, was added to both naive and prion-propagating cells towards the end of 
each incubation period to assess the efficacy of manipulations on the cellular 
endocytosis (Section 2.4.1).   
5.3.1 Conversion of PrPC to PrPSc is a post-translational event 
To delineate the cellular pathways utilised during the biosynthesis of protease-
resistant PrPSc, naive and prion-propagating PrP-224AlaMYC cells were treated with 
brefeldin A (BFA). BFA inhibits transport of proteins from the ER to the Golgi, and 
induces retrograde protein transport from the Golgi apparatus to the ER (Misumi et al., 
1986; Doms et al., 1989; Lippincott-Schwartz et al., 1989; Taraboulos et al., 1994). 
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This leads to an accumulation of proteins inside the ER. PrP-224AlaMYC cells treated 
with BFA were stained with a Golgi marker to validate the effects of BFA on the 
treated cells showing that the Golgi apparatus is disassembled in cells treated with 
BFA (Figure  5-1, bottom panel, red, white arrow). Moreover, numbers of RML prion-
infected cells were counted, demonstrating that BFA reduced the proportion of cells 
producing de novo PrPSc (as shown using naive cells), as well as the number of cells 
propagating PrPSc (as shown using prion-propagating cells) by about 80 % (Figure  5-2 
A and B). This suggests that PrPC transport to the plasma membrane is essential for 
PrP conversion and prion propagation. Figure  5-3 shows the confocal images of both 
naive and prion-propagating PrP-224AlaMYC cells treated with BFA and, as the 
vehicle used, dimethyl sulfoxide (DMSO, control condition). Close examination of 
control DMSO-treated cells infected with RML prions revealed that PrPSc had a sub-
cellular distribution that was essentially the same as non-DMSO treated PrP-
224AlaMYC and wild type PK1 cells (Section 4.3.1); i.e. strong staining at the plasma 
membrane and the PNC. However, the sub-cellular distribution of PrPSc changed 
dramatically in BFA-treated RML prion-infected PrP-224AlaMYC cells, in which 
diffuse PrPSc staining was noted at the plasma membrane and inside the cells (plasma 
membrane/diffuse perinuclear staining) (Figure  5-3 A and B, bottom panels, green). 
These confocal images of BFA-treated cells also showed that BFA does not inhibit the 
internalisation of transferrin, as Texas-red labelled transferrin was internalised into the 
cells and localised with the PNC.  
In addition to naive and prion-propagating PrP-224AlaMYC cells, chronically 
infected PK1 cells (iPK1) (i.e. cells producing PrPSc for at least 25 days) were also 
treated with BFA and the levels of PrPSc in the cells were measured directly using 
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quantitative immunoblotting. The amount of PrPSc was significantly reduced in BFA-
treated iPK1 cells, consistent with the findings obtained for naive and prion-
propagating PrP-224AlaMYC cells (Figure  5-2 C). 
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Figure 5-1 BFA disassemble the Golgi apparatus in PrP-224AlaMYC cells 
PrP-224AlaMYC cells were treated with BFA and DMSO (control condition) prior to staining 
with GM130 (Golgi marker, red). The Golgi sacks were clearly dispersed in PrP-224AlaMYC 
cells treated with BFA (bottom panel, red, white arrow). Nuclei were stained with DAPI 
(blue). Scale bar = 30 µm. 
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Figure 5-2 PrPSc propagation in RML prion-infected PrP-224AlaMYC and iPK1 cells 
treated with BFA 
(A) Naive PrP-224AlaMYC cells were pre-treated with BFA or DMSO for 30 minutes, and 
then they were exposed to 0.1 % RML prions for a further four hours. (B) Prion-propagating 
PrP-224AlaMYC cells were exposed to BFA or DMSO for four hours prior to formic acid 
extraction and immunostaining with anti-MYC antibodies. The numbers of anti-MYC positive 
cells were counted in both BFA- and DMSO- treated cells. The results were normalised to the 
control condition (DMSO) and is shown as a proportion of the control. Note that in both naive 
and prion-propagating cells BFA reduces the number of RML prion-infected cells by about 80 
%. (C) Lysates from chronically infected PK1 cells (iPK1 cells) (i.e. cells producing PrPSc for 
at least 25 days) treated with BFA or DMSO were analysed by SDS-PAGE electerophoresis 
and immunoblotted with an anti-PrP antibody (ICSM35). The band intensity for PrPSc was 
measured in iPK1 cells treated with BFA or DMSO and is shown as proportion of cellular 
PrPSc. Quantitative densitometry of blots showed PrPSc expression was reduced by about 60 % 
in BFA-treated cells. Mean + SEM of four independent experiments are shown. * P < 0.05, ** 
P < 0.01. 
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Figure 5-3 Sub-cellular distribution of MYC-tagged PrPSc in RML prion-infected PrP-
224AlaMYC cells treated with BFA 
(A) Naive and (B) prion-propagating PrP-224AlaMYC cells were exposed to BFA or DMSO 
and Texas red-labelled transferrin (red). Cells were fixed and formic acid extracted prior to 
immunostaing with anti-MYC antibodies (green). Single channels and merged confocal images 
are shown, as indicated. Note that neither BFA nor DMSO has affected the internalisation of 
transferrin (red, A and B). Cells treated with DMSO showed the typical plasma membrane and 
PNC PrPSc distribution (green, A and B top panels). However, cells treated with BFA had 
membrane diffuse perinuclear staining (green, A and B bottom panels). Nuclei were stained 
with DAPI (blue). Scale bar = 15 µm. 
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5.3.2 The role of plasma membrane and endocytic pathways in 
prion conversion and propagation 
To examine the role of plasma membrane and endosomal compartments in 
prion conversion, naive and prion-propagating PrP-224AlaMYC cells were incubated 
at 4°C / 20°C or treated with nocodazole or bafilomycin. To identify the pathways 
involved in prion conversion, it was necessary to determine the extent to which each 
treatment affected endocytic pathways in pharmacologically manipulated PrP-
224AlaMYC cells. To this end, the trafficking of Texas-red labelled transferrin was 
analysed ( Section 5.3). Immunostaining of cells infected with RML prions following 
formic acid extraction under control conditions (i.e. addition of DMSO vehicle) had 
normal sub-cellular PrPSc localisation. Prominent plasma membrane and PNC staining 
of PrPSc was observed in nearly all of the DMSO-treated cells. Texas-red labelled 
transferrin was localised with the PNC, marking early/late and recycling endosomes. 
Consistent with earlier observations, a partial colocalisation of PrPSc with Texas-red 
labelled transferrin was observed (Figure  5-5 A and B, top panels, Figure  5-7 and 
Figure  5-8 top panels, Figure  5-12 A and B, top panels).  
Endocytosis is not essential for prion conversion and propagation 
Studies have shown that cellular endocytosis is blocked at 4°C in mammalian 
cells (Goldenthal et al., 1984). To examine, therefore, the role of endocytosis in PrP 
conversion and prion propagation, naive and prion-propagating PrP-224AlaMYC cells 
were both incubated at 4°C (Section 5.3). Inhibition of endocytosis by incubating the 
cells at 4°C was shown to reduce the number of RML prion-infected cells 
significantly, but did not completely eradicate RML prion infection (Figure  5-4 A and 
B). No Texas-red labelled transferrin was internalised into the cells incubated at 4°C, 
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demonstrating that endocytosis was severely restricted (Figure  5-5 A and B, bottom 
panels, red). To observe the cellular localisation of PrPSc, RML prion-infected cells 
treated under different conditions, were categorised into seven phenotypes of PrPSc 
distribution (Figure  5-6 A and B) and the percentage of the cells showing each 
phenotype in different treatment conditions were quantified. In cells incubated at 37°C 
(control condition), PrPSc was mostly localised at the plasma membrane and PNC 
(Figure  5-5 A and B, top panels, green, Figure  5-6 A and B), whereas a significant 
number of RML prion-infected cells (about 50 %) incubated at 4°C showed PrPSc 
staining only at the plasma membrane (Figure  5-5 A and B, bottom panels, green, 
Figure  5-6 A and B). This suggests that the plasma membrane may play an important 
role in the conversion of PrPC to PrPSc, and endocytosis may not be necessary for PrP 
conversion and prion propagation. Incubation of iPK1 cells at 4°C also reduced the 
level of PrPSc significantly (Figure  5-4 C), suggesting that the mechanisms that results 
in initial PrP conversion and prion propagation are similar. 
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Figure 5-4 Inhibition of prion endocytosis reduces but does not eliminate PrPSc 
production and propagation 
(A) Naive and (B) prion-propagating PrP-224AlaMYC cells incubated at 4°C or control 
temperature (37°C) were fixed, formic acid extracted and immunostained with anti-MYC 
antibodies. The numbers of anti-MYC positive cells were counted in both DMSO and 4°C 
treated cells. The results were normalised to the control condition (37°C) and is shown as 
proportion of the control. Incubation of naive and prion-propagating cells at 4°C radically 
decreased the number of RML prion- infected cells but it did not completely eliminate PrP 
conversion and prion propagation. (C) Lysates from iPK1 cells incubated at 4°C or control 
temperature (37°C) were analysed by SDS-PAGE electerophoresis and immunoblotted with 
anti-PrP antibody (ICSM35). The amount of PrPSc in iPK1 cells after each treatment was 
measured using quantitative densitometry. The levels of PrPSc expression was reduced by 
about 60 % at 4°C. Mean + SEM of four independent experiments are shown. * P < 0.05, ** P 
< 0.01. 
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Figure 5-5 Sub-cellular distribution of MYC-tagged PrPSc in RML prion-infected PrP-
224AlaMYC cells treated at 4°C 
Confocal images of (A) naive and (B) prion-propagating PrP-224AlaMYC cells incubated at 
4°C or control temperature (37°C) and exposed to Texas red-labelled transferrin (red). Cells 
were fixed and formic acid extracted prior to immunostaing with anti-MYC antibodies (green). 
Single channels and merged confocal images are shown as indicated. Note that incubation at 
4°C has severely inhibited the internalisation of transferrin (red, A and B). Cells incubated at 
4°C mostly had PrPSc localised on their cell surface (green, A and B top panels). Nuclei were 
stained with DAPI (blue). Scale bar = 15 µm. 
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Figure 5-6 Cellular localisation of MYC-tagged PrPSc at 4°C in naive and prion-
propagating PrP-224AlaMYC cells  
The cell phenotypes of (A) naive and (B) prion-propagating PrP-224AlaMYC cells were 
observed and quantified after incubation at 4°C. In compare to cells treated at 37°C, higher 
percentages of both naive and prion-propagating cells have the plasma membrane staining at 
4°C. Mean + SEM of four independent experiments are shown. 
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Trafficking events downstream of early endocytosis do not appear to 
be involved in PrP conversion and prion propagation     
 Nocodazole is an anti-neoplastic agent that interferes with polymerisation of 
microtubules and results in the loss of microtubule dependent processes in the cell 
(Bayer et al., 1998). One consequence of treating cells with nocodazole is an 
accumulation of endocytosed material in endosomal carrier vesicles (ECV), a 
compartment intermediate between early and late endosomes (Gruenberg et al., 1989). 
This causes inhibition of cellular trafficking immediately following endocytosis, as 
progression to downstream compartments including late endosomes, lysosomes and 
endosomal recycling compartments is prevented. In naive and prion-propagating PrP-
224AlaMYC cells, this resulted in the accumulation of small endocytic vesicles 
labelled with Texas-red labelled transferrin at the cell periphery, with little or no 
staining apparent at the PNC (Figure  5-7 and Figure  5-8, second panels, red). 
Nocodazole did not have a significant effect on the number of RML prion-infected 
cells (Figure  5-9 A and B). However, treatment of naive and prion-propagating PrP-
224AlaMYC cells with nocodazole had a noticeable effect on the sub-cellular 
distribution of PrPSc. Nearly all of the RML prion-infected cells showed a strong 
plasma membrane and peripheral PrPSc distribution (Figure  5-7 and Figure  5-8, second 
panels, green, Figure  5-10 A and B), whilst PrPSc was mostly found at the typical 
plasma membrane and PNC appearance in DMSO-treated cells (Figure  5-7 and Figure 
 5-8, top panels, green, Figure  5-10 A and B). In cells treated with nocodazole, 
intracellular staining of PrPSc was restricted to small puncta that showed only a low 
level of colocalisation with labelled transferrin (Figure  5-7 and Figure  5-8, second 
panels). 
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To confirm the results obtained from treating cells with nocodazole, naive and 
prion-propagating PrP-224AlaMYC cells were also treated with bafilomycin or 
incubated at 20°C. Bafilomycin arrests the transport of endocytosed materials in early 
endosomes and, therefore, inhibits cellular trafficking from early to late compartments 
(Bayer et al., 1998). A shift in temperature to 20°C has been shown to slow trafficking 
progression to lysosomes and the ERC in many cell types (Blighta and Morgana, 
1987). Neither treatment with bafilomycin treatment nor a 20°C temperature shift 
affected Texas-red labelled transferrin transport into the PrP-224AlaMYC cells (Figure 
 5-7 and Figure  5-8, third and fourth panels, red), and consistent with the effect of 
nocodazole shown above, they did not reduce the number of RML prion-infected PrP-
224AlaMYC cells (Figure  5-9 A and B). Taken together, these findings suggest that 
PrP conversion and prion propagation take place at the plasma membrane and/or early 
in the endocytic pathway and late endosomes/lysosomes are not involved in the PrPSc 
formation and propagation. Further validation was obtained by manipulating iPK1 
cells in the same way. The levels of PrPSc found in iPK1 cells treated with nocodazole, 
bafilomycin or incubated at 20°C correlated well with the proportion of RML prion-
infected cells in manipulated PrP-224AlaMYC cells (Figure  5-9 C). 
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Figure 5-7 Sub-cellular distribution of MYC-tagged PrPSc in naive PrP-224AlaMYC cells 
after treatment with nocodazole, bafilomycin or 20°C temperature shift 
Naive PrP-224AlaMYC cells were incubated at 20°C or exposed to DMSO, nocodazole or 
bafilomycin and Texas red-labelled transferrin (red) then fixed and formic acid extracted prior 
to immunostaing with anti-MYC antibodies (green). Single channel and merged confocal 
images are shown as indicated. RML prion-infected PrP-224AlaMYC cells treated with 
nocodazole showed strong plasma membrane and peripheral PrPSc distribution. However, 
RML prion-infected cells incubated at 20°C, or treated with DMSO or bafilomycin mostly had 
PrPSc localised at their plasma membrane and PNC. Note that in cells treated with nocodazole, 
Texas-red labelled transferrin has accumulated in the small endocytic vesicles at the cell 
periphery, with little or no staining apparent at the PNC and only a low level of colocalisation 
with PrPSc. Nuclei were stained with DAPI (blue). Scale bar = 15 µm. 
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Figure 5-8 Sub-cellular distribution of MYC-tagged PrPSc in prion-propagating PrP-
224AlaMYC cells after treatment with nocodazole, bafilomycin or 20°C temperature 
shift 
Confocal images of prion-propagating PrP-224AlaMYC cells treated with nocodazole or 
bafilomycin or incubated at 20°C, and exposed to Texas red-labelled transferrin (red). Cells 
were fixed and formic acid extracted prior to immunostaing with anti-MYC antibodies (green). 
Single channels and merged confocal images are shown as indicated. Nocodazole has blocked 
trafficking of transferrin to the PNC; however, the trafficking of transferrin is not impaired by 
bafilomycin treatment or a 20°C temperature shift (red). Note that cells treated with 
nocodazole mostly had PrPSc localised on the plasma membrane and cell periphery (green). 
Nuclei were stained with DAPI (blue). Scale bar = 15 µm. 
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Figure 5-9 Inhibition of PrP trafficking beyond the early endosomes does not affect PrP 
conversion and prion propagation 
(A) Naive and (B) prion-propagating PrP-224AlaMYC cells exposed to nocodazole or 
bafilomycin, or incubated at 20°C were fixed, formic acid extracted and immunostained with 
anti-MYC antibodies. Cells treated with DMSO were used as the control condition.  The 
numbers of anti-MYC positive cells were counted, the results were normalised to DMSO-
treated cells and are shown as proportion of the control. Note that the number of RML prion-
infected cells was slightly increased after nocodazole treatment and 20°C temperature shift, 
whereas bafilomycin did not affect the proportion of PrPSc positive cells. (C) Lysates from 
iPK1 cells treated as above were analysed by SDS-PAGE electerophoresis and immunoblotted 
with an anti-PrP antibody (ICSM35). The amount of PrPSc in iPK1 cells after each treatment 
was measured using quantitative densitometry. The levels of PrPSc expression did not change 
significantly in manipulated iPK1 cells. Mean + SEM of four independent experiments are 
shown. 
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Figure 5-10 Cellular localisation of MYC-tagged PrPSc in naive and prion-propagating 
PrP-224AlaMYC cells treated with nocodazole 
Cellular phenotypes of (A) naive and (B) prion-propagating PrP-224AlaMYC cells were 
observed and quantified after indicated treatments. Note that the cellular localisation of PrPSc 
has shifted from membrane/perinuclear to membrane/peripheral after nocodazole treatment. 
Cells treated with DMSO were used for the control condition. Mean + SEM of four 
independent experiments are shown. 
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PrP endocytosis is not dependent on dynamin  
Several lines of evidence have suggested that PrPC is internalised via a 
dynamin dependent pathway (Magalhaes et al., 2002; Sunyach et al., 2003; Sarnataro 
et al., 2009). To examine the mechanisms by which PrPSc is endocytosed, and observe 
how impairment of dynamin-dependent endocytosis affects PrP conversion and 
cellular trafficking of PrPSc, naive and prion-propagating PrP-224AlaMYC cells were 
treated with dynasore. Dynasore is a small molecule GTPase inhibitor that targets 
dynamin-1, dynamin-2 and dystrophin-related protein 1 (Drp1, the mitochondrial 
dynamin) (Macia et al., 2006). Therefore, Dynasore is meant to block any dynamin-
dependent processes in the cell such as clathrin-coated vesicle formation in 
endocytosis, ligand uptake through caveolae and the pathway from recycling 
endosomes to the plasma membrane (Abazeed et al., 2005; Cao et al., 2005; Damke et 
al., 1994; Hill et al., 2001; Van Dam and Stoorvogel, 2002; Nabi and Le, 2003). 
Treatment of PrP-224AlaMYC cells with dynasore did not change the number of RML 
prion-infected cells (Figure  5-11 A and B), but had a partial effect on the distribution 
of PrPSc, with most of the cells showing a localisation with the PNC but lacking the 
typical plasma membrane staining (Figure  5-12 A and B, bottom panels, green - 
arrows, Figure  5-13 A and B). Significantly, very little Texas-red labelled transferrin 
was internalised into the dynasore treated cells (Figure  5-12 A and B, bottom panels, 
red), indicating that dynamin, which is essential for clathrin-mediated endocytosis of 
transferin, was effectively inhibited. The lack of PrPSc on the plasma membrane and its 
presence at the PNC in the absence of transferrrin suggest that endocytosis of PrPSc 
does not require dynamin, whereas its recycling to the cell surface does. As shown in 
several studies, formation of the ERC and their transport to the cell surface require 
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dynamin (Van Dam and Stoorvogel, 2002; Pagano et al., 2004). The effect of dynasore 
was also tested in chronically infected PK1 cells. The proportion of cells that were 
infected with RML prions in iPK1 cells was similar to those seen in naive and prion-
propagating cells (Figure  5-11 C). In a recent study by Marijanovic et al., the ERC was 
suggested to be the likely site of prion conversion. Their results showed that the 
recycling of PrP through the ERC is required for PrPSc production (Marijanovic et al., 
2009). Figure  5-11 C shows that blocking the formation of the ECR does not affect the 
number of cells producing PrPSc. Hence, in contrast to the finding presented by 
Marijanovic et al., the results presented here showed that the ERC and/or return of 
PrPSc to the cell surface are not required for PrP conversion and prion propagation. 
Moreover, these observations demonstrate that internalisation of PrPSc is independent 
of both caveolae- and clathrin-mediated endocytosis.  
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Figure 5-11 Inhibition of dynamin-dependent processes in RML prion-infected PrP-
224AlaMYC and iPK1 cells does not affect PrPSc production and propagation  
(A) Naive and (B) prion-propagating PrP-224AlaMYC cells were treated with dynasore and 
DMSO, and then fixed, formic acid extracted and immunostained with anti-MYC antibodies. 
The numbers of anti-MYC positive cells were counted in both DMSO- and dynasore-treated 
cells. The results were normalised to the control condition (DMSO) and are shown as a 
proportion of the control. Inhibition of dynamin-dependent processes in naive and prion-
propagating cells using dynasore did not affect the number of RML prion- infected cells (C) 
Lysates from iPK1 cells treated with dynasore and DMSO were analysed by SDS-PAGE 
electrophoresis and immunoblotted with an anti-PrP antibody (ICSM35). The amount of PrPSc 
in iPK1 cells after each treatment was measured using quantitative densitometry. Note that the 
levels of PrPSc expression did not change after the indicated treatments. Mean + SEM of four 
independent experiments are shown. 
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Figure 5-12 Sub-cellular distribution of MYC-tagged PrPSc in RML prion-infected PrP-
224AlaMYC cells treated with dynasore 
Confocal images of (A) naive and (B) prion-propagating PrP-224AlaMYC cells exposed to 
dynasore and Texas red-labelled transferrin (red). DMSO treatment was used as the control 
condition. Cells were fixed and formic acid extracted prior to immunostaing with anti-MYC 
antibodies (green). Single channels and merged confocal images are shown as indicated. It was 
noticed that dynasore treatment at 4°C had severely inhibited the internalisation of transferrin 
(red, A and B). Dynasore- treated cells mostly had PrPSc localised in their PNC with no PrPSc 
on their plasma membrane (green, A and B bottom panels, arrows). Nuclei were stained with 
DAPI (blue). Scale bar = 15 µm. 
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Figure 5-13 Cellular localisation of MYC-tagged PrPSc in naive and prion-propagating 
PrP-224AlaMYC cells treated with Dynasore 
Cellular phenotypes of (A) naive and (B) prion-propagating PrP-224AlaMYC cells were 
observed and quantified after indicated treatments. Note that the number of cells with PrPSc 
localised in the PNC significantly increased as compared to DMSO-treated cells. Mean + SEM 
of four independent experiments are shown. 
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5.3.3 Prion conversion first occurs at the cell surface within one 
minute of prion exposure  
Impairing protein trafficking in PrP-224AlaMYC cells suggested that 
conversion of PrPC to PrPSc occurs on the plasma membrane and/or early in the 
endocytic pathway. Moreover, the data presented in the previous chapter revealed that 
PrP-224AlaMYC cells produce PrPSc as little as one minute exposure to RML prions 
(Section 4.3.2). It was also demonstrated that the number of RML prion-infected cells 
rose steeply in the first two minutes following RML prion exposure indicating that this 
is the period when most cells first begin to synthesise de novo PrPSc (Figure 4.6 B). 
These findings allowed the cellular site of initial prion conversion to be studied. 
Examination of cells fixed after one minute of prion exposure revealed that the 
MYC-tagged PrPSc signal was only present at the plasma membrane (Figure 4.7, 1 
min). Orthogonal projections of serial confocal sections also clearly showed that PrPSc 
was localised only at the cell surface (Figure  5-14 A, 1 min, white arrows). This 
cellular distribution was strikingly different from the more typical plasma membrane 
and intracellular localisation observed in cells that had been exposed to prions for 
longer times (Figure  5-14 A, 180 min, arrows). Categorising the cells into three 
phenotypes of different PrPSc distributions (plasma membrane, plasma membrane 
/diffuse intracellular and plasma membrane/perinuclear) and examining each 
phenotype at different times following RML prion exposure revealed a rapid transition 
from the plasma membrane distribution seen at the earliest time-point to the typical 
plasma membrane/PNC distribution observed later (Figure  5-14 B). Indeed, cells 
showing exclusively plasma membrane MYC-tagged PrPSc staining disappeared after 
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two minutes exposure to RML prions, consistent with rapid PrPSc formation, 
endocytosis and trafficking.  
To confirm this result, the endocytosis of Texas-red labelled transferrin was 
directly compared with the formation and trafficking of MYC-tagged PrPSc. 
Transferrin endocytosis and trafficking occurred rapidly, reaching a steady-state 
distribution at the PNC between 8 and 16 minutes (Ghosh, 1994) (Figure  5-15, red, 
yellow arrows). In the same cells, PrPSc attained a steady-state distribution in nearly all 
cells by four minutes exposure to prions (Figure  5-14 B, Figure  5-15, green, white 
arrows). Therefore, de novo prion protein conversion, endocytosis and trafficking 
proceeds at similar rates or faster than transferrin trafficking. 
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Figure 5-14 Prion conversion first occurs at the cell surface within one minute of prion 
exposure 
 (A) PrP224-AlaMYC cells were exposed to RML prions for the indicated times then fixed and 
formic acid extracted prior to staining with anti-MYC antibodies (green). Orthogonal 
projections (red and green squares) of serial confocal sections are shown alongside one z-
section taken from the middle of the cell (as indicated by the guide lines). A cell fixed after 1 
min exposure to RML prions shows PrPSc immunostaining only at the cell surface (1 min, 
white arrow). An adjacent cell in the field that has high levels of plasma membrane PrPSc also 
shows low intracellular levels of PrPSc (1 min, yellow arrow). Cells exposed to prions for 180 
minutes show the typical equilibrium distribution of PrPSc, with strong immunostaining at the 
plasma membrane (white arrows – 180 min) and in the PNC (yellow arrow -180 min). Nuclei 
were stained with DAPI (blue). Scale bar = 10 µm. (B) Quantification of cell phenotypes 
observed at different time points following prion exposure. Transition from the plasma 
membrane or diffuse intracellular PrPSc distribution to the steady-state distribution is rapid and 
reflects the steep rise in the proportion of infected cells. Mean + SEM of four independent 
experiments are shown. * P < 0.05, ** P < 0.01. 
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Figure 5-15 De novo prion protein conversion, endocytosis and trafficking proceeds at 
similar rates or faster than transferrin trafficking 
PrP-224AlaMYC cells were exposed to RML prions and Texas red-labelled transferrin (red) 
for the indicated times then fixed and formic acid extracted. Merged confocal images of cells 
stained with anti-MYC antibodies (green). Initially PrPSc shows a plasma membrane 
distribution (1 min, arrow) and/or diffuse intracellular distribution (2 min, arrow) then rapidly 
attains its steady-state distribution concentrated at the plasma membrane and PNC (4 min, 
white arrow indicates strong PNC stain). Transferrin could be observed in small puncta at the 
cell periphery, reaching its equilibrium distribution in recycling endosomes at the PNC (yellow 
arrows) between 8 and 16 minutes. Nuclei were stained with DAPI (blue). Scale bar = 15 µm.   
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Lack of intracellular MYC-tagged PrPSc and its presence at the cell surface 
after one minute of RML prion exposure strongly suggests that conversion of PrPC to 
PrPSc first occurs on the plasma membrane prior to endocytosis and intracellular 
trafficking. To test this hypothesis, pre-cooled PrP-224AlaMYC cells were incubated 
with RML prions at 4°C. This temperature shift effectively abolished endocytosis, as 
confirmed by the lack of transferrin uptake (Figure  5-16 A and B). Significantly, PrPSc 
accumulated only on the cell surface under these conditions (Figure  5-16 A, arrows). 
Orthogonal projections of confocal sections taken through these infected cells revealed 
the plasma membrane distribution of MYC-tagged PrPSc (Figure  5-16 B, arrows). 
These data clearly demonstrated that endocytosis is not necessary to produce misfolded 
PrPSc, and that a direct plasma membrane interaction between cellular PrPC and 
exogenous prions is sufficient to generate de novo PrPSc. However, the efficiency of 
the conversion at 4°C was reduced, consistent with the data showed in section  5.3.2 
(Figure  5-16 C).   
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Figure 5-16 Conversion of PrPC to PrPSc occurs initially on the cell surface 
(A) Pre-cooled PrP-224AlaMYC cells were exposed to RML prions, and Texas red-labelled 
transferrin (red) was added for 2 minutes on ice. The cells were then fixed and formic acid 
extracted. Merged confocal images of cells stained with anti-MYC antibodies (green). MYC-
tagged PrPSc was detected only at the plasma membrane (arrow). No transferrin has been 
endocytosed at this temperature. Nuclei were stained with DAPI (blue). Scale bar = 15 µm. (B) 
Pre-cooled PrP-224AlaMYC cells were exposed to RML prions for 2 minutes on ice then fixed 
and formic acid extracted. Orthogonal reconstructions of serial confocal slices are shown (red 
and green boxes) alongside one z-slice taken from near the middle of the cells (as indicated by 
the guide lines). The cells were fixed after 2 minutes and stained with anti-MYC antibodies 
(green). Formic acid-resistant PrP (PrPSc) is formed on the cell surface of one of the cells in the 
field (arrow), no intracellular PrPSc was detected. Nuclei were stained with DAPI (blue). Scale 
bar = 15 µm. (C) PrP-224AlaMYC cells were exposed to RML prions for 3 hours at 37°C or 
on ice then fixed and formic acid extracted. The percentage of anti-MYC positive (prion 
infected) cells observed at 37°C and 4°C was quantified. Intact lipid raft integrity on the cell 
surface requires for efficient prion conversion. Mean + SEM of three independent experiments 
Intact lipid raft integrity on the cell surface required for efficient prion conversion is shown 
(background levels found in uninfected cells for each condition has been subtracted from the 
mean). 
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Rapid prion conversion on the cell surface may point to a mechanism whereby 
PrP misfolding is a stochastic event catalysed by an interaction with PrPSc in a 
favourable environment. This could be provided by lipid rafts, specialised membrane 
microdomains known to be present in the plasma membrane and enriched in PrPC 
(Madore et al., 1999; Vey et al., 1996). Therefore, the role of lipid rafts in prion 
protein conversion was tested using reagents that disrupt lipid raft integrity. Two 
reagents were used that affect lipid raft function by different mechanisms: filipin (Ying 
et al., 1992), which binds and sequesters plasma membrane cholesterol; and U18666A, 
which inhibits cholesterol transport to rafts (Cenedella, 2009). Both of these 
compounds abrogated the initial de novo prion conversion in our cellular system 
(Figure  5-17). This is consistent with a lipid raft-dependence of the prion conversion 
process as described previously (Marella et al., 2002; Stengel et al., 2006) and 
suggests that the initial conversion process is occurring within these domains on the 
plasma membrane  
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Figure 5-17 Intact lipid raft integrity on the cell surface required for efficient prion 
conversion   
PrP-224AlaMYC cells were pre-treated with filipin or DMSO for 30 minutes or U18666A for 
16 hours then exposed to RML prions for 3 hours in the continued presence of inhibitors or 
DMSO. Cells were then fixed and formic acid extracted prior to immunostaining with anti-
MYC antibodies. The percentage of anti-MYC positive (RML prion infected) cells was 
quantified. Mean + SEM of three independent experiments are shown (background levels 
found in non-infected cells for each condition have been subtracted from the mean). * P < 
0.05. Filipin and U18666A abrogated the initial de novo prion conversion in our cellular 
system indicating lipid raft integrity is required for prion infection.   
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5.4 Discussion 
Conversion of PrPC to PrPSc is the key cellular event in prion pathogenesis. 
Prion conversion is thought to occur at a site where the two protein forms meet and 
are able to physically interact (Prusiner, 1998a). To date, no specific intracellular 
compartment has been definitely identified as having sole responsibility for this event, 
as several compartments have been proposed using different cell systems (Caughey et 
al., 1991; McKinley et al., 1991b; Arnold et al., 1995; Barmada and Harris, 2005; 
Pimpinelli et al., 2005; (Godsave et al., 2008; Marijanovic et al., 2009). Based on 
analyses of the sub-cellular localisation of different PrP forms, the plasma membrane 
and endolysosomal compartments have been proposed as possible locations for the 
PrP conversion process (Section 1.6.2 and Section  5.1). There are contrasting data 
about PrPC and PrPSc localisation (Shyng et al., 1993; Sunyach et al., 2003), and these 
inconsistencies are mostly likely related to the lack of antibodies specific to PrPSc, and 
the need for a protein denaturation step to hydrolyse PrPC and reveal the PrPSc 
epitope. Moreover, study of the cellular site where PrPC and PrPSc first meet for 
conversion to be catalysed has proven difficult as newly made PrPSc is 
immunologically indistinguishable from PrPSc species in the brain homogenate 
inocula. Therefore, previous works studying the cellular site of initial PrP conversion 
have relied on prolonged culture of cell lines that stably propagate prions to clear any 
inocula-derived PrPSc, which is known to persist in cell cultures for two weeks or 
more (Giri et al., 2006; Cronier et al., 2004), before the cell biology of newly formed 
PrPSc can be analysed (Bosque and Prusiner, 2000). This means that fundamental 
information such as where the initial site of PrP conversion occurs has not yet been 
elucidated. Impairment of PrP trafficking in the unique cell system in which epitope 
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tagged-PrPSc is produced, combined with effective protocols to remove PrPC, have 
allowed examination of the initial site of PrP conversion, in this thesis work.  
Several studies indicate that the conversion of PrPC to PrPSc is a post-
translational event that occurs after the protein reaches the cell surface (Caughey and 
Raymond, 1991; Borchelt et al., 1992; Taraboulos et al., 1992). Indeed, both the 
exposure of PrPC to anti-PrP antibodies and the release of nascent PrP from the cell 
surface, either by PIPLC or hydrolysis with dispase and trypsin prevent the formation 
of PrPSc (Caughey and Raymond, 1991; Borchelt et al., 1992; Enari et al., 2001). 
Gilch et al., showed that down-regulation of PrPC on the cell surface using Suramin, 
which induces intracellular re-routing of PrP from post-ER compartments to acidic 
vesicles, interferes with PrPSc propagation in cell culture and scrapie infected animals 
(Gilch et al., 2001). BFA has shown to inhibit PrPC export to the plasma membrane 
by blocking its transport from ER to Golgi (Misumi et al., 1986; Doms et al., 1989); 
(Lippincott-Schwartz et al., 1989; Taraboulos et al., 1992). The data presented in this 
chapter demonstrated that treatment of PrP-224AlaMYC cells with BFA significantly 
reduced PrPSc formation and propagation suggesting that the ER-Golgi is insufficient 
for synthesis of PrPSc, and that PrPC transport to the cell surface is essential for this 
process, consistent with previous findings (Taraboulos et al., 1992). Recent findings 
have shown that stimulating the retrograde transport and accumulation of PrP in the 
ER through over-expression of the constitutively active, small GTPase Rab6a, 
increases the production of PrPSc in infected cells (Beranger et al., 2002). This 
suggests the possibility that PrPSc undergoes retrograde transport to the Golgi 
apparatus and/or to the ER following its production. These findings might explain the 
diffuse PrPSc staining noted in RML prion-infected PrP-224AlaMYC cells treated 
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with BFA. PrPC has a half-life of approximately three to five hours. Therefore, it is 
possible that in the cell system presented here BFA treatment was not long enough to 
completely deplete cellular PrPC and the residual protein on the plasma membrane or 
in the endocytic compartments converted to PrPSc, and via retrograde transport PrPSc 
then reached the Golgi apparatus and the ER followed by many GPI-linked proteins 
(Muñiz and Riezman, 2000). Due to the BFA treatment, the Golgi stacks get 
dispersed and fuse with the ER. In addition, the trans-Golgi network (TGN) mixes 
with the early endosomal system after BFA treatment (Lippincott-Schwartz et al., 
1991; Wood et al., 1991), which may explain why the PrPSc staining looked diffuse.  
Arnolds et al., showed the presence of PrPSc in sub-cellular structures that 
contain the cation-independent mannose 6-phosphate receptor, ubiquitin-protein 
conjugates, beta-glucuronidase, and cathepsin B, and termed them late endosome-like 
organelles (Arnold et al., 1995). PrPC will enter such compartments for normal 
degradation and, therefore, it was suggested that these organelles may be the site of 
PrPC conversion into infectious PrPSc. In contrast, the data presented in this chapter 
demonstrated that impairment of PrP trafficking beyond early endocytosis (by 
incubating the cells at 20°C or using nocodazole or bafilomycin) does not affect PrP 
conversion and prion propagation, arguing against the involvement of late 
endosomes/lysosomes in PrPSc production. This is in agreement with several lines of 
evidence that suggest the formation of PrPSc occurs prior to entry into lysosomes. First, 
lysosomotropic amines block the digestion of the NH2-terminal ninety amino acids of 
PrPSc, but they do not interfere with the formation of PrPSc (Caughey et al., 1991; 
Taraboulos et al., 1991). Second, lysosomotropic amines do not alter substantially the 
degradation of PrPC (Taraboulos et al., 1991a), suggesting that it might be degraded 
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before reaching lysosomes. Thirdly, kinetic studies indicate that PrPSc acquires 
protease resistance approximately one hour before exposure to lysosomal proteases 
and digestion of the NH2 terminus (Taraboulos et al., 1991b). Moreover, Marijanovic et 
al., identified the ERC as the likely site of PrP conversion (Gousset et al., 2009). 
However, blocking the PrP trafficking to the ERC by incubating PrP-224AlaMYC 
cells at 4°C or 20°C, or treating them with nocodazole, bafilomycin or dynasore did 
not affect the conversion of PrPC into PrPSc. These data rule out the absolute necessity 
for the ERC in PrPSc formation, and suggest that PrP conversion and prion propagation 
occurs at the plasma membrane and/or early in the endocytic pathways in agreement 
with previous findings (Section 1.6.2 and Section  5.1).   
In neuronal cells, a major pathway for internalisation of prion protein appears is 
via clathrin-mediated endocytosis, a process that is dynamin-dependent (Sunyach et 
al., 2003; Sarnataro et al., 2009) (Section 1.6.1). Moreover, transfection of neuronal 
cell lines with a dominant negative mutant of dynamin I (K44A), which blocks fission 
of invaginated coated pits from the plasma membrane, inhibits PrPC endocytosis 
suggesting that PrPC is internalised via a dynamin-dependent (clathrin-mediated 
endocytosis) pathway (Magalhaes et al., 2002). However, inhibition of any dynamin-
dependent processes in PrP-224AlaMYC cells using dynasore did not inhibit the 
internalisation, formation and propagation of PrPSc, implying that the internalisation of 
PrPSc is not dynamin-dependent in our cell system. This observation is supported by 
Wadia and colleagues showing that endocytic uptake of PrP in N2a cells occur by lipid 
raft-dependent macropincytosis, which does not require dynamin (Wadia et al., 2008). 
These data also propose that PrPC and PrPSc might use different internalisation 
pathways. 
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Furthermore, MYC-tagged PrPSc accumulated in the PNC of PrP-224AlaMYC 
cells treated with dynasore, with no PrPSc localised on the cell surface. This suggests 
that although the internalisation of PrPSc is not dynamin-dependent, its recycling back 
to the cell surface is. These data also propose that PrPSc formation does not require 
cell-surface recycling, again in agreement with previous findings (Beranger et al., 
2002).  
Blocking of endocytosis by incubating PrP-224AlaMYC cells at 4°C clearly 
demonstrated that endocytosis is not necessary to produce misfolded PrPSc, and that a 
direct plasma membrane interaction between cellular PrPC and exogenous prions is 
sufficient to generate de novo PrPSc. This concurs with previous findings proposing 
that the plasma membrane is a potential site of PrP conversion (Caughey and 
Raymond, 1991; Kanu et al., 2002; Veith et al., 2008), and is consistent with the 
observed PrPSc distribution reported in different cell and in vivo systems (Jeffrey et al., 
2000; Caughey and Baron, 2006; Veith et al., 2008). Detailed spatial analysis of PrP-
224AlaMYC cells shortly after RML prion exposure further confirmed that PrPSc 
forms on the plasma membrane. However, the efficiency of the PrP conversion at 4°C 
was reduced. This may reflect a slower reaction rate due to the lower temperature, as 
might be expected for a protein folding-driven phenomenon (Oliveberg et al., 1995). 
Alternatively, it might reflect a reduced prion conversion rate in the absence of a 
contribution from internal components. This suggests also that the plasma membrane is 
the initial site of prion conversion and early endocytic compartments may continue or 
accelerate the PrP conversion process following the endocytosis of PrPSc. Therefore, 
the observation that prion infection was reduced at 4°C may be consistent with an 
important role for internal cellular compartments in PrPSc propagation.   
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Our data also suggest that PrP conversion and prion propagation is dependent 
on the presence of intact lipid rafts (Madore et al., 1999; Vey et al., 1996). Supporting 
this idea, co-factors found enriched in lipid rafts have been shown to stimulate 
synthetic prion conversion (Deleault NR et al., 2007; Taylor et al., 2009; Abid and 
Soto, 2006) and reagents that disrupt raft integrity abrogate PrPSc propagation in cells 
(Marella et al., 2002; Gousset et al., 2009). Recombinant trans-membrane forms of 
PrPC that are not directed to rafts do not seed PrPSc formation in prion-infected N2a 
cells (Taraboulos et al., 1995; Kaneko et al., 1997b). Furthermore, lipid rafts have 
shown to be the key intermediates in the retrograde transport route. Preventing PrP 
conversion and prion propagation with filipin and U18666A reagents, which disrupt 
lipid rafts, further supported the possible involvement of the retrograde route in prion 
trafficking.  
The unique cell system utilised here has allowed new insights into the dynamic 
nature of PrPSc trafficking in the cell. The ability to analyse the trafficking events 
immediately following exposure to exogenous prions has revealed that PrPSc initially 
forms at the cell surface and is then rapidly endocytosed via a dynamin-independent 
process and possibly travel through retrograde route to the Golgi-ER. Indeed, after one 
minute exposure to RML prions, many cells already contain intracellular PrPSc, often 
in a diffuse cellular distribution that possibly reflects a transition through an 
endosomal compartment. After four minutes exposure to prions, the distribution of 
PrPSc obtains a steady-state that is concentrated at the PNC and at the cell surface, as 
described previously (Kristiansen et al., 2005; Caughey et al., 1991; Arnold et al., 
1995).  
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5.5 Summary 
The work in this chapter revealed that intracellular re-routing of PrP prevents 
propagation of PrPSc. It suggests that the conversion of PrPC to PrPSc is a post-
translational event that occurs after the protein reaches the cell surface. It was shown 
that the late endosomes, lysosomes and ERC do not appear to be key sites of PrP 
conversion and prion propagation, whilst the plasma membrane and early endocytic 
compartments are involved in this key process. Most importantly, studying the early 
events of RML prion infection suggests that the plasma membrane is the initial site of 
prion conversion and that the cell surface is sufficient for the process. Finally, it was 
suggested that PrPSc may travel to the perinuclear region of the cell via retrograde 
transport system and intact lipid rafts are essential for this pathway and the production 
of PrPSc. 
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6 Conclusions and future plans  
6.1 Thesis summary and conclusions 
The work presented in this thesis aimed to investigate the earliest event in prion 
infection using a novel cell system. Specifically, it aimed to assess the timescale that 
PrPC is converted to PrPSc following exposure to RML prions and identify the initial 
cellular site of PrPSc formation and propagation. 
Work presented here reported on the generation of a unique cell system in 
which a novel MYC-tagged PrPC is expressed in a neuroblastoma cell line where the 
endogenous PrPC has been silenced using RNAi. This engineered PrPC chimera (PrP-
224AlaMYC) was shown to support prion replication resulting in the production, for 
the first time, of a true bona fide, infectious epitope-tagged PrPSc as evidenced by both 
in vitro and mouse bioassays. The capacity of PrP-224AlaMYC cells to produce 
epitope-tagged PrPSc combined with established methods to remove PrPC and 
specifically visualise de novo PrPSc generated in the recipient cell (pre-treatment with 
formic acid and proteinase K), allowed the earliest events in cellular prion infection 
and PrP misfolding to be studied for the first time. The work has also enabled initial 
dissection of intracellular PrPSc trafficking pathways. 
The data presented here showed that prion infection of cells is extremely rapid, 
occurring within one minute of prion exposure. It was also suggested that conversion 
of PrPC to PrPSc is a post-translational event and that the plasma membrane is the 
initial site of prion conversion. Pharmacological interventions revealed that late 
endosomes, lysosomes and the endosomal recycling compartments do not appear to be 
primary sites of PrP conversion and prion propagation. Instead, it appears that de novo 
Conclusions and future plans 
205  
 
PrPSc is first synthesised at the plasma membrane as early as one minute and is rapidly 
endocytosed via a dynamin-independent process and trafficked to internal 
compartments adjacent to the nucleus (i.e. PNC). Disruption of the Golgi apparatus 
and the ER altered the sub-cellular distribution of PrPSc preventing PNC build up. This 
suggests that following synthesis on the plasma membrane, PrPSc is endocytosed and 
undergoes retrograde transport through the trans-Golgi network, the Golgi apparatus 
and the ER in a similar manner to other GPI-linked proteins (Muñiz and Riezman, 
2000). Consistent with this theory, disruption of lipid rafts by filipin and U18666A 
treatment prevented prion infection and PrPSc propagation. The critical link between 
PrPSc trafficking and prion-mediated neurotoxicity currently remains unclear. Further 
work will therefore investigate how PrPSc accesses the cytosol and subsequently 
interacts with the UPS. 
6.2 Suggestions for future work 
6.2.1 Understanding the pathways by which PrPSc accesses the 
cytosol 
Several lines of evidence have suggested a role for ubiquitin-proteasome 
system (UPS) dysfunction in the pathogenesis of prion diseases (Kristiansen et al., 
2005; Kristiansen et al., 2007). Kristiansen and colleagues demonstrated that mild 
proteasome inhibition in prion-infected neuronal cells results in the formation of large 
cytosolic perinuclear aggresomes containing PrPSc, heat shock chaperone 70 (Hsc70), 
ubiquitin, proteasome subunits, and vimentin. Aggresome formation was associated 
with activation of caspases 3 and 8 and subsequent apoptosis (Kristiansen et al., 2005). 
Two well-characterised UPS substrates (IкB and P27) were found to accumulate in the 
brains of prion-infected mice, supporting the hypothesis that prion diseases are 
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associated with UPS dysfunction (Kristiansen et al., 2005). A follow-up study has 
since demonstrated that disease-associated PrP specifically inhibits the proteolytic β 
subunits of the 26S proteasome via a direct, high affinity interaction (Kristiansen et al., 
2007; Deriziotis et al., unpublished data). These studies suggest that direct inhibition 
of the proteasome by PrPSc is a key component in prion toxicity. In order to inhibit the 
proteasome directly, PrPSc must gain access to the cytosolic compartment, a process 
that is currently poorly understood. As a membrane protein, mature PrPC would not 
normally be exposed to the cytosol. In combination with previous studies, the work 
presented in this thesis demonstrated that PrPSc is generated from PrPC at the cell 
surface and/or shortly after internalization (Campana et al., 2005) (Chapter 5). As a 
result, PrPSc must traverse, either the plasma membrane itself, or one of the internal 
membranes, in order to access the cytosol. 
Possible sites of PrPSc entry to the cytosol could be investigated using the 
unique PrP-224AlaMYC expressing neuroblastoma cell system. After internalisation 
PrPSc may undergo retrograde transport to the trans-Golgi network, the Golgi apparatus 
and the ER where PrPSc transfer to the cytosol could be facilitated by ER translocation 
machinery. This hypothesis is supported by studies suggesting that wild type and 
certain mutant forms of PrP misfolded in the ER are substrates for endoplasmic 
reticulum associated protein degradation (ERAD) (Zanusso et al., 1999; Yedidia et al., 
2001). Due to the UPS inhibition observed in prion diseases, subsequent degradation 
of cytosolic misfolded PrP may be impaired, leading to accumulation in the cytosol 
(Ma and Lindquist, 2001; Yedidia et al., 2001). Alternatively, cytosolic build up of 
misfolded PrP species may result from inefficient translocation into the ER, resulting 
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in a proportion of the PrP molecules to not enter the ER at all (Ashok and Hegde, 
2009). 
 Independent from ER, PrPSc may traffic to lysosomes and leak to the cytosol 
from lysosomal compartments. Several lines of evidence suggest trafficking of PrPSc to 
lysosomes: a) the N-terminal domain of PrPSc can be truncated by lysosomal proteases 
(Caughey et al., 1991); b) PrPSc accumulates rapidly in the cell following lysosomal 
protease inhibition (Marijanovic et al., 2009); and c) the work presented in this thesis 
and several other studies have demonstrated the partial colocalisation of PrPSc with 
lysosomal markers (Caughey et al., 1991; McKinley et al., 1991b; Borchelt et al., 
1992). Amyloid protofibrils have been shown to form pores in cell membranes leading 
to destabilisation (Lashuel et al., 2002). This provides a plausible mechanism for PrPSc 
release into the cytosol from lysosomes or autophagosomes. In support of this theory, 
PrPC and PrPSc are both known to interact with lipids (Campana et al., 2005) and 
recombinant β-sheet rich PrP has been reported to disrupt membrane integrity 
(Sanghera and Pinheiro, 2002). It is therefore possible that PrPSc is transported through 
the lysosomal system and enters the cytosol via membrane destabilisation. 
Interestingly, lysosomal rupture has been identified as a possible source of spongiform 
vacuolar appearances in prion-infected neurons (Lowe et al., 1992). 
The above trafficking pathways can be mapped using a panel of endomembrane 
regulating Rab proteins tagged with monomeric red fluorescent proteins (mRFP) 
(Deinhardt et al., 2006). Rab GTPases regulate many steps of membrane trafficking, 
including vesicle formation, vesicle movement along actin and tubulin networks, and 
membrane fusion (Martinez and Goud, 1998). Following transfection with wild type 
versions of these small GTPases, PrP-224AlaMYC cells could be prion infected and 
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colocalisation with PrPSc could be investigated by segmenting and counting punctate 
structures from confocal immunofluorescence images (Gniadek and Warren, 2007). In 
parallel, the effect of blocking the endocytic trafficking pathway at specific sites could 
be investigated by expressing dominant-negative versions of Rabs and RNAi knock 
down of key trafficking intermediates. This will result in the blockage of the endocytic 
trafficking pathway at specific sorting positions. In particular, the effect of loss of Rab 
5 (early endosomes), Rab 4 and Rab 11 (recycling endosomes), Rab 7 (late 
endosomes), Rab 9 (late endosomes/trans-Golgi network), Rab 6a (trans-Golgi 
network/ER), Rab 6 (early endosomes/ trans-Golgi network) and clathrin heavy chain 
RNAi (CHC RNAi, clathrin dependent endocytosis) can be examined on PrPSc 
localisation and aggregate formation. After applying the trafficking manipulation on 
the cells, cytosolic accumulation of PrPSc could be monitored by colocalisation with 
specific cytosolic marker proteins (Hsc70 and the 20S proteosome (Kristiansen et al., 
2005)) and proteosome activity assays (a surrogate assay of cytosolic PrPSc, (Dantuma 
et al., 2000; Berkers et al., 2005; Kisselev and Goldberg, 2005; Kristiansen et al., 
2007)). Cytosolic PrPSc build up will indicate the role of the donor compartment 
immediately prior to the trafficking impairment in production of cytosolic PrPSc. This 
approach has already been used successfully to map intracellular trafficking pathways 
(Deinhardt et al., 2006a; Deinhardt et al., 2006b) and may enable us to identify the 
site(s) where PrPSc accesses the cytosol to inhibit the UPS and potentially mediate 
neurotoxicity. 
6.2.2 A novel cell system to study the UPS activity 
Chronically infected PK1 cells stably propagating prions show decreased 
proteasomal activity and are more sensitive to cell death after mild UPS inhibition than 
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non-infected cells (Kristiansen et al., 2005). This suggests that their UPS is impaired 
due to the presence of PrPSc. PrP-224AlaMYC cells present the unique opportunity to 
study the temporal relationship between the uptake of exogenous PrPSc, production of 
de novo PrPSc and inhibition of the UPS. The total and cytosolic PrPSc build up can be 
followed using anti-MYC antibodies. Infection of PrP-224AlaMYC cells with RML 
prions would allow levels of total and cytosolic PrPSc to be correlated with UPS 
activity in a detailed time-course. The proteasome activity in cell lysates could be 
assayed by using highly sensitive fluorogenic peptide substrates (Kristiansen et al., 
2007). Furthermore, UPS activity in intact cells could be measured by adding cell 
permeable fluorescent β-subunit activity probes (Verdoes et al., 2006) or by assessing 
proteasome reporter substrate accumulation in cells stably transfected with UbG76V-
GFP (Dantuma et al., 2000; Kristiansen et al., 2007). The effect of mild proteasome 
inhibition could also be analysed as a mimetic of cell toxicity. The unique cell system 
presented in this thesis allows differentiation of individual cells that have internalised 
exogenous PrPSc but not synthesised de novo PrPSc (Figure 4-9). UPS activity can be 
assessed in these cells using fluorescent, cell-permeable activity-based probes such as 
Bodipy TMR-Ahx3L3VS (MV151), which specifically targets all active subunits of 
the proteasome and immunoproteasome in individual living cells, to determine if de 
novo PrPSc production is necessary to cause UPS inhibition (Verdoes et al., 2006). 
Prion infection of PrP-KD cells, which do not propagate prions (Section 3.3.1 and 
Figure 3-1 B), could also be used to determine whether de novo PrPSc production is 
necessary for UPS impairment. In this way the intracellular effects of prion exposure 
and de novo PrPSc synthesis could be dissociated. 
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6.2.3 A novel cell system to study prion cytotoxicity 
Whilst in vivo studies of prion disease pathogenesis have repeatedly identified 
marked neuronal loss (Aguzzi et al., 2008), mouse neuroblastoma cells and their 
derivatives do not exhibit prion-induced cell death under normal in vitro conditions. 
The cells may be able to compensate by dividing before the PrPSc load reaches toxic 
levels or by metabolising misfolded PrP with greater efficiency. Creating a model of 
prion infection induced cell toxicity in post-mitotic neurons would therefore be useful. 
Differentiated mouse neuronal stem cells (NSC) are susceptible to prion infection and 
replicate many disease characteristics including prion-induced toxicity and ultimately 
cell death (Milhavet et al., 2006). However, NCS have limited use as models of early 
prion infection due to the difficulties in the distinction of de novo PrPSc from inocula-
derived PrP which is known to persist in the cells for several weeks (Giri et al., 2006; 
Cronier et al., 2004). To overcome this limitation, NSC lines expressing MYC-tagged 
PrP construct (Figure 3-2) could be generated. Transduction of NSC derived from 
FVB PrP-/- mice with retroviral constructs encoding 224AlaMYC-tagged PrP would 
allow isolation of prion susceptible NSC lines expressing MYC-tagged PrPSc. To avoid 
problems with inocula clearance, previous NSC studies used semi-purified prions or a 
low dose of inocula (Milhavet et al., 2006; Cronier et al., 2004). Both approaches were 
associated with poor prion infection and propagation efficiency. The development of 
NSC lines expressing MYC-tagged PrPSc could avoid these limitations through the use 
of high dose inocula. NSC differentiation can be induced by growth factor withdrawal 
using established methods (Milhavet et al., 2006). This produces a mixed population 
of post-mitotic neuronal cells (neurons, astrocytes and glia) which can be manipulated 
towards different cell fates by trophic factor treatment, allowing cultures enriched in 
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neurons to be produced (Panchision et al., 1998). Studying prion-infected, 
differentiated NSC lines will allow comparison of the spatial and temporal features of 
prion infection already observed in the neuroblastoma cell model (Chapter 4 and 
Chapter 5) with those in differentiated neurons. It will also enable us to study prion 
trafficking in compartmentalised neurons using the methods outlined in this thesis.  
Prion infected, differentiated NSC and immortalised human stem cells die 
earlier in culture than mock infected control cells (Milhavet et al., 2006). If PrP-
224AlaMYC neural stem cell derivates recapitulate this characteristic, they could 
therefore provide a unique model to study prion induced cytotoxicity and cell death. 
PrP-224AlaMYC neural stem cells could be infected with prions and alterations in 
nuclear morphology, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick 
end labelling (TUNEL), membrane permeability, lysosomal physiology and casapse 
activation could be analysed at serial time-points. 
Manipulating proteasome activity in chronically infected PK1 cells is known to 
affect PrPSc levels (Kristiansen et al., 2005). Furthermore, a detailed in vivo study in 
Professor Tabrizi’s lab has revealed that UPS impairment is a very early event in prion 
disease pathogenesis (unpublished data). These data therefore suggest that the UPS 
plays a crucial role in PrPSc metabolism. Differentiated mouse neuronal stem cells 
expressing PrP-224AlaMYC can provide a unique model to examine the temporal 
relationship between prion infection, dysfunction of the UPS and neurotoxicity. A 
detailed time-course study could be performed on PrP-224AlaMYC mouse neuronal 
stem cells to correlate PrPSc levels with UPS activity and cellular toxicity. A range of 
proteosome activators and inhibitors (Lee et al., 2010; Verdoes et al., 2006), are 
currently available and could be used to investigate the direct effects of UPS 
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modulation on PrPSc levels and cytotoxicity. For example, RML prion-infected, 
differentiated NSC can be treated with proteasome activators to examine if this 
treatment will extend the cell’s lifespan and determine if this corresponds to increased 
PrPSc clearance. 
The temporal relationship between UPS function and ER stress in prion disease 
could also be addressed using a NSC system. N2a neuroblastoma cells treated with 
PrPSc produce a fast and sustained increase in intracellular calcium levels (Hetz et al., 
2003). Pre-treatment with thapsigargin that depletes ER calcium stores is known to 
reduce the increase in calcium observed with PrPSc (Hetz et al., 2003). This indicates 
that the ER is involved in PrPSc cytotoxicity, however, it remains unclear whether the 
role of the ER in prion disease pathogenesis is primary or secondary to the UPS 
dysfunction (Hetz et al., 2003; Hetz et al., 2007). UPS dysfunction that occurs in 
response to prion infection (Kristiansen et al., 2007), may result in the accumulation of 
misfolded proteins in the ER that were destined for degradation by ERAD, resulting in 
ER stress (Ciechanover and Brundin, 2003; Imai et al., 2001; Nishitoh et al., 2002). 
Recently, abortive translocation of nascent PrP in response to ER stress has been 
demonstrated (Rane et al., 2008). This results in the accumulation of cytosolic PrP 
which is known to be cytotoxic in both cell and in vivo systems (Ma et al., 2002; Rane 
et al., 2004; Rambold et al., 2008; Wang et al., 2009), representing another possible 
mechanism of prion-induced toxicity. Serial time-course studies in RML prion-
infected, differentiated NSC would help to determine the relative contribution of ER 
stress and UPS dysfunction to neurotoxicity and thus assess to what extent UPS 
dysfunction can be considered a true pathogenic mechanism rather than an 
epiphenomenon of the disease process itself. 
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7 Appendices   
Appendix I  
Appendix II  
Mammalian PrP protein schematic with putative FLAG and MYC 
tag insert sites 
MANLGYWLLALFVTMWTDVGLC(DYKDDDDKG)KKRPKPGG(DYKDDDDK
G)WNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWGQPHGG
SWGQPHGGGWGQGGGT(DYKDDDDKG)HNQWNKPSKPKTNLKHVAGAAAA
GAVVGG(EQKLISEEDL)LGGYMLGSAMSRPMIHFGN(DYKDDDDKG)DWEDR
YYRENMYRYPNQVYYRPVDQ(DYKDDDDKG)YSNQNNFVHDCVNITIKQHT
VTTTTKGENFT(DYKDDDDKG)ETDVKMMERVVEQMCVTQYQKESQA(EQKL
ISEEDL)YYDGRRSSSTVLFSSPPVILLISFLIFLIVG 
Mouse PrP amino acid sequence with highlighted FLAG 
and MYC tag insert sites 
Blue = signal peptide 
Red = GPI anchor signal sequence 
Highlighted = positions for FLAG tag insert 
Highlighted = positions for MYC tag insert 
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Appendix III 
 
pLNCX2 retroviral vector map1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1From http://www.clontech.com/products/detail.asp?product_id=10523&tabno=2 
Appendices 
215  
 
Appendix IV 
FLAG1 N-C  
Primers for generation of FLAG and MYC-tagged PrP constructs 
5’- GACTACAAAGACGATGACGATAAAGGCAAAAAGCGGCCAAAGCCTGG-3’ 
FLAG1 C-N  
3’-CTGACTACAGCCGGAGACGCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCGCAGAGGCCGACATCAGTC-3’ 
 
FLAG 2 N-C  
5’- GACTACAAAGACGATGACGATAAAGGCTGGAACACCGGTGGAAGCC-3’ 
FLAG 2 C-N  
3’-GCCGGTTTCGGACCTCCCCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCCCCTCCAGGCTTTGGCCG-3’ 
 
FLAG3 N-C  
5’-GACTACAAAGACGATGACGATAAAGGCCATAATCAGTGGAACAAGCCC-3’ 
FLAG 3 C-N  
3’-CCGGTTCCTCCCCCATGGCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCGGTACCCCCTCCTTGGCC-3’ 
 
FLAG 4 N-C  
5’- GACTACAAAGACGATGACGATAAAGGCGACTGGGAGGACCGCTAC-3’ 
 
FLAG 4 C-N  
3’-GGGTACTAGGTAAAACCGTTGCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCGTTGCCAAAATGGATCATGGG-3’ 
 
FLAG 5 N-C  
5’- GACTACAAAGACGATGACGATAAAGGCTACAGCAACCAGAACAACTTC-3’ 
 
FLAG 5 C-N  
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3’-GATGTCCGGTCACCTAGTCCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCCTGATCCACTGGCCTGTAG-3’ 
 
FLAG 6 N-C 
5’-GACTACAAAGACGATGACGATAAAGGCGAGACCGATGTGAAGATGATG-3’ 
FLAG 6 C-N 
3’-GTTCCCCCTCTTGAAGTGGCTGATGTTTCTGCTACTGCTATTTCCG-5’ 
5’-GCCTTTATCGTCATCGTCTTTGTAGTCGGTGAAGTTCTCCCCCTTG-3’ 
 
MYC1 N-C 
5’-GAACAGAAACTGATCTCTGAAGAAGACCTGCTTGGTGGCTACATGCTG-3’ 
MYC1 C-N 
3’- CACGACACCACCCGCCACTTGTCTTTGACTAGAGACCTCTTCTGGAC-5’    
5’- CAGGTCTTCTTCAGAGATCAGTTTCTGTTCGCCCCCCACTACTGCCC-3’ 
 
MYC2 N-C 
5’-GAACAGAAACTGATCTCTGAAGAAGACCTGTATTACGACGGGAGAAGA-3’ 
MYC2 C-N 
3’-TGTTTCTTAGAGTCCGACTTGTCTTTGACTAGAGACCTCTTCTGGAC-5’    
5’-CAGGTCTTCTTCAGAGATCAGTTTCTGTTCGGCCTGGGACTCCTTCT-3’ 
FLAG sequence 
5’-GACTACAAAGACGATGACGATAAAGGC-3’ 
 
3’-CTGATGTTTCTGCTACTGCTATTTCCG-5’ 
 
MYC sequence 
5’-GAACAGAAACTGATCTCTGAAGAAGACCTG-3’ 
 
3’-CTTGTCTTTGACTAGAGACCTCTTCTGGAC-5’ 
 
mPrP Sequence       
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5' primer (Clontech):  
5'-AGCTCGTTTAGTGAACCGTCAGATC-3'  
My version 
5’-CGGAATTCCGTTTAGTGAACCGTCAGATC-3’ 
3' primer (Clontech):  
5'-ACCTACAGGTGGGGTCTTTCATTCCC-3' 
My version 
5’-CCGCTCGAGTACAGGTGGGGTCTTTCATTC-3’ 
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